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Summary 
 
  
Summary 
The oncogenic MYC protein is a transcriptional regulator of multiple cellular processes 
and is aberrantly activated in a wide range of human cancers. MYC is an unstable protein 
rapidly degraded by the ubiquitin-proteasome system. Ubiquitination can both positively 
and negatively affect MYC function, but its direct contribution to MYC-mediated 
transactivation remained unresolved. 
To investigate how ubiquitination regulates MYC activity, a non-ubiquitinatable MYC 
mutant was characterized, in which all lysines are replaced by arginines (K-less MYC). 
The absence of ubiquitin-acceptor sites in K-less MYC resulted in a more stable protein, 
but did not affect cellular localization, chromatin-association or the ability to interact with 
known MYC interaction partners. 
Unlike the wild type protein, K-less MYC was unable to promote proliferation in 
immortalized mammary epithelial cells. RNA- and ChIP-Sequencing analyses revealed 
that, although K-less MYC was present at MYC-regulated promoters, it was a weaker 
transcriptional regulator. The use of K-less MYC, a proteasomal inhibitor and 
reconstitution of individual lysine residues showed that proteasomal turnover of MYC is 
required for MYC target gene induction. ChIP-Sequencing of RNA polymerase II 
(RNAPII) revealed that MYC ubiquitination is dispensable for RNAPII recruitment and 
transcriptional initiation but is specifically required to promote transcriptional elongation. 
Turnover of MYC is required to stimulate histone acetylation at MYC-regulated 
promoters, which depends on a highly conserved region in MYC (MYC box II), thereby 
enabling the recruitment of BRD4 and P-TEFb and the release of elongating RNAPII from 
target promoters. Inhibition of MYC turnover enabled the identification of an intermediate 
in MYC-mediated transactivation, the association of MYC with the PAF complex, a 
positive elongation factor, suggesting that MYC acts as an assembly factor transferring 
elongation factors onto RNAPII. The interaction between MYC and the PAF complex 
occurs via a second highly conserved region in MYC’s amino terminus, MYC box I. 
Collectively, the data of this work show that turnover of MYC coordinates histone 
acetylation with recruitment and transfer of elongation factors on RNAPII involving the 
cooperation of MYC box I and MYC box II.  
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Zusammenfassung 
Der Transkriptionsfaktor MYC ist an der Regulation einer Vielzahl biologischer Prozesse 
beteiligt ist und spielt bei der Tumorentstehung und des Tumorwachstum eine 
entscheidende Rolle. MYC ist ein kurzlebiges Protein, das durch das Ubiquitin-Proteasom-
System abgebaut wird. Die Ubiquitinierung von MYC hat auch einen stimulierenden 
Einfluss auf dessen transkriptionelle Aktivität. Dabei blieb jedoch der Mechanismus, der 
dieser Beobachtung zugrunde liegt, bislang ungeklärt. 
Um den direkten Einfluss von Ubiquitinierung auf die Aktivität von MYC zu untersuchen, 
wurde in der vorliegenden Arbeit eine MYC Mutante analysiert, in der alle Lysine zu 
Argininen mutiert wurden (K-less MYC). Die Mutation der Ubiquitin-Verknüpfungsstellen 
resultierte in einem stabileren Protein, hatte jedoch keinen Einfluss auf die zelluläre 
Lokalisation oder Assoziation mit bekannten Interaktionspartnern. Im Vergleich zu 
Wildtyp (WT) MYC war K-less MYC jedoch in der Vermittlung MYC-induzierter 
biologischer Phänotypen stark beeinträchtigt. Mittels RNA- und ChIP-Sequenzierungen 
konnte gezeigt werden, dass K-less MYC zwar an MYC-regulierte Promotoren bindet, in 
der transkriptionellen Aktivität aber stark beeinträchtigt ist und diese Zielgene nicht 
aktivieren kann. Dabei war K-less MYC noch in der Lage, RNA Polymerase II (RNAPII) 
zu den Zielpromotoren zu rekrutieren und die Transkription dort zu initiieren, jedoch war 
der Übergang zur Elongation blockiert. Die Verwendung eines Proteasom-Inhibitors sowie 
die Rekonstitution einzelner Lysine in K-less MYC zeigten, dass der proteasomale Abbau 
von MYC für die Aktivierung von Zielgenen benötigt wird. Der proteasomale Abbau ist 
für die Histon-Acetylierung von Bedeutung, die von einer hoch konservieren Region in 
MYC, der MYC Box II, abhängt. Durch die WT MYC-vermittelte Induktion der Histon-
Acetylierung können folglich die Proteine BRD4 und P-TEFb an die Promotoren rekrutiert 
werden. Diese Proteine spielen bei dem Übergang der initiierenden RNAPII zur 
elongierenden RNAPII eine essentielle Rolle. 
Darüber hinaus ermöglichte die Inhibition des MYC Abbaus die Identifizierung eines 
Zwischenschritts der MYC-abhängigen Transaktivierung: die Assoziation von MYC mit 
dem positiven Elongationskomplex, dem PAF-Komplex. Dieser wird über eine zweite 
hochkonservierte Region in MYC, der MYC Box I, rekrutiert. Somit kann angenommen 
werden, dass MYC als eine Verbindungsstelle fungiert, die positive Elongationsfaktoren 
auf die RNAPII transferiert. 
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Zusammenfassend resultieren die Daten dieser Arbeit in einem Model, nach dem der 
proteasomale Abbau von MYC die Histon-Acetylierung mit der Rekrutierung und dem 
Transfer von Elongationsfaktoren auf die RNAPII koordiniert, was der Kooperation von 
MYC Box I und MYC Box II bedarf. 
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1 Introduction 
1.1 Ubiquitin-proteasome system (UPS) 
1.1.1 Ubiquitin-conjugation cascade 
Ubiquitin is a highly conserved small protein consisting of 76 amino acids. It can be 
covalently attached to its substrate protein via a peptide bond between the C-terminal 
glycine of ubiquitin and a free amino group of the target protein. Typically, ubiquitin is 
attached to the ε-amino group of an internal lysine, but it can also be conjugated to a free 
α-amino group of the N-terminal amino acid of a substrate protein (Breitschopf et al., 
1998; Ciechanover and Ben-Saadon, 2004). 
The conjugation of ubiquitin is a multistep reaction involving at least three types of 
enzymes (E1, E2 and E3). First, an E1 ubiquitin-activating enzyme activates ubiquitin in 
an ATP-dependent manner. This process results in an energy-rich thioester bond formed 
between the cysteine in the active center of the E1 enzyme and the C-terminal glycine of 
ubiquitin. Subsequently, the activated ubiquitin is transferred to a cysteine of a ubiquitin-
conjugating enzyme (E2). During the third step ubiquitin is transferred to its actual 
substrate protein. This process is catalyzed by an ubiquitin ligase (E3), which is largely 
responsible for the substrate specificity of the system (Hershko and Ciechanover, 1998) 
(Fig. 1.1). 
 
Figure 1.1: Schematic illustration of the ubiquitin-conjugation cascade 
Ubiquitination of a substrate involves at least three enzymes. The ubiquitin-activating enzyme E1 
activates ubiquitin (Ub) in an ATP-dependent reaction (1) and transfers the activated ubiquitin to 
the ubiquitin-conjugating enzyme (E2) (2). The third step involves the action of the ubiquitin ligase 
(E3), which either catalyzes the transfer from the E2 directly to the substrate protein (RING-type 
E3 ligases) (3a) or via a covalent ubiquitin-E3 intermediate (HECT-E3 ligases) (3b). 
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When a single ubiquitin molecule is attached to a single site of the target protein, the 
substrate is monoubiquitinated. Further ubiquitin molecules can be attached to the first one 
in order to build a polyubiquitin chain. Under certain circumstances, an ubiquitin-chain 
elongation factor (E4) is required for the extension of an existing short ubiquitin chain 
(Hoppe et al., 2004; Koegl et al., 1999). 
Ubiquitin itself possesses seven internal lysine residues (K6, K11, K27, K29, K33, K48 
and K63) and an amino-terminal methionine, which can all serve as attachment sites. This 
leads to a broad range of chain formations with eight different homotypic and several 
possible heterotypic chains. The types of chains differ in topology and determine the 
biological outcome of ubiquitination (Komander and Rape, 2012). K48-linked ubiquitin 
chains of at least four ubiquitin moieties are considered to be a degradation signal for the 
26S proteasome, a multiprotein complex with proteolytic capacity (see also 1.1.2). K63-
linked chains are implicated in DNA repair and regulation of protein activity and K29-
linked chains participate in lysosomal protein degradation (Ikeda and Dikic, 2008). 
Recently, several studies have challenged the classical view that distinct chain types 
mediate exclusively a specific process in the cell. For instance, K48-linked chains do not 
necessarily result in proteasomal degradation while non-K48-linked ubiquitin chains can 
also mediate proteasome-dependent turnover (Flick et al., 2004; Kim et al., 2011; 
Kirkpatrick et al., 2006). 
 
The ubiquitin-conjugation cascade has a hierarchical structure, which is reflected by the 
encoded enzymes. The human genome encodes for two ubiquitin-activating enzymes, 
around 40 ubiquitin-conjugating enzymes and more than 600 ubiquitin ligases (Jin et al., 
2007; Li et al., 2008; Pickart and Eddins, 2004). 
The E3 ubiquitin ligases can be subdivided into two major classes characterized by their 
structural domains and the resultant distinct mechanisms. The HECT (homologous to the 
E6-AP carboxyl terminus) E3 ligases contain a conserved cysteine in their HECT domain 
that forms a thioester with activated ubiquitin of the ubiquitin-E2 conjugate. This results in 
a covalent ubiquitin-E3 intermediate before the ubiquitin is transferred to the substrate 
protein. In contrast, the RING (really interesting new gene) and U-box (UFD2 homology) 
E3 ligases transfer ubiquitin directly from the E2 to the target protein by mediating the 
association between the E2 enzyme and the substrate protein (Fig. 1.1) (Hatakeyama et al., 
2001; Lorick et al., 1999; Pickart, 2001). 
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RING-type E3 ligases can act as monomers, dimers or multi-subunit complexes such as 
cullin-RING ligases (CRL). One example of a CRL is the SCF-complex (SKP1-CUL1-F-
Box), which consist of the scaffolding protein CUL1, the RING-domain containing protein 
RBX1, which recruits the E2, and the adapter protein SKP1, which binds a member of the 
F-box protein family. The F-box protein mediates substrate recognition via a protein-
protein-interaction domain such as WD40 or leucine-rich repeats. This interaction often 
occurs in a phosphorylation-dependent manner, whereby the WD40 domain recognizes a 
phosphorylated motif (phosphodegron) of the substrate. The F-box protein is incorporated 
into the SCF-complex by binding SKP1 and CUL1 via the F-box domain (Petroski and 
Deshaies, 2005; Zheng et al., 2002). 
Ubiquitination is a reversible process and can be counteracted by deubiquitinating enzymes 
(DUBs), a specific group of proteases. Some DUBs associate with their substrate and trim 
the ubiquitin chain, others remove the entire chain, highlighting that ubiquitination is not 
necessarily a terminal process (Komander et al., 2009). 
Several proteins were identified that are structurally very similar to ubiquitin. These 
ubiquitin-like (Ubl) post-translational modifiers include, amongst others, SUMO (small 
ubiquitin-related modifier) and NEDD8. SUMO and NEDD8 are also attached to lysine 
residues of proteins and function as regulators of many cellular processes including DNA 
repair and signal transduction (Kerscher et al., 2006). 
1.1.2 The 26S proteasome 
The degradation of polyubiquitinated substrates is mediated by the 26S proteasome, which 
is located in the cytosol and nucleus of all eukaryotic organisms. The 26S proteasome is a 
multimeric enzyme complex consisting of the catalytically active 20S core particle capped 
by either one or two 19S regulatory particles (Voges et al., 1999). 
The 20S has a barrel-formed structure built by two α- and two β-heteroheptameric rings. 
The proteolytic active sites of the proteasome with chymotryptic-, tryptic-, and caspase-
like activities are located on the interior surface of the β-rings thereby shielding the 
protease activity from the environment to prevent unspecific proteolysis. The two α-rings 
are positioned at the outside and form an antechamber to the central catalytic chamber. 
The 19S regulatory particle is composed of a base and a lid. The lid mediates binding and 
deubiquitination of the substrate whereas the base with its AAA-ATPases (ATPase 
associated with diverse cellular activities) is important for the unfolding of the substrate 
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and opening of the outer α-ring of the 20S core particle to allow translocation into the 
catalytic chamber for degradation (Pickart and Cohen, 2004). 
1.2 The ubiquitin-proteasome system in transcriptional regulation 
Besides its general role in protein turnover, ubiquitination has been implicated in several 
biological processes such as DNA damage, receptor internalization, ribosome function and 
transcriptional regulation. Ubiquitination affects transcription on multiple levels thereby 
regulating, for instance, chromatin structure and transcription factor activity. 
1.2.1 Regulation of chromatin structure by ubiquitin  
The first identified ubiquitinated protein was the histone H2A (Goldknopf et al., 1975). 
Monoubiquitination of H2A is a highly abundant modification in mammalian cells and is 
associated with transcriptional repression. The polycomb protein RING1B was the first 
identified ubiquitin ligase that modifies H2A at K119 (Wang et al., 2004). Recently, it has 
been reported that monoubiquitination of H2A (H2Aub) stimulates H3K27 trimethylation 
on H2Aub nucleosomes, a chromatin mark associated with transcriptional silencing (Kalb 
et al., 2014). 
In contrast to H2Aub, monoubiquitination of H2B (H2Bub) has been mainly implicated in 
transcriptional activation. In yeast, H2Bub is required for H3K4 di- and trimethylation, an 
active mark for transcription. Moreover, H2Bub stimulates the activity of the histone 
chaperone FACT (facilitates chromatin transcription), which displaces H2A/H2B dimers in 
front of the elongating RNA polymerase II and reassembles them again, enabling efficient 
transcription (Pavri et al., 2006). Additionally, deubiquitination of H2B, which can be 
mediated by the DUB activity of the SAGA coactivator complex or the recently described 
DUB USP42, can stimulate transcription. This results in a model in which active cycling of 
ubiquitination and deubiquitination of H2B is required for efficient transcriptional 
activation (Chandrasekharan et al., 2010; Hock et al., 2014; Zhang et al., 2008). 
1.2.2 Role of the proteasome and proteasomal subunits in transcriptional 
regulation 
Genome-wide studies in yeast revealed that proteasomal subunits associate with highly 
transcribed genes (Auld et al., 2006). Interestingly, several genes were either bound by 20S 
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or 19S subunits of the proteasome suggesting that the subcomplexes mediate different 
functions at different promoters (Sikder et al., 2006). 
A role for the 19S particle in transcriptional regulation has been described for the HIV-1 
transactivator TAT. Ubiquitination of TAT by HDM2 stimulates its transcriptional activity 
without leading to proteasomal degradation. Moreover, TAT stimulates dissociation of the 
proteasome into the 19S and 20S particles and recruits the 19S subunit to the HIV-1 
promoter where it facilitates transcriptional elongation (Brès et al., 2003). Other studies in 
yeast have reported a role of a 19S subcomplex in transcriptional regulation. This 
subcomplex is called APIS (AAA-ATPases of the proteasome independent of 20S) and 
consists of the ATPase subunits. APIS is recruited to actively transcribed genes in yeast to 
stimulate efficient transcriptional elongation (Ferdous et al., 2001; Gonzalez et al., 2002). 
The 26S proteasome was detected in regions of transcribed genes with an accumulation of 
RNA polymerase II at the 3’end of genes and at possible pausing sites of RNA polymerase 
II raising the possibility that the proteasome functions at these sites to resolve stalled RNA 
polymerase elongation complexes (Gillette et al., 2004). 
A more recent study reported that the entire 26S proteasome is recruited to active sites of 
transcription and that there were no differences in 19S or 20S occupancy. The authors 
suggested that in some cases the chaperone function of the 19S base is required for gene 
expression whereas in other cases the proteolytic function of the proteasome is important 
(Geng and Tansey, 2012). Nevertheless, the proteasome does not seem to mediate the same 
function at all promoters. Inhibition of proteasomal function in yeast resulted in an 
activation of genes involved in mitochondrial function and stress response whereas histone 
genes and genes involved in protein synthesis were downregulated (Auld et al., 2006; 
Dembla-Rajpal et al., 2004; Fleming et al., 2002). 
1.2.3 Proteolytic function 
The most obvious way, in which the UPS affects transcription in a proteolytic manner, is 
by degrading the transcriptional regulator, thereby reducing its abundance in the cell and 
limiting its transcriptional activity. One example is β-catenin, which becomes 
phosphorylated and degraded in the absence of WNT signaling. Active WNT signaling 
leads to loss of this phosphorylation and thus stabilizes β-catenin, leading to the activation 
of transcription (Hart et al., 1999). 
 13 
 
Introduction 
 
  
Importantly, ubiquitin-mediated proteolysis of a transcriptional activator can also have a 
stimulating effect on its activity. This more counterintuitive idea was first based on the 
observation that several transcriptional activators are unstable proteins whose activities 
correlate with protein turnover (Molinari et al., 1999; Wang et al., 2010). Moreover, the 
transactivation domain of an activator often overlaps with its degron, a sequence directing 
protein degradation (Salghetti et al., 2000). 
Activity of the yeast transcriptional activator Gcn4 depends on the E3 ligase SCF-CDC4. 
Influencing Gcn4 turnover by mutating either the E3 ligase or inhibiting proteasomal 
activity resulted in a reduced transcriptional activity (Lipford et al., 2005). Interestingly, 
activator turnover is often mediated by phosphorylation and the corresponding kinases can 
be subunits of the transcription machinery. The general transcription factor TFIIH, one 
component of the preinitiation complex, phosphorylates the androgen receptor (AR). This 
phosphorylation is a key step in transactivation, leading to ubiquitination and proteasomal 
degradation of AR at promoters. The turnover of AR is required for efficient transcription 
and mutations of the phosphorylation site disrupted its transactivation potential 
(Chymkowitch et al., 2011). 
What is the biological significance of coupling proteasomal turnover to efficient 
transactivation? Degradation of a transcriptional activator could ensure that an activator 
stimulates only one round of transcription. Turnover could also limit the time an activator 
spends at a promoter and at the same time ensure that only a persistent signal can lead to 
multiple rounds of activation (Geng et al., 2012). A similar mechanism has been described 
for SRC-3, a coactivator of nuclear receptors. SRC-3 is ubiquitinated by SCF-FBW7 in a 
phosphorylation-dependent manner. Monoubiquitination of SRC-3 initially stimulates 
transcriptional activity, but it becomes degraded once the ubiquitin is extended to an 
ubiquitin chain. It was suggested that the ubiquitination functions as a “transcriptional time 
clock”, defining a certain time window in which the coactivator functions (Wu et al., 
2007). 
 
But why is turnover in some cases required to stimulate transcription? Deshaies and 
colleagues described some mechanisms how degradation might be necessary for gene 
expression. First, activator turnover could help to disrupt the preinitiation complex (PIC) 
and enable RNA polymerase II to leave the promoter and transcribe the gene (Fig. 1.2 B). 
Second, a preinitiation complex needs to be reassembled after each round of transcription 
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and activator turnover helps to clear the promoter (Fig. 1.2 A) (Lipford and Deshaies, 
2003). Tansey and colleagues extended this model by including phosphorylation of the 
activator. The phosphorylation by kinases of the transcriptional machinery could mark the 
activator as “used up”, keeping it inactive and unable to stimulate further rounds of 
transcription. The removal by proteasomal degradation would clear the promoter making it 
accessible for a new preinitiation complex (Geng et al., 2012) (Fig. 1.2). 
 
 
Figure 1.2: Model for stimulation of gene expression by activator turnover  
Proteasomal turnover of a transcriptional activator can help to release RNA polymerase II by 
disrupting the preinitiation complex (PIC) (1). Activator turnover can help to clear the promoter 
from a “spent” PIC (2). In both scenarios, phosphorylation of the activator by kinases of the 
transcription machinery can induce the turnover. (GTF, general transcription factor; TF, 
transcription factor; RNAPII, RNA polymerase II) Adapted from (Geng et al., 2012; Lipford and 
Deshaies, 2003). 
 
1.2.4 Non-proteolytic function 
Ubiquitination of a transcription factor can influence its activity independently of its 
proteasomal turnover. Several studies have established that ubiquitination affects cellular 
localization and chromatin association of transcription factors. One example is the 
transcription factor FOXO4, which becomes monoubiquitinated after oxidative stress, 
resulting in nuclear translocation and activation of FOXO4-dependent genes.  
Interestingly, oxidative stress also enhances the binding of the DUB USP7 to FOXO4, 
leading to its deubiquitination and nuclear exclusion. FOXO4 is then available for another 
round of activating monoubiquitination (van der Horst et al., 2006). In this way, the cells 
ensure that only a persistent signal leads to multiple rounds of activation, highlighting how 
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the interplay between ubiquitination and deubiquitination tightly regulates a cellular 
response. 
Several different mechanisms have been described for the negative control of transcription 
factor activity by ubiquitination. One transcription factor, for which different mechanisms 
have been established, is the yeast transcription factor Met4. Met4 regulates a set of genes 
involved in sulfur metabolism (MET genes), when methionine levels are low. During 
culture in rich medium, when sufficient organic sulfur sources are present, Met4 becomes 
ubiquitinated and MET genes are not activated. However, this ubiquitination does not 
result in proteasomal degradation. Instead, the ubiquitin chain blocks recruitment of a 
cofactor thereby inhibiting the function of Met4 (Kaiser et al., 2000). Another group 
proposed a different mechanism how ubiquitination of Met4 prevents activation of MET 
genes. Kuras et al. demonstated that Met4 ubiquitination triggers its recruitment to a 
different set of promoters resulting in the expression of SAM genes. The SAM genes are 
required for the synthesis of S-adenosylmethionine, which is not present in rich medium 
but can be produced from methionine (see Fig. 1.3 A) (Kuras et al., 2002). Recently, a 
mechanism has been described, how ubiquitination of Met4 might prevent it from binding 
to promoters of MET genes to maintain repression. Cdc48 is an ubiquitin-selective 
chaperone that belongs to the AAA-ATPase protein family. It possesses segregase activity 
and uses the energy of ATP hydrolysis to remove ubiquitinated proteins from binding 
partners or cellular structures (Dantuma and Hoppe, 2012; Rape et al., 2001). Cdc48 is 
involved in regulation Met4 promoter occupancy by stripping ubiquitinated Met4 off the 
MET gene promoters. With this non-proteolytic mechanism, the cell keeps Met4 level 
constant and is thereby able to quickly respond to changes in methionine levels (Ndoja et 
al., 2014) (see Fig. 1.3 B). 
How Cdc48 regulates promoter occupancy of ubiquitinated transcription factors was first 
described for the yeast transcriptional repressor MATα2, an important regulator of mating 
type switching. Upon the signal for mating type switching, MATα2 becomes 
polyubiquitinated leading to removal of the transcriptional repressor from chromatin and 
subsequent proteasomal degradation. Extraction of MATα2 terminates its repressive 
function and mating type switching can occur (Wilcox and Laney, 2009). 
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Figure 1.3: Mechanisms how ubiquitination of a transcription factor affects its chromatin 
association 
Ubiquitination of a transcription factor can affect its chromatin association in multiple ways. It can 
help to recruit it to certain promoters (A), it can lead to extraction of the activator from chromatin 
by the AAA-ATPase p97 (B) or monoubiquitination can prevent the removal from chromatin by 
the 19S base particle of the proteasome (C). 
 
In human cells it was described that p97 (the mammalian Cdc48 orthologue) prevents 
DNA-binding of ubiquitinated receptor-activated SMADs (R-SMADs) thereby attenuating 
TGF-β signaling. Upon TGF-β signaling, R-SMADs get deubiquitinated by USP15. This 
prevents the ubiquitin-dependent extraction from chromatin and transcriptional activation 
of TGF-β-R-Smad target genes (Inui et al., 2011). 
In contrast to ubiquitin-dependent removal of transcription factors from promoters, 
monoubiquitination of the yeast transcriptional activator Gal4 is required to retain it on 
chromatin highlighting the diverse effects of transcription factor ubiquitination on 
chromatin association (see Fig. 1.3 C) (Archer et al., 2008). 
1.3 The oncogenic transcription factor MYC 
The proto-oncogene c-MYC was originally identified as a cellular homolog of the viral 
oncogene v-myc, which induces myelocytomatosis in chickens (Sheiness and Bishop, 
1979). c-MYC is highly conserved during evolution and expressed in all vertebrates as 
well as Drosophila melanogaster and the Northern sea star Asterias vulgaris (Gallant et al., 
1996; Walker et al., 1992). 
In addition to c-MYC, the MYC protein family includes N-MYC and L-MYC. The gene 
encoding for L-MYC was identified as a c-MYC-related gene being amplified in small cell 
lung cancer whereas the N-MYC encoding gene is amplified in neuroblastoma cell lines 
and primary tumors (Nau et al., 1985; Schwab et al., 1983). 
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The majority of c-MYC transcripts are initiated at two promoters (Wierstra and Alves, 
2008). The alternative translation initiation start sites result in the expression of different 
isoforms. Translation starting from a CUG start codon produces the minor isoform p67 
with 454 amino acids whereas translation at the AUG in the second exon results in the 
expression of the shorter isoform p64 with 439 amino acids (Blackwood et al., 1994; Hann 
et al., 1988). The c-MYC p64 isoform is the predominant form and will be hereafter 
referred to as “MYC”. 
MYC expression is deregulated in a wide variety of, if not all, human cancers. In Burkitt’s 
lymphoma, chromosomal translocation of the MYC gene to one of the immunoglobulin 
enhancer loci leads to elevated MYC expression (Taub et al., 1982). Amplifications of the 
MYC gene have been observed in different solid tumors such as prostate and mammary 
carcinoma (Escot et al., 1986; Jenkins et al., 1997). Moreover, activation of upstream 
pathways can lead to increased expression of MYC. In colorectal cancer for example, 
activation of the WNT/β-catenin pathways results in an increased MYC transcription (He et 
al., 1998). Furthermore, MYC protein stability is increased in several malignancies (see 
1.3.5), highlighting that different mechanism can result in deregulated MYC expression. 
1.3.1 Structural and functional domains of MYC 
MYC is a member of the basic helix-loop-helix leucine zipper transcription factor family 
with an amino-terminal acidic-type transregulatory and a carboxy-terminal DNA-binding 
and dimerization domain. MYC contains several conserved domains, called MYC boxes 
(MB), which are also found in the related proteins N- and L-MYC. 
 
Figure 1.4: Schematic domain structure of MYC 
MYC contains a N-terminal transregulatory domain (TRD, green box), several conserved MYC 
boxes (yellow boxes, MYC box I – IV) and a nuclear localization signal (NLS). The C-terminal 
basic region helix-loop-helix/leucine zipper domain (BR-HLH/LZ, blue boxes) mediates DNA-
binding and dimerization. The PEST sequence and D element are located in the central part of the 
protein. Identified interaction sites of E3 ligases or their substrate recognition subunits targeting 
MYC are illustrated in the lower part of the figure. Adapted from (Farrell and Sears, 2014). 
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MBI and MBII are located within the N-terminal transregulatory domain (TRD), which is 
required for transcriptional activation and repression (Kato et al., 1990; Lee et al., 1996). 
One important function of MBI is the regulation of MYC stability. Phosphorylation of 
threonine-58 and serine-62 within MBI mediate proteasomal degradation of MYC (Sears et 
al., 1999; 2000). MBII serves as an interaction platform for multiple proteins important for 
MYC-mediated gene regulation. Cofactors like TRRAP (transactivation/transformation-
associated protein), an adaptor protein that recruits the histone acetyltransferase GCN5 to 
MYC, interact with MYC via MBII (McMahon et al., 1998; 2000). MBIIIa is important for 
transcriptional repression by MYC and inhibits apoptosis thereby increasing 
transformation capability (Herbst et al., 2005). MBIIIb was recently described to be 
important for the interaction with WDR5, a protein that mediates MYC recruitment to 
chromatin (Thomas et al., 2015). The so-called D-element, a region important for 
ubiquitin-independent proteolysis of MYC, overlaps with MBIIIa (Herbst et al., 2004). In 
addition to the D-element, MYC contains the central PEST sequence, which is also 
important for MYC degradation. The PEST sequence is rich in the amino acids proline (P), 
glutamic acid (E), serine (S) and threonine (T) and deletion of this element stabilizes MYC 
without affecting its ubiquitination (Gregory and Hann, 2000). For N-MYC it has been 
reported that MBIV is involved in the regulation of apoptosis, DNA binding and 
transformation capability (Cowling et al., 2006). Moreover, MYC carries a canonical 
lysine-rich nuclear localization signal (NLS) (Dang and Lee, 1988). The carboxy-terminal 
basic region (BR) is important for sequence-specific DNA-binding and the helix-loop-
helix/leucine zipper domain (HLH/LZ) mediates dimerization with other HLH/LZ 
containing proteins like MAX (MYC-associated factor X) (Blackwood and Eisenman, 
1991). In addition, this region also mediates interaction with the transcription factor MIZ1 
(MYC-interacting zinc finger protein 1) and the histone acetyltransferases p300 and CBP 
(Peukert et al., 1997; Vervoorts et al., 2003). 
1.3.2 Biological functions and transcriptional regulation by MYC 
MYC is required for normal embryonic development. Homozygous deletion of MYC is 
embryonically lethal, probably due to defects in the placenta (Davis et al., 1993; Dubois et 
al., 2008). Conditional MYC deletion in the epiblast revealed a requirement for MYC in 
the hematopoietic system underlining the importance of MYC for normal development 
(Dubois et al., 2008). 
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MYC can activate and repress gene expression and thereby affects many different 
biological processes. Moreover, MYC regulates transcription by all three RNA 
polymerases. Besides regulating RNA polymerase II targets, MYC can promote expression 
of ribosomal RNAs transcribed by RNA polymerase I and of tRNAs and 5S rRNA 
transcribed by RNA polymerase III (Arabi et al., 2005; Gomez-Roman et al., 2003; 
Grandori et al., 2005; Steiger et al., 2008). 
Thus, MYC regulates a huge set of target genes and thereby affects many different 
biological processes ranging from proliferation and cell growth to apoptosis (Eilers and 
Eisenman, 2008). 
Recently, it was described that, rather than being a specific transcriptional regulator, MYC 
functions as a general transcriptional amplifier that globally enhances transcription (Lin et 
al., 2012; Nie et al., 2012). 
1.3.2.1 Transcriptional activation by MYC 
In order to activate gene transcription MYC heterodimerizes with its partner protein MAX 
and the MYC/MAX dimer binds to specific DNA sequences, the E-boxes, which can be 
either canonical (CACGTG) or non-canonical (CANNTG, where N can be any nucleotide) 
(Blackwell et al., 1993; Blackwood and Eisenman, 1991). MYC occupies almost all open 
promoters and binding correlates with trimethylated H3K4 (Guccione et al., 2006). 
Recently, it has been demonstrated that the interaction of MYC with WDR5 is important 
for recruitment of MYC to chromatin (Thomas et al., 2015). To induce transcription, MYC 
recruits many co-activators, such as p300 or the adaptor protein TRRAP, a core subunit of 
several macromolecular complexes that contain the histone acetyltransferases (HAT) 
GCN5 or TIP60 (see Fig. 1.5). The recruitment of HATs by MYC to its target promoters 
results in an increase of H3 and H4 acetylation that further opens the chromatin structure 
and enables transcriptional activation (Bouchard et al., 2001; Frank et al., 2003; McMahon 
et al., 2000). Examples of other MYC-recruited cofactors are the ATPases TIP48 and 
TIP49, which possess helicase activity and are part of several chromatin remodeling 
complexes (Wood et al., 2000). 
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Figure 1.5: Transcriptional activation by MYC 
Schematic illustration of MYC-mediated transactivation of target genes. The MYC-MAX 
heterodimer binds to E-box sequences within open promoters with H3K4 trimethylated histones 
and recruits coactivators. The coactivors induce H3 and H4 acetylation and chromatin remodeling. 
The recruitment of P-TEFb leads to RNA polymerase II (RNAPII) Ser2 phosphorylation and 
subsequent productive elongation. 
 
Moreover, MYC regulates transcriptional activation by interacting with components of the 
transcription apparatus and thereby affecting different steps in the transcription cycle. 
The transcription cycle is a multistep process involving several different proteins and is 
regulated at multiple steps. First, RNA polymerase II (RNAPII) is recruited to the 
promoter in a hypophosphorylated state and together with general transcription factors 
(GTFs) forms the pre-initiation complex. The promoter acquires an open conformation and 
transcription initiation starts with the transcription of short, unstable transcripts. RNAPII 
contains a highly repetitive carboxy-terminal domain (CTD) with the conserved motif 
Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (YSPTSPS). The mammalian RNAPII contains 52 
of these repeats. Early in the transcription cycle, RNAPII gets phosphorylated at Ser7 and 
Ser5 primarily by the CDK7 subunit of TFIIH. Even though the role of Ser7 
phosphorylation is less studied, the function of Ser5 phosphorylation is well understood. 
Phosphorylation of this site is stimulated by the Mediator complex, a conserved 
multiprotein complex, triggering promoter clearance. It stimulates the recruitment of the 
5’end capping machinery to the nascent mRNA. Once the short transcripts acquire a 
certain length, the RNAPII escapes from the promoter, defining the transition from 
intitiation to productive elongation (Heidemann et al., 2013; Shandilya and Roberts, 2012; 
Svejstrup, 2004). 
MYC stimulates the recruitment of RNAPII to promoters and mediates Ser5 
phosphorylation of the CTD by recruiting TFIIH and Mediator in a MBII-dependent 
manner (Bouchard et al., 2004; Walz et al., 2014). 
The transition to productive elongation is often delayed by promoter-proximal pausing. 
RNAPII remains associated with the nascent RNA transcript but requires further signals to 
 21 
 
Introduction 
 
  
resume elongation. The RNAPII is held in the pausing state by the negative elongation 
factor NELF, a protein with four subunits (A, B, C/D and E) and DSIF (DRB sensitivity-
inducing factor), consisting of the proteins SPT4 and SPT5. The paused state of RNAPII 
may also be maintained by additional proteins (Adelman and Lis, 2012). The release of 
RNAPII into productive elongation requires phosphorylation of Ser2 within its CTD. In 
mammals, Ser2 is primarily phosphorylated by the positive elongation factor P-TEFb. 
Besides phosphorylating RNAPII, P-TEFb also phosphorylates DSIF, leading to the 
dissociation of NELF from the complex and turning DSIF from a negative into a positive 
elongation factor, which remains associated with the elongating RNAPII through the gene 
(Adelman and Lis, 2012). Ser2 phosphorylation functions as a recruitment signal for 
several positive elongation and splicing factors. Moreover, 3’end processing factors and 
factors being important for mRNA export are also recruited by the Ser2-phosphorylated 
polymerase (Heidemann et al., 2013). 
MYC regulates transcriptional elongation by interacting with P-TEFb (Eberhardy and 
Farnham, 2002). The release of elongating RNAPII from a paused state is thought to be a 
key mechanism for MYC-driven transactivation (Bouchard et al., 2004; Rahl and Young, 
2014; Rahl et al., 2010; Walz et al., 2014). 
 
Whether MYC acts as a general amplifier, as it has been described for MYC in activated 
B-cells, or as a transcription factor with a specific set of target genes might depend on the 
cellular context and MYC levels. 
Recently, it has been described that promoter affinities and MYC level play an important 
role whether MYC activates gene expression profiles of normal proliferating cells or 
oncogenic signatures. Promoters with high-affinity binding sites, representing mostly 
physiological targets, are already saturated in normal proliferating cells. An increase in 
MYC level leads to an enhanced occupancy of low affinity promoters, which results in 
activation of oncogenic gene expression profiles (Walz et al., 2014). Moreover, high MYC 
levels lead to an invasion of enhancers, potentially increasing its transcriptional output (Lin 
et al., 2012; Sabò et al., 2014b). 
1.3.2.2 Transcriptional repression by MYC 
In addition to directly activating transcription, MYC can downregulate gene expression 
either in a direct or indirect manner. A mechanism for indirect MYC-mediated 
transcriptional repression is the induction of specific microRNAs (miRNAs). MYC 
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regulates the expression of miR17-92, which in turn represses proteins important for 
induction of senescence or apoptosis, thereby maintaining a survival program (Li et al., 
2014). 
To directly repress gene expression independent of another transcription factor, MYC 
recruits the histone deacetylase 3 (HDAC3) in a MBIII-dependent manner to E-box 
containing promoters, thereby reducing H3 and H4 acetylation (Kurland and Tansey, 
2008). 
Another mechanism for MYC-mediated transcriptional repression operates via the 
interaction with other transcription factors like MIZ1 or SP1 (Gartel et al., 2001; Peukert et 
al., 1997). In this context, MYC displaces co-activators and recruits co-repressors, such as 
HDACs or DNA methyltransferases (e.g. DNMT3a) (Brenner et al., 2005; Staller et al., 
2001). 
Interestingly, the repressive MYC-MIZ1 complex does not only lead to repression of 
MIZ1-induced target genes but also attenuates MYC-mediated activation. The ratio of 
MYC-MIZ1 complexes at promoters determines the direction of the transcriptional output 
(Walz et al., 2014). In cellular systems with low levels of MYC, MIZ1 acts as a sequence-
specific transcription factor that binds to a MIZ1-binding motif and activates, among 
others, genes involved in autophagy (Wolf et al., 2013). These MIZ1-binding sites possess 
a low MYC/MIZ1 ratio, meaning more MIZ1 is bound than MYC and are regulated by 
MIZ1 but not by MYC. Elevated MYC level lead to the cooperative binding of MIZ1 to 
many MYC-regulated promoters, which dampens the transcriptional response to MYC 
(Walz et al., 2014; Wiese et al., 2015; 2013). 
1.3.3 Regulation of MYC expression and functionality 
Since MYC regulates many different biological processes and can contribute to almost all 
aspects of tumor development and tumor maintenance it is absolutely critical for a cell to 
keep MYC function and levels tightly regulated. This regulation occurs on multiple levels 
ranging from regulation of MYC mRNA expression to regulation of MYC function and 
stability by posttranslational modifications. 
1.3.3.1 Transcriptional and post-transcriptional regulation of MYC 
Transcription of the MYC gene is tightly regulated at the level of transcription initiation 
and elongation and the MYC promoter is bound by many different transcription factors, 
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which are regulated by multiple signal transduction cascades including WNT, MAPK and 
TGFβ (Levens, 2010). Interestingly, BRD4, a BET bromodomain protein, is a 
transcriptional co-activator of MYC and inhibition of BRD4 leads to downregulation of 
MYC expression (Delmore et al., 2011). BRD4 and Mediator co-occupy many enhancers of 
actively transcribed genes. A selected group of bound enhancers, the so-called stretch- or 
super-enhancers, are up to 50 kb large and bind high levels of Mediator and BRD4. Super-
enhancers can act on oncogenes including MYC (Lovén et al., 2013). Inhibition of BRD4 
preferentially disrupts super-enhancers, making BRD4 inhibitors such as JQ1 attractive 
drugs to target MYC expression (Delmore et al., 2011; Filippakopoulos et al., 2010). 
MYC mRNA is relatively unstable with a half-life of approximately 20 min "#$%&!'(!$)*+!,-./0. Translation of MYC is regulated by several mechanisms including IRES-dependent 
translation and miRNAs-dependent pathways (Carter et al., 1999; Kress et al., 2011; 
Sachdeva et al., 2009; Sampson et al., 2007). 
1.3.3.2 Post-translational regulation of MYC 
The MYC protein is targeted by different post-translational modifications, including 
acetylation, phosphorylation and ubiquitination, which have various effects on MYC 
function and protein stability. 
1.3.3.2.1 Acetylation 
For efficient transcriptional activation, MYC recruits different HATs to promoters and 
induces histone acetylation (see 1.3.2.1). However, MYC does not only recruit these 
cofactors to promoters but is itself a substrate of HATs, such as GCN5, TIP60 and 
p300/CBP.  
CBP acetylates MYC in vitro and in cells and overexpression of CBP leads to reduced 
ubiquitination of MYC and increased protein stability (Vervoorts et al., 2003). Acetylation 
of MYC by TIP60 and GCN5 increases the half-life of MYC (Patel et al., 2004). Lysines 
of mouse MYC, which are acetylated by GCN5, have been mapped in vivo and include 
K149 close to MBII, K323 in the NLS and K417 in the leucine zipper domain. Several 
lysines of human MYC are acetylated by p300 (K143, K148, K157, K275, K317, K323, 
K371). In contrast to other HATs, acetylation by p300 increases MYC protein turnover 
(Faiola et al., 2005; Zhang et al., 2005). Whether acetylation of MYC might mediate 
protein-protein interactions or influence MYC function in another way is still unknown. 
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1.3.3.2.2 Sumoylation 
Sumoylation is another post-translational modification of proteins, which, similar to 
ubiquitin, targets lysine residues. Sumoylation of proteins can have various effects. It can 
affect the cellular localization of a protein, interfere with the binding of another protein or 
serve as an interaction platform (Geiss-Friedlander and Melchior, 2007). MYC and N-
MYC are sumoylated with K349 being the major SUMO-acceptor site in N-MYC and 
K326 or K323 being the major acceptor site in MYC. Sumoylation of the endogenous N-
MYC protein could be detected after heat shock but had no effect on stability or activity of 
the protein (Sabò et al., 2014a). 
The MYC sumoylation site K326 was also identified by mass spectrometry of transfected 
MYC. However, mutation of the SUMO acceptor site had no effect on MYC half-life or 
activity (Kalkat et al., 2014). Therefore, it remains unresolved, whether sumoylation of 
MYC influences its biological activity in some contexts. 
1.3.3.2.3 Phosphorylation 
MYC is a well-established phosphoprotein and phosphorylation sites in MYC can be found 
all over the protein. The first identified phosphorylation sites in MYC are clusters of 
residues that reside within the PEST domain (T247/T248/S249/S250/S252) and near the 
BR (T343/S344/S347/S348), which are modified by the casein kinase 2 (CK2) (Lüscher et 
al., 1989). Although the functional relevance of these phosphorylation events remains 
unclear, it was suggested that CK2 phosphorylation in the PEST domain stabilizes MYC 
(Channavajhala and Seldin, 2002). Phosphorylation of the cluster close to the BR affects 
the transformation capability of MYC, since mutation of these sides to alanine result in 
gain-of-function alleles with increased transforming activity (Wasylishen et al., 2013). 
Besides these phosphorylation sites in the central and C-terminal part of MYC, several 
sites are located within the TRD. The kinase ABL phosphorylates up to five tyrosine 
residues with the major site being Y74. MYC phosphorylated at Y74 resides in the 
cytoplasm and its presence correlates with ABL activity in tumors. Nevertheless, the 
precise function of phospho-Y74 MYC in the cytoplasm remains open (Sanchez-Arévalo 
Lobo et al., 2013). S62 and S71 can be phosphorylated by c-Jun N-terminal kinase (JNK) 
and these phosphorylation events promote MYC-induced apoptosis (Noguchi et al., 1999). 
Several other phosphorylation sites in MYC have been mapped but the best characterized 
sites are T58 and S62, which are located in MBI (Alvarez et al., 1991; Henriksson et al., 
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1993). Different growth-stimulating signal transduction pathways regulate these 
phosphorylation events and S62 was shown to be phosphorylated by the Ras-activated 
mitogen-activated kinase (MAPK) (also known as extracellular signal-regulated kinases, 
ERK), which has a stabilizing effect on MYC (Sears et al., 2000). Whether S62 
phosphorylation strictly depends on MAPK in vivo remains unclear (Lutterbach and Hann, 
1999), since S62 can also be phosphorylated by CDK2 (Hydbring et al., 2010). 
T58 and S62 phosphorylation are interdependent because phosphorylation of T58 by the 
glycogen synthase kinase 3 β (GSK3β) requires the priming phosphorylation at S62 
(Gregory et al., 2003; Lutterbach and Hann, 1994). The prolyl isomerase PIN1 isomerizes 
MYC, enabling the protein phosphatase 2A (PP2A) to dephosphorylate MYC at S62 (Yeh 
et al., 2004). The dephosphorylation of S62 is required for subsequent proteasomal 
degradation of T58-phosphorylated MYC, because this phosphorylation site functions as a 
phosphodegron and is recognized by the ubiquitin ligase SCF-FBW7 (Welcker et al., 
2004b; Yada et al., 2004). 
1.3.3.2.4 Ubiquitination 
Several different ubiquitin ligases have been identified that target MYC (Farrell and Sears, 
2014). Ubiquitination can have various effects and either inhibit or promote proteasomal 
degradation and either stimulate or inhibit MYC transcriptional activity. 
FBW7 (F-box and WD40 repeat domain-containing 7) is a substrate specificity factor of 
the SCF ubiquitin ligase complex and one of the best-studied ubiquitin ligases targeting 
MYC. As mentioned previously, FBW7 is a tumor suppressor protein that recognizes 
phosphorylated T58 in MBI leading to MYC ubiquitination and subsequent proteasomal 
degradation (Welcker et al., 2004a; Yada et al., 2004). FBW7 was also shown to 
ubiquitinate MYC in vitro (Welcker et al., 2004b). Mutations in the phosphodegron 
recognized by FBW7 (T58) are found in Burkitt’s lymphomas and are associated with 
increased MYC stability (Bahram et al., 2000; Gregory and Hann, 2000). FBW7 exists in 
three isoforms (α, β, γ) that differ in their cellular localization. FBW7α is a nuclear protein 
and FBW7γ is present in the nucleolus. Both isoforms mediate proteasomal degradation of 
MYC. FBW7β is cytosolic and not involved in MYC degradation (Welcker et al., 2004a).  
Several other ubiquitin ligases were identified that target MYC for proteasomal 
degradation, including FBX29, TRIM32, TRUSS, PIRH2 and CHIP (Farrell and Sears, 
2014). FBX29 is a substrate recognition factor of an SCF-like ubiquitin ligase, consisting 
of the scaffold protein CUL7, the RING finger protein ROC1 and SKP1 (Dias et al., 2002). 
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It was identified as a MYC-interacting protein using a mass spectrometry approach. 
Overexpression of FBX29 reduces MYC level and inhibits MYC transcriptional activity 
(Koch et al., 2007). TRIM32 is a RING-finger ubiquitin ligase promoting MYC 
proteasomal turnover in neuronal progenitor cells to induce neuronal differentiation 
(Schwamborn et al., 2009). Another ubiquitin ligase for MYC identified in a proteomic 
approach is TRUSS (tumor necrosis factor receptor-associates ubiquitous scaffolding and 
signaling protein), an adaptor protein for the CUL4-DDB1 (damage-specific DNA-binding 
protein 1) ubiquitin ligase complex (Lee and Zhou, 2007). Initially identified as a binding 
partner for N-MYC, TRUSS ubiquitinates both, MYC and N-MYC. As FBW7 and 
TRIM32, TRUSS appears to be a negative regulator of MYC activity, leading to its 
ubiquitination and proteasomal degradation (Choi et al., 2010). The ubiquitin ligase PIRH2 
also mediates MYC ubiquitination and proteasomal degradation. (Hakem et al., 2011). 
Recently, the carboxyl terminus of HSC70-interacting protein (CHIP) has been described 
as an ubiquitin ligase targeting MYC for proteasomal degradation, resulting in decreased 
MYC target gene induction (Paul et al., 2013). 
Ubiquitination of MYC by SCF-β-TrCP does not mediate proteasomal turnover but instead 
stabilizes MYC (Popov et al., 2010). Ubiquitination and thus stabilization of MYC by β-
TrCP is required for a cell-cycle reentry after S-phase arrest. PLK1 (polo-like kinase 1) 
phosphorylates MYC in a region between amino acids 278 to 283, creating a 
phosphodegron that is bound by β-TrCP. Moreover, β-TrCP assembles heterotypic non-
proteolytic ubiquitin chains at the amino-terminus of MYC thereby stabilizing MYC and 
preventing the assembly of degrading K48 ubiquitin chains by FBW7. 
The ubiquitin ligase HUWE1 (HECT, UBA and WWE containing 1) belongs to the 
HECT-E3 ubiquitin ligases and ubiquitinates MYC in vivo and in vitro (Adhikary et al., 
2005). Six lysine residues of MYC, overlapping with the NLS, were shown to be modified 
by HUWE1 with K63-linked ubiquitin chains. Similar to β-TrCP, this ubiquitination does 
not lead to proteasomal degradation of MYC but is important for its transcriptional activity 
by promoting recruitment of the coactivator p300 (Adhikary et al., 2005). HUWE1 does 
not only ubiquitinate MYC but also N-MYC and MIZ1, leading to their proteasomal 
degradation (Inoue et al., 2013; Yang et al., 2010; Zhao et al., 2008a). A recent paper 
demonstrates that HUWE1 antagonizes the assembly of MYC/MIZ1 repressive complexes 
at MYC-responsive genes by degrading MIZ1 and thereby preventing a decreases in the 
transcriptional response (see 1.3.2.2) (Peter et al., 2014). In colon carcinoma cell lines, 
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inhibition of HUWE1 by small molecules resulted in a stabilization of MIZ1 and a 
subsequent accumulation of MYC/MIZ1 repressive complexes at growth associated MYC 
target genes preventing their activation. This suggests that MYC function can be targeted 
by inhibition of ubiquitin ligases (Peter et al., 2014; Schaub and Cleveland, 2014). 
Another E3 ligase which ubiquitinates MYC without leading to its proteasomal 
degradation is SCF-FBXO28, whose activity is cell cycle-regulated. Phosphorylation by 
cyclin-dependent kinase 1/2 (CDK1/2) activates the F-box protein FBXO28 and active 
SCF-FBXO28 ubiquitinates MYC at the S- and G2/M-phases of the cell cycle and 
stimulates its transcriptional activity by promoting p300 recruitment (Cepeda et al., 2013). 
In contrast to other ligases, which stimulate MYC transcriptional activity, ubiquitination by 
SCF-SKP2 (S-phase kinase-associated protein 2) leads to proteasomal turnover of MYC 
but at the same time stimulates its activity (Kim et al., 2003; Lehr et al., 2003). This effect 
is dependent on the F-box domain of SKP2, suggesting that ubiquitin ligase activity is 
required for the stimulating effect on MYC function. Furthermore, von der Lehr et al. 
showed that SKP2 and components of the proteasome are present at MYC-regulated 
promoter, suggesting that ubiquitination of MYC by SKP2 could occur on chromatin (Lehr 
et al., 2003). Ubiquitination of the TRD of MYC appears to be specifically required for the 
SKP2-mediated effects on MYC, since mutation of lysines within this region results in a 
decreased transforming capacity and canonical target gene induction (Zhang et al., 2013). 
Ubiquitination of MYC can be reverted by deubiquitinating enzymes. The ubiquitin 
specific protease USP28 was identified in an shRNA screen, which was performed to 
identify genes essential for MYC function (Popov et al., 2007). USP28 was shown to 
antagonize FBW7α-mediated ubiquitination of MYC and thereby stabilizes the protein. 
USP28 is highly expressed in colon cancer and deletion of Usp28 in a murine model of 
colorectal cancer attenuates tumorigenesis and prolongs survival (Diefenbacher et al., 
2014; Popov et al., 2007). USP37 directly deubiquitinates and stabilizes MYC in lung 
cancer (Pan et al., 2014). Recently, USP36 was identified as a deubiquitinating enzyme 
that specifically antagonizes FBW7γ-mediated ubiquitination thereby stabilizing MYC in 
the nucleolus (Sun et al., 2015). 
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1.4 Objectives of the thesis 
The oncogenic transcription factor MYC is a central driver of tumorigenesis that is 
required for sustained tumor growth. However, it has been challenging to target MYC 
directly for cancer therapy. Therefore, it is important to understand how MYC function and 
activity is regulated in order to develop new therapeutic strategies. 
MYC is an unstable protein that is rapidly turned over by the ubiquitin-proteasome system. 
Ubiquitination can both, stimulate and inhibit MYC function. Since several ubiquitin 
ligases seem to redundantly promote MYC ubiquitination and since these ligases have a 
broad spectrum of other substrates, it has been challenging to investigate the direct 
contribution of MYC ubiquitination to its transcriptional activity. 
To address this problem, we generated a MYC mutant, in which all lysine residues were 
replaced by arginines: this preserves the positive charge of the amino acid but prevents 
ubiquitination due to the absence of a free amino group. 
The objective of this thesis was to characterize this mutant and investigate how the absence 
of ubiquitination acceptor sites affects MYC activity. It should be analyzed whether there 
is a site-preference for ubiquitination that influences MYC activity. Finally, the detailed 
mechanism for the stimulating effect of MYC ubiquitination on its activity should be 
elucidated. 
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2 Materials 
2.1 Chemicals 
All chemicals were purchased from the companies AppliChem, Calbiochem, Invitrogen, 
Merck, Roth and Sigma-Aldrich. If not otherwise indicated, solutions and buffers were 
prepared in ddH2O. 
2.2 Buffers and solutions 
Ammonium persulfate  (10%) 5.0 g ammonium persulfate were dissolved in 50 ml 
ddH2O, aliquots were stored at -20°C 
 
Ampicillin stock solution 10 g ampicillin were solubilized in 100 ml ddH2O and 
sterile filtered; aliquots were stored at -20°C 
 
β-galactosidase buffer  60 mM Na2HPO4 
  1 mM MgSO4 
  10 mM KCl 
 
Blocking solution for  5% (w/v) skim milk powder in TBS-T 
PVDF membrane 
 
Blocking solution for ChIP  5 mg/ml BSA in PBS 
 
BCA buffer A  1% BCA-Na2 
  2% Na2CO3 x H2O 
 
BCA buffer B  4% CuSO4 x 5 H2O 
  0.16% Na-tartrate 
  0.4% NaOH 
  0.95% NaHCO3 
 
Bis-Tris (3.5 x)  1.25 M Bis-Tris 
 
Bis-Tris stacking gel  4% (v/v) acrylamide / bisacrylamide 
  1 x Bis-Tris 
  0.03% (v/v) APS  
  0.05% (v/v) TEMED 
 
Bis-Tris separation gel   8-15% (v/v) acrylamide / bisacrylamide 
  1 x Bis-Tris 
  0.03% (v/v) APS 
  0.05% (v/v) TEMED 
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Bradford reagent   0.01% (w/v) Coomassie Brilliant Blue G250 
  8.5% phosphoric acid 
  4.75% ethanol 
  solution was filtered and stored in the dark 
 
Crystal violet solution  0.1% (w/v) crystal violet 
  20% (v/v) ethanol 
 
ChIP elution buffer  50 mM Tris, pH 8.0 
  1 mM EDTA 
  1% SDS 
  50 mM NaHCO3 
 
ChIP swelling buffer  25 mM HEPES, pH 7.8 
  1.5 mM MgCl2 
  10 mM KCl 
  0.1% NP-40 
  1 mM DTT, freshly added 
  0.5 mM PMSF, freshly added 
 
ChIP high salt buffer  50 mM HEPES, pH 7.9 
  500 mM NaCl 
  1 mM EDTA 
  1% Triton X-100 
  0.1% Na-deoxycholate 
  0.1% SDS 
  0.5 mM PMSF, freshly added 
 
ChIP LiCl buffer  20 mM Tris, pH 8.0 
  1 mM EDTA 
  0.5% NP-40 
  0.5% Na-deoxycholate 
  0.5 mM PMSF freshly added 
 
ChIP lysis buffer  20 mM Tris, pH 7.5 
  150 mM NaCl 
  1% NP-40 
  1% Na-deoxycholate 
  0.1% SDS 
  1 mM EDTA 
 
Denaturing lysis buffer (2 x)  50 mM Tris, pH 8.0 
  2% SDS 
  20 mM EDTA 
  20 mM DTT 
 
DNA loading buffer (6 x)  10 mM EDTA, pH 8.0 
  0.2% (w/v) Orange G 
  40% (w/v) sucrose 
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HBS for transfection (2 x)  280 mM NaCl  
1.5 mM Na2HPO4 
50 mM HEPES 
adjusted to pH 7.05 with 5N NaOH 
sterile filtered 
 
HEGN lysis buffer (2 x)  40 mM HEPES pH 7.9 
  2% NP-40 
  0.4 mM EDTA 
  20 mM sodium pyrophosphate 
  20 mM sodium fluoride 
 
Luciferase substrate solution  25 mM glycylglycine solution 
15 mM K3PO4 (pH 8.0) 
4 mM EGTA 
15 mM MgSO4 
0.1 mM CoA 
75 !M luciferin, freshly added 
2 mM ATP, freshly added 
  1mM DTT, freshly added 
 
Miniprep lysis buffer  0.2 N NaOH 
  1% SDS 
 
Miniprep precipitation buffer  3 M KOAc, pH 5.2 
 
Nuclease incubation buffer  150 mM HEPES, pH 7.9 
  1.5 mM MgCl2 
  150 mM KOAc 
 
Nucleoplasmic extraction buffer 20 mM HEPES, pH 7.9 
  3 mM EDTA 
  10% glycerol 
  150 mM KOAc 
  1.5 mM MgCl2 
 
NuPAGE transfer buffer (20 x) 500 mM Bis-Tris 
  500 mM Bicine 
  20.5 mM EDTA 
  0.1 mM chlorobutanol 
 
NuPAGE transfer buffer   1x NuPAGE transfer buffer with 
(ready to use)  20% methanol 
 
MOPS running buffer (20 x)  1 M MOPS 
  1 M Tris 
  20 mM EDTA 
  2% SDS 
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MOPS running buffer   1x MOPS running buffer with 
(ready to use)  5 mM sodium bisulfite 
 
PBS (1 x)  137 mM NaCl 
  2.7 mM KCl 
  10.1 mM Na2HPO4 
  1.76 mM KH2PO4 
  the solution was autoclaved 
 
PI-FACS buffer  38 mM sodium citrate 
  54 !M propidium iodide  
  24 !g/ml RNase A 
 
Phosphatase inhibitor Ser/Thr phosphatase inhibitor (Sigma, P0044),  
Tyr phosphatase inihibitor (Sigma, P5726),  
used 1:200 
 
Phenylmethylsulfonylfluorid  150 mM in isopropanole 
(PMSF) 
 
Polyethylenimin (PEI)  450 !l PEI (10%, MW 25,000 g/mol, Sigma) 
  150 !l HCl (2 N) 
  49.5 ml ddH2O 
 
Protease inhibitor  protease inhibitor cocktail (Sigma, P8340), 
used 1:800 
 
Proteinase K  10 mg/ml in ddH2O 
 
RIPA lysis buffer  50 mM HEPES, pH 7.9 
  140 mM NaCl 
  1 mM EDTA 
  1% Triton X-100 
  0.1% Na-deoxycholate 
  0.1% SDS 
  1 mM PMSF freshly added 
  protease and phosphatase inhibitors freshly added 
 
RNase A (10 mg/ml)  100 mg RNase A (Roth) in 
  27 !l 3 M sodium acetate, pH 5.2 
  9 ml ddH2O 
  aliquots à 450 !l 
  boiled for 30 min at 100°C to inactivate DNases 
  50 !l 1M Tris, pH 7.4 added per aliquot 
  stored at -20°C  
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Sample buffer (6 x)   1.2 g SDS 
  6 mg bromphenol blue 
  4.7 ml 100% glycerol  
  1.2 ml 0.5 M Tris, pH 6.8 
  2.1 ml ddH2O 
  the solution was heated up, 
  0.93 g DTT was dissolved, 
  solution was aliquotted and keep frozen at -20°C 
 
Silver gel fixing solution  30 % (v/v) ethanol 
  10 % (v/v) acetic acid 
 
Silver gel sensitization solution 6.8 % (w/v) NaCH3COO 
  30% (v/v) ethanol 
  0.2% (w/v) Na2S2O3 x 5 H2O, added before use 
  0.125% (w/v) glutaraldehyde, added before use 
 
Silver gel staining solution  0.2% (w/v) AgNO3 
  0.0074% formaldehyde, added shortly before use, 
  stored protected from light 
 
Silver gel developing solution 3% Na2CO3 
  0.0037% formaldehyde 
  pH<11.5 (titrate with NaHCO3) 
 
Silver gel stopping solution   1% (w/v) glycin 
 
Stripping buffer (10 x)  2 M glycin, pH 2.5 
  2% Tween-20 
 
Sucrose buffer  10 mM HEPES, pH 7.9 
  0.34 M sucrose 
  3 mM CaCl2 
  2 mM MgOAc 
  0.1 mM EDTA 
 
TAE (50 x)  2 M Tris, pH 8.0 
  5.7% acetic acid 
  50 mM EDTA 
 
TBS (20 x)  500 mM Tris base 
  2.8 M NaCl 
  adjusted to pH 7.4 with concentrated HCl 
 
TBS-T  1 x TBS 
  0.2% Tween-20 
 
TE  10 mM Tris, pH 7.4 
  1 mM EDTA, pH 8.0  
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TNT lysis buffer  25 mM Tris, pH 8.0 
  250 mM NaCl 
  1% Triton X-100 
 
Ubi-buffer A  6 M guanidine-HCl 
0.1 M Na2HPO4/NaH2PO4 
10 mM imidazole 
 
Ubi-buffer B  25 mM Tris-HCl, pH 6.8 
  20 mM imidazole 
 
2.3 Standards, enzymes and kits 
2.3.1 Standards 
DNA marker  Gene Ruler 1 kb Plus DNA ladder (Thermo Scientific) 
Protein marker PageRulerTM Prestained Protein Ladder (Thermo Scientific) 
2.3.2 Enzymes 
Benzonase    Novagene/VWR International 
M-MLV Reverse Transcriptase Promega 
Phusion HF DNA polymerase Thermo Scientific 
Restriction endonuclease  Thermo Scientific, New England Biolabs (NEB) 
RNase-free DNase   Qiagen 
SYBR Green qPCR Master Mix Thermo Scientific 
T4 DNA ligase   Thermo Scientific 
2.3.3 Kits 
Experion DNA 1K analysis kit     Bio-Rad 
Experion RNA StdSense Analysis Kit    Bio-Rad 
GeneJET Gel Extraction Kit       Thermo Scientific 
GeneJET PCR Purification Kit      Thermo Scientific 
Immobilon Western HRP Substrate     Millipore 
MinElute PCR Purification Kit     Qiagen 
NEBNext® ChIP-Seq Library Prep Master Mix Set for Illumina® NEB 
NEBNext® Multiplex Oligos for Illumina® (Index Primer Set 1) NEB 
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NEBNext® Multiplex Oligos for Illumina® (Index Primer Set 2) NEB 
NEBNext® Poly(A) mRNA Magnetic Isolation Module  NEB 
NEBNext® UltraTM RNA Library Prep Kit for Illumina®  NEB 
PureLinkTM HiPure Plasmid Maxiprep Kit    Invitrogen 
QIAquick Purification Kit      Qiagen 
QIAquick Gel Extraction Kit     Qiagen 
Quanti-iTTM PicoGreen ® dsDNA Assay Kit    Life technologies 
RNeasy Mini Kit       Qiagen 
 
2.4 Nucleic acids 
2.4.1 Primers 
Primers used in this study were synthesized by Sigma-Aldrich or Operon and listed in the 
following tables.  
 
Table 2.1: Primers used for cloning  
fw = forward, rev = reverse 
Name Application Sequence 5’ to 3’ 
MYC_BamHI_fw MYC cloning CGCGGATCCACCATGCCCCTCAACGTTAGCTTC 
MYC_EcoRI_rev MYC cloning ATCCGGAATTCTTACGCACAAGAGTTCCGTAG 
MYC-HA-
EcoRI_rev MYC cloning 
ATCCGGAATTCTTAGGCGTAATCTGGAACATC
GTATGGGTACGCACAAGAGTTCCGTAGCTG 
MYC_AgeI_fw MYC cloning GCTACCGGTATTTAAATATGCCCCTCAACGTTAGCTT 
MYC-SpeI_rev MYC cloning GCGTTAATTAAACTAGTTTACGCACAAGAGTTCCGTA 
MYC-HA_SpeI_rev MYC cloning AATGGACTAGTTTAGGCGTAATCTGGAACATCGTATGGGTA CGCACAAGAGTTCCGTAGCTG 
MYC_attB1_fw MYC cloning GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGCCCCTCAACGTTAGCTT 
HA_attB2_rev MYC cloning GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAGGCGTAATCTGGAACAT 
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Primers used for qRT-PCR were designed with the program Universal ProbeLibrary from 
Roche. For this prupose, primers were selected to be intron-spanning to avoid 
amplification of genomic DNA. 
 
Table 2.2: Primers used for qPCR  
The name indicates, which mRNA or DNA region was amplified. TSS = transcription start site, 
TES = transcription end site 
Name Application Sequence (5’ to 3’) forward primer 
Sequence (5’ to 3’) reverse 
primer 
FBXW8 TSS ChIP GTGATAGGCAGCAGAGCTGA TGTACGCACGTGGTGGTC 
NCL TSS ChIP CTACCACCCTCATCTGAATCC TTGTCTCGCTGGGAAAGG  
Ctrl region ChIP TTTTCTCACATTGCCCCTGT 
TCAATGCTGTACCAGGCA
AA 
GNL3 TSS ChIP GTGACGCTCGTCAGTGG  CATATTGGCTGTAGAAGGAAGC 
GNL3 TES ChIP GATCAGGCCACAGGTTACAA 
TGCTGAATGACTGGAAA
GAAGA 
U2 promoter ChIP TTTGCTCCCACTGCCGTC CTGAGTCTTTCGGTGCCC 
GNL3 qRT-PCR TATCCATGGGGCTTACAAGG 
CTGGACTTCGCAGAGCA
AG 
PLD6 qRT-PCR CTCAACGGCTCGCAAATC GCCTGGGTCTTGATCGTG 
TFAP4 qRT-PCR ACGGAGAGAAGCTCAGCAAG 
TGAAGCGCTTGAGCTGTG
T 
RRP12 qRT-PCR CCGTGACCCTTCAGGTGTA 
GCCCTTGAGGACTGAGC
ATA 
FBW7 qRT-PCR CAGCAGTCACAGGCAAATGT 
GCATCTCGAGAACCGCTA
AC 
SKP2 qRT-PCR CTGTCTCAAGGGGTGATTGC 
TGTACACGAAAAGGGCT
GAA 
MYC qRT-PCR TCCTACGTTGCGGTCACA GCTCGGTCACCATCTCCA 
b2M qRT-PCR GTGCTCGCGCTACTCTCTC 
GTCAACTTCAATGTCGGA
T 
 
2.4.2 RNA oligonucleotides 
siRNA oligonucleotides were purchased from Dharmacon as a pool of four RNA 
oligonucleotides targeting the corresponding gene (ON-TARGETplus SMARTpool). As a 
control siRNA, the ON-TAGETplus Non-targeting Pool was used. 
siCtrl  ON-TARGETplus Non-targeting Pool D-001810-10 
siSKP2 ON-TARGETplus SMARTpool  L-003324-00 
siFBW7 ON-TARGETplus SMARTpool  L-004264-00 
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2.4.3 Plasmids 
Plasmids used in this study are listed in the following tables. All plasmids listed in tables 
2.3 – 2.5 were already available in the group of Prof. Martin Eilers. 
Table 2.3: Empty vectors used in this study 
Vector Description 
pcDNA3.1 eukaryotic expression vector with CMV-promoter 
pLEGO-iG2-puro-
IRES-GFP 
lentiviral expression vector with SFFV-promoter, puromycin 
resistance and eGFP, obtained from Boris Fehse 
pRRL-SFFV-
IRES-Hygro 
lentiviral expression vector with SFFV-promotor and hygromycin 
resistance, generated by Katrin E. Wiese 
pDONR221 vector to generate entry clone for gateway cloning, Invitrogen 
pINDUCER21 Dox-inducible cDNA expression vector with IRES GFP 
 
Table 2.4: Packaging vectors used for lentivirus production 
Name Description 
psAX.2  plasmid for lentivirus production, encoding for virion packaging system 
pMD2.G  plasmid for lentivirus production, encoding for virion envelope  
 
Table 2.5: Plasmids used in this study, which were already available in the lab of Prof. Eilers 
Name Description 
pcDNA3.1-Flag-MYC eukaryotic expression vector with coding sequence (CDS) of human MYC with N-terminal Flag-tag 
pcDNA3.1-His6-
Ubiquitin 
eukaryotic expression vector with CDS of UBIQUITIN with N-
terminal hexa-histidin (His6)-tag 
pcDNA3.1-HA-WT 
MYC 
eukaryotic expression vector with CDS of human MYC with N-
terminal hemagglutinin (HA)-tag 
pcDNA3.1-HA-K-less 
MYC 
eukaryotic expression vector with CDS of human K-less MYC 
with N-terminal HA-tag 
pcDNA3.1-HA-K52o 
MYC 
eukaryotic expression vector with CDS of human K52o MYC 
with N-terminal HA-tag 
pcDNA3.1-MIZ1 eukaryotic expression vector with CDS of human MIZ1 
pTK-Ebox firefly luciferase reporter construct with prothymosin-α promotor containing a canonical E-box (Gaubatz et al., 1995) 
CMV-β-Gal eukaryotic expression vector with CMV-promoter and β-Gal CDS  
pRetroSuper-puro-
scrambled 
retroviral vector for shRNA expression, RNA pol III-dependent 
H1-RNA promotor, puromycin resistance, non-targeting control 
shRNA (Brummelkamp et al., 2002) 
pRetroSuper 
puromycin shMax1 
retroviral vector for shRNA expression, RNA pol III-dependent 
H1-RNA promotor, puromycin resistance, shMAX, NKI library 
pRetroSuper 
puromycin shMax2 
retroviral vector for shRNA expression, RNA pol III-dependent 
H1-RNA promotor, puromycin resistance, shMAX, NKI library 
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Table 2.6: Plasmids generated for this project 
Name Description 
pcDNA3.1-WT MYC eukaryotic expression vector with CDS of human WT MYC 
pcDNA3.1-K-less MYC eukaryotic expression vector with CDS of human K-less MYC 
pcDNA3.1-HA-WTN-KC 
MYC 
eukaryotic expression vector with CDS of human WTN-KC 
MYC with N-terminal HA-tag 
pcDNA3.1-HA-KNWTC 
MYC 
eukaryotic expression vector with CDS of human -KNWTC 
MYC with N-terminal HA-tag 
pLEGO-WT MYC lentiviral expression vector with CDS of human WT MYC 
pLEGO-K-less lentiviral expression vector with CDS of human K-less MYC 
pLEGO-WTN-KC 
lentiviral expression vector with CDS of human WTN-KC 
MYC 
pLEGO-KNWTC 
lentiviral expression vector with CDS of human -KNWTC 
MYC 
pLEGO-WT-HA lentiviral expression vector with CDS of human WT MYC with C-terminal HA-tag 
pLEGO-K-less-HA lentiviral expression vector with CDS of human K-less MYC with C-terminal HA-tag 
pLEGO-K52o-HA lentiviral expression vector with CDS of human K52o MYC with C-terminal HA-tag 
pRRL-WT MYC lentiviral expression vector with CDS of human WT MYC 
pRRL-K-less MYC lentiviral expression vector with CDS of human K-less MYC 
pRRL-WTN-KC 
lentiviral expression vector with CDS of human WTN-KC 
MYC 
pRRL-KNWTC 
lentiviral expression vector with CDS of human -KNWTC 
MYC 
pRRL-K52o lentiviral expression vector with CDS of human K52o MYC 
pRRL-WT-HA lentiviral expression vector with CDS of human WT MYC with C-terminal HA-tag 
pRRL-K-less-HA lentiviral expression vector with CDS of human K-less MYC with C-terminal HA-tag 
pINDUCER21-WT-HA Dox-inducible lentiviral expression vector with CDS of human WT MYC with C-terminal HA-tag 
pINDUCER21-K-less-
HA 
Dox-inducible lentiviral expression vector with CDS of human 
K-less MYC with C-terminal HA-tag 
pINDUCER21-HA-
WTN-KC 
Dox-inducible lentiviral expression vector with CDS of human 
WTN-KC MYC with C-terminal HA-tag 
pINDUCER21-HA-
WTN-KC 
Dox-inducible lentiviral expression vector with CDS of human 
-KNWTC MYC with C-terminal HA-tag 
pINDUCER21-K52o-
HA 
Dox-inducible lentiviral expression vector with CDS of human 
K52o MYC with C-terminal HA-tag 
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2.5 Antibodies 
Table 2.7: List of primary antibodies  
IB = immunoblot, ChIP = chromatin immunoprecipitation, IF = immunofluorescence, IP = 
immunoprecipitation 
Antibody Host / Isotype Application Description / Source of supply 
"-TUBULIN rabbit, polyclonal IgG IB E-19-R, Santa Cruz, sc-12462 
acetylated 
histone H3 rabbit, polyclonal IgG ChIP #06-599, Millipore 
acetylated 
histone H4 rabbit, polyclonal IgG ChIP #06-866, Millipore 
acetylated 
lysine rabbit, polyclonal IgG IB #9441, Cell Signaling 
BRD4 rabbit, polyclonal IgG IB A301-985A100, Bethyl 
CDK2 rabbit, polyclonal IgG IB M2, Santa Cruz, sc-163 
CDK9 rabbit, polyclonal IgG ChIP Santa Cruz, sc-484 
CDK9 rabbit, polyclonal IgG IB Santa Cruz, sc-8338 
cleaved-
PARP mouse, monoclonal IgG1 IB 51-9000017, BD Pharmingen 
CTR9 rabbit, polyclonal IgG ChIP, IB A301-395, Bethyl 
FLAG-tag mouse, monoclonal IgG1 IP, IB M2, F3165, Sigma-Aldrich 
HA-tag rabbit, polyclonal IgG ChIP, IF, IB Abcam, ab9110 
histone H2B rabbit, polyclonal IgG IB Abcam, ab1790 
histone H3 rabbit, polyclonal IgG ChIP Abcam, ab1791 
HELLS rabbit, polyclonal IgG IB produced by Dr. Björn von Eyß 
MAX rabbit, polyclonal IgG ChIP, IP, IB C17, Santa Cruz, sc-197 
MIZ1 rabbit, polyclonal IgG IP H190, Santa Cruz, sc-22837 
MIZ1 mouse, monoclonal IB 10E2, produced by AG Eilers 
MNT rabbit, polyclonal IgG ChIP, IB sc-769, Santa Cruz 
MYC mouse, monoclonal IgG1 IB 9E10, produced by AG Eilers 
MYC rabbit, polyclonal IgG IP, IB N-262, Santa Cruz, sc-764 
MYC rabbit, polyclonal IgG IB Y69, Abcam, ab32072 
MYC T58p rabbit, polyclonal IgG IB Abcam, ab28842 
MYC S62P rabbit, polyclonal IgG IB Abcam, ab51156 
RNAPII total rabbit, polyclonal IgG ChIP N20, sc-899X, Santa Cruz 
RNAPII 
Ser2p rabbit, polyclonal IgG ChIP Abcam, ab5095 
RNAPII 
Ser5p mouse, monoclonal IgG1 ChIP 
CTD4H8, MMS-128P, 
Covance 
SPT5 mouse, monoclonal IgG1 IB A-3, sc-133097 
VINCULIN mouse, monoclonal IgG1 IB V9131, Sigma-Aldrich 
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Table 2.8: List of secondary antibodies 
IB = immunoblot, IF = immunofluorescence 
Antibody Host Application Description / Source of supply 
Alexa Fluor® 647 anti-
rabbit IgG goat IF A-21244, Life Technologies 
anti-mouse IgG-HRP donkey IB sc-2314, Santa Cruz 
anti-rabbit IgG-HRP donkey IB sc-2313, Santa Cruz 
anti-rabbit IgG-HRP 
TrueBlot mouse IB eB182, 18-8816-33, Biomol 
FITC mouse anti-BrdU mouse FACS B44, 347583, BD Biosciences 
 
2.6 Peptides 
Biotinylated N-MYC peptides were kindly provided by Richard Bayliss and Mark 
Richards (University of Leicester, UK). 
N-MYC28-89,  1&2(&%3456#7##454886#9:6687#;<==47>>6!66>"69?84@7A997669<B:7C>>7D7><8!
with the following modifications: 
non-phosphorylated 
phosphorylated at T58  
phosphorylated at S62 
phosphorylated at T58 and S62 
2.7 Strains and cell lines 
2.7.1 Bacterial strains 
DH5α Escherichia coli, genotype F– #80lacZ$M15 
$(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, 
mK+) phoA supE44 %– thi-1 gyrA96 relA1; used for 
plasmid amplification 
 
XL1 blue  Escherichia coli, genotype recA1 endA1 gyrA96 thi-1 
hsdR17 supE44 relA1 lac [F ! proAB lacIqZ"M15 
Tn10 (Tetr)], used for amplification of lentiviral 
plasmids  
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2.7.2 Human cell lines 
293TN   human embryonic kidney cell line (ATCC) 
HeLa   human cervix carcinoma cell line (ATCC) 
IMECs  human immortalized mammary epithelial cell line 
(kindly provided by Victoria Cowling and Michael Cole) 
MCF10A  human immortalized mammary epithelial cell line 
(kindly provided by Mohamed Bentires-Alj) 
2.8 Cultivation media and supplements 
2.8.1 Media and antibiotics for bacterial cell culture 
LB-medium  10% (w/v) Bacto tryptone 
  0.5% (w/v) yeast extract 
  1% (w/v) NaCl 
 
LB-agar LB-medium with 1.2% (w/v) Bacto agar was first 
autoclaved, then heated in a microwave oven, cooled 
down to 50°C, antibiotics were added and 20 ml was 
poured into 10 cm dishes 
 
Antibiotics The following antibiotics were added to LB-medium 
and LB-agar plates: 
  Ampicillin  100 !g/ml 
  Kanamycin  30 !g/ml 
  Chloramphenicol 25 !g/ml 
2.8.2 Media for mammalian cell culture 
293TN, HeLa DMEM containing 4.5 g/l glucose and 0.584 g/l L-
glutamine (Sigma) 
10% (v/v) FBS (Biochrom, heat inactivated for 30 
min at 56°C before usage) 
  1% (v/v) penicillin / streptomycin (Sigma) 
 
IMECs DMEM/F12 with 365 mg/l L-glutamine (Gibco® Life 
Technologies) 
  0.5% (v/v) penicillin / streptomycin (Sigma) 
  10 !g/ml insulin (Sigma) 
  0.5 !g/ml hydrocortisone (Sigma) 
  20 ng/ml EGF (Life technologies) 
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MCF10A  DMEM/F12 with 365 mg/l L-glutamine (Gibco® Life 
Technologies) 
     1% (v/v) penicillin / streptomycin (Sigma) 
     5% horse serum (Sigma) 
     10 !g/ml insulin (Sigma) 
     0.5 !g/ml hydrocortisone (Sigma) 
     20 ng/ml EGF (Life technologies) 
     100 ng/ml cholera toxin (Sigma) 
2.8.3 Antibiotics for mammalian cell culture 
For selection of stably infected cells, the following antibiotics with the indicated 
concentrations were used: 
Puromycin (InvivoGen) 1 !g/ml 
Hygromycin (InvivoGen) 80 !g/ml 
2.8.4 Additional supplements 
     Stock concentration  used concentration 
Chloroquine (Sigma)   25 mM in ddH2O  25 !M 
Cycloheximid (CHX, Sigma) 100 !g/!l in EtOH  100 !g/ml 
Doxycyclin (Dox, Sigma)  1 mg/ml in EtOH  250 ng/ml 
MG-132 (Calbiochem)  20 mM in EtOH  10 !M 
Protamine sulfate (Sigma)  4 mg/ml in ddH2O  5 !g/ml 
2.9 Consumables 
Consumables such as cell culture dishes, reaction tubes and other disposable plastic items 
were purchased from the companies Applied Biosystems, Eppendorf, Greiner, Kimberley-
Clark, Nunc, Sarstedt and VWR. 
2.10 Equipment and membranes 
Automated Electrophoresis  Experion™ Automated Electrophoresis 
System (Bio-Rad) 
 
Chemiluminescence imaging  LAS-4000 mini (Fujifim) 
 
Cell culture incubator  BBD 6220 (Heraeus) 
 
Cell Counter  Casy® cell counter (Innovatis) 
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Centrifuges  Avanti J-26 XP (Backman Coulter) 
  Eppendorf 5417 R (Eppendorf) 
  Eppendorf 5425 (Eppendorf) 
  Eppendorf 5430 (Eppendorf) 
  Galaxy MiniStar (VWR) 
  Multifuge 1S-R (Heraeus) 
 
Deep-sequencer  Genome Analyzer IIx (Illumina) 
 
Flow cytometer  BD FACS CantoTM II (BD Biosciences) 
 
Heating block  Dry Bath System (Starlab) 
  Thermomixer® comfort (Eppendorf) 
 
Heat Sealing  ALPTM 50V (Thermo Scientific) 
 
Incubator shaker  Model G25 (New Brunswick Scientific) 
 
Luminometer GloMax 96 Microplate Luminometer 
(Promega) 
 
Microscopes   Axiovert 40CFL (Zeiss) 
  TCS SP5 (Leica) 
 
PCR thermal cycler  Mastercycler pro S (Ependorf) 
 
Photometer  Multiscan Ascent (Thermo Labsystems) 
UltrospecTM 3100 pro UV/Visible 
(Amersham Biosciences) 
Spectrofluorometer NanoDrop 1000 (Thermo 
Scientific) 
 
Power supply  Power Pac (Bio-Rad) 
  Consort EV231/EV243 (Roth) 
 
PVDF transfer membrane Immobilon-P transfer membrane (Millipore) 
 
Quantitative RT-PCR machine Mx3000P (Stratagene) 
 
SDS-PAGE system  Minigel (Bio-Rad) 
  Mini-PROTEAN Tetra Cell (Bio-Rad) 
 
Sterile bench  HeraSafe (Heraeus) 
 
Ultrasonifier  Digital Sonifier® W-250 D (Branson) 
 
UV fluorescent table  Maxi UV fluorescent table (Peqlab) 
 
Vortex mixer  Vortex-Genie 2 (Scientific Industries) 
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Water bath     Julabo ED-5M water bath (Julabo) 
Memmert waterbath (Memmert) 
 
Immunoblot transfer chamber  PerfectBlue Tank Electro Blotter Web S 
(Peqlab) 
 
Whatman filter paper  Gel Blotting Paper (Schleicher and Schuell) 
 
2.11 Software and online programs 
ApE plasmid editor    by M. Wayne Davis 
BD FACSDiva 6.1.2    BD Biosciences 
Bedtools     (Quinlan and Hall, 2010) 
Bowtie v.0.12.8    www.bowtie-bio.sourceforge.net 
FlowJo 8.8.6     FlowJo, LLC 
IllustratorTM, PhotoshopTM, AcrobatTM Adobe Inc. 
Integrated Genome Browser   (Nicol et al., 2009) 
LAS AF 2.0     Leica 
Mac OS X     Apple Inc. 
Multi Gauge     Fujifilm 
MSigDB 3.1     (Subramanian et al., 2005) 
      www.broadinstitute.org/gsea/msigdb/index.jsp 
MxPro qPCR Software   Stratagene 
Office 2011 Mac    Microsoft Inc. 
Papers      Mekentosj 
Prism4      GraphPad Software Inc. 
R 3.1.1     R foundation 
Samtools      (Li et al., 2009) 
UCSC Genome Bioinformatics  http://genome.ucsc.edu 
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3 Methods 
3.1 Cell biology methods 
3.1.1 Cultivation of eukaryotic cell lines 
All eukaryotic cell lines were cultivated in a cell incubator at 37°C, 5% CO2 and a relative 
humidity of 95%. 
3.1.1.1 Passaging of cells 
For maintenance of an adherent cell line, cells were passaged every two to three days. The 
medium was removed, cells were washed with PBS and trypsinized to detach them from 
the cell culture dish. The enzymatic activity of trypsin was inhibited by addition of serum-
containing medium. The cells were transferred into a 15 ml tube and centrifuged at 300 x g 
for 5 min. Supernatant was removed, the cell pellet resuspended in the appropriate cell 
culture medium and a fraction of the cell suspension was replated on a new cell culture 
dish with fresh medium. For plating cells at a specific cell number, the cell number of a 
suspension was either determined with a Neubauer counting chamber or with the CASY 
cell counter. 
3.1.1.2 Freezing of cells 
For long-term storage, cells were frozen and stored in liquid nitrogen. To this end, cells 
were detached from their cell culture dish by trysinization (see 3.1.1.1), spun down, 
resuspended in freezing medium and transferred to cryo vials. The cryo vials were first 
stored in an MrFROSTY freezing container at -80°C to ensure slow freezing (1°C per min) 
and then transferred to liquid nitrogen storage tanks. 
3.1.1.3 Thawing of cells 
Frozen cells were quickly thawed in a 37°C water bath and transferred into a medium-
filled tube. To remove all traces of DMSO, cells were centrifuged at 300 x g for 5 min, the 
cell pellet was resuspended in fresh medium and the cells were plated on a cell culture 
dish. 
 46 
#
Methods 
#
# #
3.1.2 Synchronization of IMECs by EGF withdrawal 
To synchronize immortalized mammary epithelial cells (IMECs), the cells were seeded at a 
specific cell number obtaining approximately 50% confluence on the next day. Then, cells 
were washed twice with PBS, medium without EGF was added and the cells were 
cultivated for 24-48 h.  
3.1.3 Transfection of siRNA 
Transfection of synthetic siRNAs (Dharmacon) was performed with the transfection 
reagent LipofectamineTM RNAiMAX (Invitrogen). First, cells were washed with PBS and 
provided with medium without antibiotics. For transfection, 20 !M siRNA was diluted 
with Opti-MEM (Invitrogen) up to 500 !l and, in a separate tube, 10 !l LipofectamineTM 
RNAiMAX was diluted with 490 !l Opti-MEM. The reactions were incubated for 5 min at 
RT, mixed and incubated for another 20 min. The transfection mix was added dropwise to 
the cells. After 8-10 h, the medium was changed to full medium. The cells were harvested 
48 h after transfection for further analysis. 
3.1.4 Transfection of plasmid DNA 
One of the following methods was used to transfect mammalian cells with plasmid DNA 
depending on the cell line. 48 h after transient transfection of cDNA expression plasmids, 
cells were harvested for further analysis. 
3.1.4.1 Calcium phosphate transfection 
Cells were seeded in an appropriate density one day before transfection. The medium was 
changed shortly before transfection and 25 !M chloroquine was added. For transfection of 
a 10 cm dish, 5–30 !g DNA was mixed with 50 !l 2.5 M CaCl2 and filled up to 500 !l 
with ddH2O. 500 !l 2x HBS was added drop wise to the reaction while vortexing to 
generate calcium phosphate-DNA complexes and this mixture was added to the cells. On 
the next day, cells were washed with PBS to remove DNA precipitates and fresh medium 
was added. 
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3.1.4.2 Transfection with polyethylenimin (PEI) 
Cells were seeded in an appropriate density 24 h before transfection. On the day of 
transfection, cells were washed with PBS and transfection medium (DMEM with 2% FCS, 
without antibiotics) was added. To transfect a 10 cm dish, 10 !g of DNA was diluted with 
Opti-MEM to 500 !l and in a second tube, 20 !l PEI (1 !g/!l) were mixed with 480 !l 
Opti-MEM. After incubation for 5 min at RT, the reactions were mixed and incubated for 
15 min at RT. The transfection mix was added dropwise to the cells. Cells were washed 
with PBS 4 to 5 h after transfection and fresh full medium was added. 
3.1.5 Production of lentiviruses 
One day before transfection, 5x106 293TN cells were plated on a 10 cm cell culture dish. 
On the next day, cells were transfected with the calcium phosphate transfection method. 
For lentivirus production 10 !g of the packaging vector psPAX2, 2.5 !g of the envelope 
vector pMD2.G and 10 !g lentiviral expression plasmid (such as pRRL, pLEGO or 
pINDUCER21)  was used for transfection. On the next day, the medium was removed and 
6 ml fresh medium was added. The first virus containing supernatant was harvested 48 h 
after transfection. Further virus containing supernatants were collected 60 h and 72 h after 
transfection. The supernatants were pooled and filtered using a syringe with 0.45 !m filter. 
The virus supernatant was either used directly for infecting cells or stored in aliquots at -
80°C. 
3.1.6 Lentiviral infection of cells 
To infect a 6 cm dish with lentivirus, 2 ml fresh medium was added to the cells together 
with 200 !l lentiviral supernatant and 2.67 !l protamine sulfate (4 !g/!l). The amount of 
virus used for infection was dependent on the lentiviral constructs, virus titer and the cell 
line that should be infected. Medium was changed approximately 24 h after infection. If 
applicable, selection with appropriate antibiotics was started 48 h after infection. To 
determine the time point when the selection was successful, a non-infected control plate 
was treated with the same selection medium. 
 48 
#
Methods 
#
# #
3.1.7 Colony formation assay (crystal violet staining) 
The crystal violet staining can be used to visualize cell densities on a cell culture dish and 
therefore determine proliferation of cells. For this purpose cells were plated with the same 
cell number and cultivated for four to eight days. Then, cells were fixed with 1% 
formaldehyde for 15 min, washed with PBS and stained for 1 h with the triphenylmethane 
dye crystal violet. Excess of the dye was washed away with desalted water and the plates 
were air dried at RT. 
3.1.8 Cumulative growth curve 
To compare proliferation capability of different stable cell lines a cumultative growth 
curve was prepared. To this end, cells were plated in equal cell numbers (150,000) in 
triplicates in 6 cm dishes. Every third day, the cells were trypsinized and the total number 
of living cells was determined with the CASY cell counter. The original cell number 
(150,000) was replated. On the basis of the total cell number (X), the increase of the cell 
number (R) was determined (R=X/150,000), the cumulative cell number (Y) of each 
passage (p) was calculated (Y(p)=Y(p-1)xR) and illustrated in a graph. 
3.1.9 Single-color competition experiment (GFP-competition) 
For a single-color competition experiment, stable cell lines were generated that expressed 
the protein of interest and the green fluorescent protein GFP. These cells were mixed with 
uninfected cells that neither expressed GFP nor the transgene. The mix ratio was 1/5 
meaning 20 % were GFP- and transgene positive cells whereas 80% were uninfected cells. 
The cell mixtures were plated with equal cell number in triplicates on 6 cm dishes. After 3 
days, cells were trypsinized, a fraction of the mix was replated and the amount of 
GFP/transgene positive cells was determined with a flow cytometer. The in- or decrease of 
GFP-positive cells over time was illustrated in a graph. 
3.1.10 Propidium iodide staining for flow cytometry (PI-FACS) 
Propidium iodide staining of DNA with subsequent analysis by FACS (fluorescence-
activated cell sorting) was used to determine DNA-content and therewith cell cycle 
distribution of cells. Propidium iodide is a fluorescent dye that intercalates into DNA. On 
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the basis of the DNA content, it can be determined whether a cell resides in the G1/G0 
(DNA content 2N), S (DNA content <2N, <4N) or G2/M (4N) cell cycle phase. Moreover, 
apoptotic (sub G1, <2N) and polyploid cells (>4N) can be identified. 
To include apoptotic cells in the measurement, cell culture supernatant containing floating 
cells was transferred into tubes and the adherent cells were trypsinized and added to the 
supernatant. Cells were spun down for 5 min at 400 x g, washed with cold PBS and again 
centrifuged. The cell pellet was resuspended in 200 !l PBS and cells were fixed by adding 
800 !l 100% ice-cold EtOH while vortexing. Fixed cells were stored over night at -20°C. 
On the next day, cells were spun down for 10 min at 400 x g and washed twice with 5 ml 
cold PBS. Cell pellets were resuspended in 400 !l 38 mM sodium citrate containing 1 !l 
RNase A (10 mg/ml stock solution) and 15 !l propidium iodide (1 mg/ml stock solution). 
After incubation at 37°C for 30 min protected from light, samples were transferred into 
FACS tubes measured with an excitation wavelengths of 488 nm, a 556 nm longpass- and 
a 585/42 nm bandpassfilter for propidium iodide (emission at 617 nm). The cell cycle 
distribution was analyzed using the BD FACSDiva 6.1.2 software. 
3.1.11 BrdU-PI-FACS 
Bromdesoxyuridin (BrdU) is a thymidine analog, which is incorporated into the DNA 
during S-phase. Cells that were in S-phase during the labeling can be identified using an 
anti-BrdU antibody. 
For labeling, cells were incubated with 10 !M BrdU for 1 h. Harvesting and ethanol 
fixation was performed analog to the procedure for the PI-FACS. After the incubation at -
20°C over night, cells were pelleted (10 min, 400 x g) and washed with cold PBS. Then, 
cells were resuspended in 1 ml 2 M HCl / 0.5% Triton X-100 and incubated for 30 min at 
RT. After pelleting, cells were resuspended in 1 ml 0.1 M Na2B4O7 (pH 8.5). Cells were 
again spun down, resuspended in 100 !l 1% BSA in PBS-T (0,5% Tween-20 in PBS) and 
20 !l anti-BrdU-FITC antibody was added. After incubation for 30 min at RT (protected 
from light), cells were washed with 200 !l 1% BSA in PBS-T and pellets resuspended in 
400 !l 38 mM sodium citrate containing 1 !l RNase A (10 mg/ ml stock solution) and 15 
!l propidium iodide. After incubation for 30 min at 37°C (in the dark), cells were 
measured by flow cytometry. 
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3.1.12 Indirect immunofluorescence 
To analyze subcellular localization of proteins, cells were plated on glass cover slips 
coated with 0.1% gelatin. On the next day, cells were washed with PBS and incubated for 
15 min in fixing solutions (4% PFA (w/v) / 2% sucrose (w/v) in PBS). Afterwards, cells 
were washed with PBS and incubated twice for 10 min in 0.1 M glycine in PBS. Cells 
were permeabilized by incubating them twice for 5 min in 0.1% NP-40 (v/v) in PBS. The 
cover slips were transferred into a wet chamber, followed by blocking for 45 min in 
blocking solution and incubation with primary antibody diluted in blocking solution over 
night at 4°C. On the next day, the cover slips were washed three times with PBS and 
incubated for 1 h with fluorescence-labeled secondary antibody at RT in the dark. Cover 
slips were washed three times with PBS. The second PBS washing solution contained 
Hoechst (1:10,000) to stain nuclei. The cover slips were mounted with Fluoromount 
(Sigma) and edges sealed with nail polish. Samples were analyzed with a fluorescence 
microscope and could be stored at 4°C protected from light. 
3.1.13 Luciferase reporter gene assay and ONPG measurement 
To determine luciferase activity, cells were plated in 6-well plates and transfected with the 
reporter constructs and expression plasmids using PEI transfection. 48 h after transfection, 
cells were washed with PBS and lysed with 250 !l passive lysis buffer (Promega) for 15 
min at RT while shaking. Lysates were transferred into a 1.5 ml tube and cleared by 
centrifugation. 50 !l lysate was pipetted into a clear bottom 96-well plate and the plate was 
placed in the Glomax 96 Microplate Luminometer. The luminometer automatically added 
100 !l luciferase substrate solution per well and measured light emission at 562 nm in 
relative light units (RLU). 
For normalization, the activity of the co-transfected β-galactosidase was determined. To 
this end, 50 !l lysate was mixed with 50 !l ONPG (5 mg/ml H2O) and 750 !l β-
galactosidase buffer. The samples were incubated at 37°C until a yellow color has 
developed and absorbance was measured at 420 nm. 
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3.2 Molecular biology methods 
3.2.1 Transformation of competent cells with plasmid DNA and plasmid 
amplification 
Chemically competent bacteria were thawed on ice and mixed with the ligation mix or 1 
!g plasmid DNA. The bacteria were incubated on ice for 30 min, followed by a heat shock 
for 90 s at 42 °C. The reactions were shortly cooled down on ice followed by the addition 
of 1 ml LB medium. Bacteria were incubated for 30 min at 37°C before plating them on 
LB-agar plates. Was the transformation performed for plasmid amplification, 50 !l 
bacteria suspension was plated on LB agar plates containing the appropriate antibiotic for 
selection. After transformation of a ligation mix, the bacteria suspension was spun down, 
resuspended in 50 !l LB medium and the complete reaction was plated. LB agar plates 
were incubated at 37°C over night. 
3.2.2 Analytical preparation of plasmid-DNA from bacteria (Miniprep) 
The analytical preparation of plasmid DNA was performed using alkaline lysis. 1.5 ml 
overnight culture was spun down and the bacteria were resuspended in 150 !l TE buffer 
containing 1.5 !l RNase A (10 mg/ml stock solution). Lysis was performed by addition of 
150 !l lysis buffer and incubation for 5 min at RT. The lysis was stopped by adding 150 !l 
precipitation buffer and the samples were centrifuged for 10 min at 18,000 x g. The 
supernatant was mixed with 1 ml 100% EtOH and the plasmid DNA was pelleted by 
centrifugation for 10 min at 18,000 x g and 4°C. The DNA pellet was washed with 70% 
EtOH, air dried and solubilized in 50 !l ddH2O. 
3.2.3 Preparative isolation of plasmid DNA (Maxiprep) 
For preparative isolation of plasmid DNA, 200 ml overnight culture was processed 
according to the manufacturer’s protocol (PureLink® HiPure Plasmid Maxiprep Kit, Life 
Technologies). The purified plasmid DNA was solubilized in TE and adjusted to a 
concentration of 1 !g/!l. 
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3.2.4 Restriction analysis of DNA  
Sequence specific hydrolysis of DNA was performed with restriction endonucleases from 
Fermentas and New England Biolabs using the recommended restriction buffers and 
enzyme amounts. A control digestion was incubated for 2 h at the recommended 
temperature and set up according to the following table: 
 1 !g DNA 
    0.4 !l restriction endonuclease 1 
    0.4 !l restriction endonuclease 2 
    1 !l 10x reaction buffer 
    ad 10 !l ddH2O 
 
For a preparative restriction digestion, the amount of DNA, restriction endonucleases, 
sample volume and digestion time was adjusted. 
3.2.5 Gel electrophoretic separation of DNA fragments 
The separation of DNA fragments by gel electrophoresis was performed depending on the 
expected fragment size using a 1-2% agarose gel in a TAE buffer. For this purpose the 
agarose was boiled in TAE buffer, supplemented with 0.3 !g/ml ethidium bromide and 
poured into a gel chamber with combs. The samples were mixed with DNA loading buffer 
and pipetted into the pockets of the gel. To determine the size of the DNA fragment, a 
DNA ladder (Thermo Scientific) was loaded next to the samples. The separation was 
preformed at 120 V for one hour and the DNA fragments were visualized due to the 
intercalated ethidium bromide on a UV transilluminator. 
3.2.6 Extraction and purification of DNA fragments and PCR products 
For purification of DNA fragments from agarose gels, the fragment was cut out of the gel 
and extracted with the gel extraction kit according to the manufacturer’s protocol 
(GeneJET Gel Extraction Kit, Thermo Scientific). 
Purification of PCR products was performed according to the manufacturer’s protocol 
(GeneJET PCR Purification Kit, Thermo Scientific). 
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3.2.7 Ligation of DNA fragments 
Ligation of DNA fragments was performed with the T4 DNA ligase (Thermo Scientific). 
The DNA fragment (insert) was used in 3x molar excess to the linearized vector. 
Ligation mix:   50 ng linearized vector 
    X ng fragment 
    1 !l T4 DNA ligase 
1 !l 10x ligation buffer 
    ad 10 !l ddH2O 
The ligation mix was incubated for 1-2 h at RT und transformed into competent bacteria. 
3.2.8 Gateway® cloning 
To clone cDNA into the pINDUCER21 vector, the Gateway® cloning technology from 
Life technologies was used. This technology is based on the site-specific recombination 
properties of the bacteriophage lambda, which integrates its DNA into the E.coli genome. 
Cloning was performed according to the manufacture’s protocol and includes two 
recombination reactions (BP and LR reaction). Briefly, primers with an attB1 or attB2 site 
were designed to amplify the cDNA of interest. The PCR product with the attB sites was 
recombined into the pDONRTM vector with the BP reaction to generate an entry clone. 
Using the LR reaction, the cDNA was then transferred from the entry clone into the 
destination vector, in this case the pINDUCER21 expression vector (Meerbrey et al., 
2011). 
3.2.9 Nucleic acid quantification 
3.2.9.1 Nanodrop 
DNA and RNA concentration was typically determined with the NanoDrop 1000. 
(PeqLab). Absorbance was measured at 260 nm. To assess the purity of the nuclei acid 
solution, the ratio of absorbance at 260 and 280 nm was determined. A ratio of ~ 1.8 for 
pure DNA and ~2.1 for pure RNA was expected. 
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3.2.9.2 PicoGreen 
The concentration of double-stranded DNA (dsDNA) was determined with the Quant-
iTTM PicoGreen® dsDNA reagent (Invitrogen). PicoGreen intercalates into dsDNA and 
the fluorescence at a wavelength of 485/535 nm can be determined. The measurement was 
performed according to the manufacturer’s protocol. DNA quantifications with PicoGreen 
were performed to determine concentrations of chromatin samples after ChIP, which were 
used for ChIP-Sequencing. 
3.2.9.3 Bioanalyzer 
RNA, which was used for library preparation for RNA-Sequencing, as well as the prepared 
DNA-libraries, were quantified with the ExperionTM Automated Electrophoresis System 
from Bio-Rad. 
3.2.10 RNA Isolation 
3.2.10.1 RNA isolation with TriFAST 
Total RNA was typically isolated with peqGOLD TriFast (Peqlab). The cell culture 
medium was aspirated and cells were lysed directly on the plate with 1 ml Trifast and 
transferred into a 1.5 ml reaction tube. 200 !l chloroform was added and the suspension 
was vortexed for 10 s. The reactions were centrifuged (10 min at 20,000 x g, 4°) to 
separate the phases and the upper aqueous phase containing the RNA (~500 !l) was 
transferred into a new reaction tube. To precipitate the RNA, 500 !l isopropanol and 1 !l 
glycogen (20 !g/!l stock solution, Fermentas) were added. The samples were incubated on 
ice for 10 min followed by centrifugation for 10 min (20,000 x g at 4°). The supernatant 
was discarded and the RNA pellet washed twice with 75% EtOH. The washed RNA pellet 
was air-dried and solubilized in 20-50 !l RNAse free ddH2O. The RNA was used for 
cDNA synthesis and stored at -80°C. 
3.2.10.2 RNA isolation with RNeasy® Mini Columns and DNase digestion (Qiagen) 
If RNA was used for RNA-Sequencing (RNA-Seq), isolation was performed with the 
RNeasy® Mini Columns and additional DNase I digestion according to manufacturer’s 
protocol. 
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3.2.11 cDNA synthesis 
For expression analysis of individual genes, the extracted total RNA was reverse 
transcribed into complementary DNA (cDNA) with random hexanucleotide primers. For 
this purpose, 0.5-2 !g total RNA was diluted with nuclease-free water up to 20 !l and 
incubated for 2 min at 65°C to dissolve secondary structures. The samples were quickly 
cooled down and 30 !l cDNA synthesis mix was added per reaction. The samples were 
incubated for 10 min at 25°C, followed by incubation at 37°C for 50 min and 70°C for 15 
min. 
 cDNA synthesis mix: 10 !l 5x First strand reaction buffer (Promega) 
    1.25 !l dNTPs (10 mM Stock, Roth) 
    2 !l random primers (2 !g/ml Stock, Roche) 
    0.2 !l RiboLock RNase Inhibitor (40 U/!l, Fermentas) 
    1 !l M-MLV reverse transcriptase (200 U/!l, Promega) 
    ad 30 !l nuclease-free water 
 
The cDNA was diluted up to 250 !l with ddH2O and 5 !l of diluted cDNA was used per 
quantitative reverse transcriptase PCR reaction (see 3.2.12.2). 
3.2.12 Polymerase chain reaction (PCR) 
3.2.12.1 PCR to amplify cDNA for cloning 
To generate new cDNA expression vectors the gene of interest was amplified from an 
existing expression vector. This allowed the addition of tags to the gene of interest, 
insertion of mutations and addition of new restriction sites.  
Standard PCR reaction: 5 ng cDNA template 
    5 !l 10x Phusion High-Fidelity (HF) reaction buffer  
1 !l dNTPs (10 mM Stock, Roth) 
    1.25 !l forward primer (10 !M Stock) 
    1.25 !l reverse primer (10 !M Stock) 
    1.5 !l DMSO (3% final concentration) 
    0.5 !l Phusion HF DNA polymerase (Fermentas) 
ad 50 !l nuclease-free water 
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Table 3.1: PCR cycling profile for cloning 
Cycle step Temperature Time Cycles 
Initial denaturation 98°C 30 s 1 x 
Denaturation 98°C 10 s 
30 x Annealing 55 – 62 °C 30 s 
Extension 72°C 15 – 30 s per kb 
Final extension 72°C 8 min 1 x 
 
For mutagenesis the desired mutation was included in the primers and the cDNA was 
amplified by overlapping PCR. First, the N-terminal and C-terminal halves of the cDNA 
from the introduced mutation were amplified. These fragments were purified, mixed in a 
molar ratio 1:1 and used as the template for amplification of the complete cDNA that 
harbors now the desired mutation. 
3.2.12.2 Quantitative real-time PCR (qPCR) 
Quantitative PCR was performed to analyze abundance of mRNAs or to analyze 
enrichment of DNA fragments after chromatin immunoprecipitation (see 3.3.11). During 
amplification of the DNA a fluorescent dye intercalates into the newly synthesized double-
stranded DNA, which can be quantified in real time.  
qPCR reaction:  5 !l diluted cDNA (see 3.2.11) or chromatin (see 3.3.11) 
    10 !l SYBRGreen Mix (Thermo Scientific) 
    5 pmol forward primer  
    5 pmol reverse primer 
ad 20 !l nuclease-free water 
 
Table 3.2: PCR cycling profile for qPCR 
Cycle step Temperature Time Cycles 
Initial denaturation 95°C 15 min 1 x 
Denaturation 95°C 30 s 
38 x Annealing 60 °C 20 s 
Extension 72°C 15 s 
Melting curve 
95°C 1 min 
1 x 60°C 30 s 
95°C 30 s 
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For quantitative reverse transcriptase PCR (analysis of cDNA), the fold induction relative 
to a control (e.g. control infected or uninduced cells) was calculated. The housekeeping 
gene !2-MICROGLOBULIN (b2M) was used for normalization. For calculation, the 
threshold cycle (CT) was determined, which indicates at which PCR cycle the fluorescence 
signal was above the background fluorescence. 
ΔCT= CTb2M - CTGene 
ΔΔCT = ΔCTcontrol - ΔCTsample 
relative expression = 2-ΔΔCT 
 
For ChIPs the result was presented as % of input.  
% of input =2CT(1% Input)-CT(IP) x 1%  (if 1% input was loaded) 
 
The qPCR measurement was always performed in triplicates. The average and standard 
deviation was calculated. 
standard deviation (SD) = !!!!!!!!!!!!   
 
3.3 Biochemical methods 
3.3.1 Preparation of whole cell protein extracts 
For whole cell protein extraction cells were washed with ice cold PBS and scraped directly 
with RIPA lysis buffer containing proteinase and phosphatase inhibitors off the cell culture 
dish. The suspension was transferred into a 1.5 ml reaction and snap-frozen in liquid 
nitrogen. The samples were thawed on ice, vortexed in between and cell debris were 
pelleted by centrifugation at 20,000 x g for 20 min at 4°C. The supernatant was transferred 
to a fresh tube and protein concentration was determined with the BCA assay (see 
3.3.3.1.). 
3.3.2 Fractionation of cell extracts 
To investigate whether a protein resides in the cytosol, nucleoplasm or is chromatin 
associated, cell extracts were fractionated. To this end, freshly harvested cells were 
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pelleted by centrifugation at 300 x g for 5 min. The cell pellet was resuspended in sucrose 
buffer with freshly added 0.5% NP-40 and protease inhibitors and pipetted carefully up 
and down with a 200 !l pipette to facilitate cytoplasmic lysis. The cell suspension were 
incubated on ice for 10 min and then centrifuged for 20 min at 3900 x g. The supernatant 
was transferred into a new tube (containing cytoplasmic proteins) and the white nuclear 
pellet was washed with sucrose fractionation buffer without any detergent and again 
centrifuged for 20 min at 3900 x g. The supernatant was discarded, the nuclei were 
homogenized in nucleoplasmic extraction buffer (2 packed nuclear volumes) and incubated 
on ice for 20 min. The homogenate was centrifuged for 30 min at 20,000 x g. The 
nucleoplasmic extract was transferred into a new tube and the pellet was resuspended in 
nuclease incubation buffer and digested with benzonase. The digested chromatin was 
cleared by centrifugation at 20,000 x g for 30 min. Protein concentration of all fractions 
was determined and analyzed by SDS-PAGE and immunoblot. 
3.3.3 Total protein quantification by colorimetric assays 
Quantification of total protein extracts lysed in RIPA buffer were performed using the 
BCA assay whereas lysates from HEGN- or TNT-lysis were quantified using the Bradford 
assay. 
3.3.3.1 Bicinchoninic acid assay (BCA) assay 
For the BCA assay, 4 !l protein lysate was pipetted into a well of a flat bottom 96-well 
plate and mixed with 200 !l BCA reagent consisting of buffer A and buffer B (50:1). The 
reaction was incubated at 37°C for 30 min and the absorbance was measured at a 
wavelength of 550 nm. A well containing only the lysis buffer with BCA reagent served as 
the blank. Protein concentration was determined on the basis of a standard curve, which 
was always included on the plate and prepared in the same lysis buffer as the lysates. 
3.3.3.2 Bradford assay 
Protein lysates prepared with HEGN- or TNT lysis were quantified according to the 
Bradford method (Bradford, 1976). 100 !l 150 mM NaCl were pipetted into cuvettes and 2 
!l protein lysate was added followed by 900 !l Bradford reagent. The reaction was mixed 
by vortexing and absorbance was measured at 595nm. A reaction containing 2 !l lysis 
buffer instead of protein lysate served as the blank. Protein concentration was determined 
according to the absorbance of the standard curve. 
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3.3.4 SDS Polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS polyacrylamide gel electrophoresis was used to separate proteins according to their 
molecular weight. Protein lysates were boiled in 6x sample buffer for 5 min at 95°C, spun 
down and equal protein amounts were loaded on a Bis-Tris polyacrylamide gel consisting 
of a 8-15% stacking and a 4% resolving gel. The PageRuler Pre-Stained Protein Ladder 
(Fermentas) was used as a molecular weight marker. Separation of the proteins was 
performed using SDS-PAGE chambers (Biorad) filled with 1x MOPS running buffer 
containing freshly added sodium bisulfite at 80-120 V. 
3.3.5 Immunoblot 
After separating protein lysates by SDS PAGE, proteins were transferred onto a PVDF 
membrane. To this purpose, a PVDF membrane was incubated in methanol for 1 min and 
equilibrated, together with the gel and several Whatman filter papers, in transfer buffer. 
The gel was layered on the PVDF membrane followed by Whatman filter papers on each 
side and fixed in a tank blot transfer chamber that was filled with 1x transfer buffer 
containing 20% methanol. The transfer was carried out in the cold room (4°C) at 300 mA 
for approximately 2-3 h depending on the molecular weight of the proteins. Subsequently, 
the membrane was blocked for 30 min in blocking buffer followed by incubation in 
primary antibody at 4°C over night. Afterwards, membranes were washed three times for 
10 min with 1x TBS-T and incubated for 1 h with secondary antibody (diluted 1:5000 in 
blocking solution) followed by additional 3 washing steps with TBS-T. Antibodies were 
visualized by chemiluminescence using the Immobilon Western Substrate (Millipore) 
according to manufacturers’ protocol and detected with the LAS-4000 imager (Fujifilm 
Global). 
Protein signals were quantified relative to the loading control using the software Multi 
Gauge. 
3.3.6 Stripping of PVDF membranes 
To remove antibodies from PVDF membranes, the membranes were incubates for 1 h in 
stripping buffer. Afterwards, membranes were washed thoroughly with TBS-T before 
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incubating them in blocking buffer. The antibody incubation and detection was performed 
according to 3.3.5. 
3.3.7 Silver staining of proteins in polyacrylamide gels 
To visualize immunoprecipitated proteins, which were subjected to mass spectrometric 
analysis, eluates were loaded on a SDS-PAGE and stained with silver staining. To this end, 
gels were first incubated for 30 min in fixing solution and then stored for at least 30 min in 
sensitization solution. After sensitization, gels were washed three times in ddH2O and 
proteins were visualized with silver staining for 20 min protected from light followed by 
incubation in developing solution until protein bands were visible. The developing was 
stopped by incubation for 10 min in stopping solution and the gels were washed two times 
in ddH2O. For long-term storage, gels were dried by vacuum drying. 
3.3.8 In vivo ubiquitination assay 
To detect ubiquitinated proteins in transfected mammalian cells, HeLa cells were 
transfected with plasmids expressing His-tagged ubiquitin and the protein of interest. 48 h 
after transfection, cells were harvested, the cell pellet was resuspended in 100 !l PBS and 
10 !l was taken as an input control. The input control was adjusted with PBS and sample 
buffer to a volume of 100 !l, the samples were boiled for 5 min at 95°C and stored at -
20°C till further use. The remaining cells were lysed with 1 ml Ubi-buffer A and the 
lysates were centrifuged at 20,000 x g for 10 min. The supernatant was transferred into a 
new tube, 50 !l of washed Ni2+-NTA beads (50% slurry) were added and the samples were 
incubated on a rotating wheel for 3 h at RT. After the incubation, beads were sedimented 
by centrifugation and washed one time with Ubi-buffer A, two times with Ubi-buffer A/B 
(mixed 1:4) and one time with Ubi-buffer B. The remaining supernatant was removed and 
10 !l 1 M imidazole was added to the beads. The beads were boiled with 100 !l sample 
buffer at 95°C for 5 min to elute His-tagged proteins. The supernatant and the previously 
taken input controls were subjected to SDS-PAGE and immunoblot analysis (see 3.3.4 and 
3.3.5). 
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3.3.9 Cycloheximide decay assay 
To determine the half-life of a protein, a cycloheximide decay assay was performed. To 
this end, cells were incubated with 100 !g/ml cycloheximide for a different period of time. 
Cells were washed with ice-cold PBS and directly lysed on the plate with RIPA lysis 
buffer and lysates were analyzed by SDS-PAGE and immunoblot (see 3.3.4 and 3.3.5). 
3.3.10 Immunoprecipitation (IP) 
3.3.10.1 Immunoprecipitation of exogenous proteins 
To detect protein-protein interaction, an immunoprecipitation under native conditions was 
performed. Cells were lysed either in TNT- or 1x HEGN-lysis buffer (supplemented with 
150 mM NaCl) containing protease- and phosphatase inhibitors and the lysates were 
sonified for 20 s (5s pulse, 10 s pause) and 20% amplitude. Lysates were centrifuged for 
20 min at 20,000 x g and 4°C to pellet cell debris. The supernatant was transferred into a 
new reaction tube and the total protein concentration was determined with the Bradford 
assay (see 3.3.3.2). The same protein amount was used per IP and thy lysates were pre-
cleared for 3 h with washed Protein A-Sepharose® 4B (Life Technologies) to remove 
proteins which bind unspecific to the sepharose. Afterwards, the sepharose was sedimented 
by centrifugation for 2 min at 2,000 x g and the supernatant was transferred to a new tube. 
An input sample was taken which was boiled with sample buffer at 95°C for 5 min and 
stored at -20°C till further use. Per IP 2 !g antibody were used and the samples were 
incubated over night at 4°C on a rotating wheel. On the next day, 50 !l Protein A-
Sepharose® 4B was added to the samples and incubated for additional 3 h on the rotating 
wheel at 4°C. The sepharose was sedimented by centrifugation and washed with 1 ml lysis 
buffer. The washing was performed three times and the samples were incubate between the 
washing steps on the rotating wheel at 4°C. When the HEGN-lysis buffer was used, the 
NaCl concentration was increased for the last washing step from 150 mM to 200 mM 
NaCl. After the last washing step, the buffer was removed and the remaining buffer 
carefully removed with a Hamilton syringe. The beads were boiled in sample buffer for 5 
min at 95°C and subjected together with the input samples to SDS-PAGE and immunoblot 
analysis. 
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3.3.10.2 Immunoprecipitation of endogenous proteins 
For immunoprecipitation of endogenous proteins, nuclear cell extracts were prepared. To 
this end, cells were incubated in hypotonic sucrose buffer with freshly added 0.1% NP-40 
and homogenized with a dounce tissue grinder. All centrifugation steps were performed at 
4°C. Nuclei were collected by centrifugation at 800 x g and lysed in high salt lysis buffer 
(1x HEGN buffer with 300 mM KCl) containing protease and phosphatase inhibitors. 
Lysates were incubated at 4°C while shaking and centrifuged at 20,000 x g for 30 min. The 
supernatant was diluted to a salt concentration of 120 mM KCl with 1x HEGN buffer and 
spun down for 15 min at 20,000 x g. Protein concentration of the nucler extract was 
determined using the Bradford assay and the same protein amount was used for 
immunoprecipitation. Nuclear extracts were incubated with antibodies coupled to 
Dynabeads over night at 4°C on a rotating wheel. Immunoprecipitates were washed four 
times with 1x HEGN-120 mM KCl, boiled in sample buffer and subjected to immunoblot 
analysis. 
3.3.10.3 Denaturing immunoprecipitation 
To immunoprecipitate a protein without interaction partners, the IP was performed under 
denaturing conditions. To this end, the cell pellet was solubilized in PBS and the same 
volume denaturing lysis buffer was added. The suspension was boiled for 10 min at 95°C 
and vortexed in between. The sample was diluted ten fold with TNT-lysis buffer and 
centrifuged for 30 min at 20,000 x g. The supernatant was subjected to 
immunoprecipitation. 
3.3.11 Peptide-pulldown assay 
Peptide-pulldown assays were performed with N-MYC MYC box I peptides and nuclear 
extracts from HeLa cells. Nuclear extracts were prepared as described for 
immunoprecipitation of endogenous proteins (see 3.3.10.2). M-280 Streptavidin 
Dynabeads were washed with TBS and resuspended in peptide binding buffer (2% BSA, 
0.05% NP-40 in TBS). 20 !g MYC peptide was added and incubated for 30 min at RT on 
a rotating wheel. Streptavidin Dynabeads were washed with TBS and resuspended in 1x 
HEGN lysis buffer (120 mM KCl). Nuclear extracts were added to the beads and incubated 
at 4°C for 2 h while rotating. The samples were washed four times with 1x HEGN lysis 
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buffer containing 120 mM KCl, resuspended in sample buffer and subjected to 
immunoblot analysis. 
3.3.12 Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation was performed to detect protein-DNA interactions. 
Therefore, proteins were cross-linked to DNA by formaldehyde, the chromatin isolated and 
subsequently fragmented. The protein-DNA fragments were precipitated using specific 
antibodies against the protein and enrichment of the DNA was detected by quantitative 
real-time PCR using primers for a certain DNA sequence.  
 
Formaldehyde fixation and chromatin isolation 
For a ChIP, cells were grown on 15 cm dishes and per IP, approximately 1x107 cells were 
used. To cross-link proteins to DNA, the cells were fixed with 1% formaldehyde for 15 
min at RT while slowly shaking. By addition of glycine to a final concentration of 125 mM 
the fixation was stopped and the plates were incubated for 5 min at RT on a shaker. To 
detect indirect chromatin binding, which was mediated by protein-protein interactions, 
cells were additionally cross-linked with disuccinimidyl glutarate (DSG) for 45 min at RT 
prior to formaldehyde cross-linking. 
The following steps were carried out on ice or at 4°C. Cells were washed twice with ice-
cold PBS and scraped off the plates with PBS containing 1 mM PMSF. After 
centrifugation for 10 min at 1000 x g, the cell pellets were resuspended in 5 ml hypotonic 
ChIP swelling buffer (the volume was increased depending on the size of the cell pellet) 
containing proteinase and phosphatase inhibitors and incubated for 10 min on ice. The cell 
membranes were disrupted by 15 strokes with a dounce homogenizer and nuclei were 
pelleted by centrifugation for 10 min at 800 x g. Nuclei were resuspended in 1 - 2.5 ml 
(depending on the size of the nuclear pellet) ChIP sonication buffer containing proteinase- 
and phosphatase inhibitors and sonified in order to obtain DNA fragments between 200 - 
300 bp. Sonication conditions and time was determined empirically for every cell line. 
Chromatin of IMECs was fragmented for 15 - 20 min at 35% amplitude (10 s pulse, 50 s 
break). After sonication the size of the fragmented chromatin was determined. 
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Chromatin size control 
For size control, 20 !l chromatin was diluted with 380 !l ChIP elution buffer, 16.8 !l 5 M 
NaCl was added and the samples were incubated at 65°C for 6 h while shaking. Then, 1 !l 
RNase A (10 mg/ml stock solution) was added, followed by incubation at 37°C for 1 h. 
Afterwards, 2 !l proteinase K (1 mg/ml stock solution) was added and the samples 
incubated at 45 °C for 2 h in a thermo shaker. Chromatin was purified by phenol-
chloroform extraction, precipitated with 100% EtOH and 3 M Na-acetate and washed with 
80% EtOH. The DNA was air-dried, solubilized in 20 !l ddH2O and loaded with 6 x DNA-
loading buffer on a 2 % agarose gel. After size control, the chromatin was centrifuged for 
60 min at 20.000 x g and the supernatant containing the soluble chromatin was transferred 
into 1.5 ml low binding microtubes. 
 
Coupling of antibodies to protein A or G dynabeads 
Per 1 !g antibody, 10 !l protein A or G dynabeads were used for ChIP. The dynabeads 
were washed three times with ChIP blocking solution. Usually 2 !g antibody was used per 
IP and incubated with the washed dynabeads in 500 !l ChIP blocking solution over night 
at 4°C on a rotating wheel. On the following day, the blocking solution was removed and 
the beads were resuspended in blocking solution (in 1/10 of the chromatin volume used for 
the ChIP) and added to the chromatin. As a reference, 1% of the chromatin was taken as an 
input sample. 
 
Immunoprecipitation 
The chromatin was incubated with the antibody-coupled dynabeads over night at 4°C on a 
rotating wheel in low binding tubes. On the next day, the beads were washed two times 
with ChIP sonication buffer, two times with ChIP high salt buffer and one time with ChIP 
LiCl buffer. After each washing step, dynabeads were sedimented with a magnetic rack, 
the buffer removed and fresh buffer added. Each washing step included an incubation for 5 
min on the rotating wheel at 4°C. 
 
Elution, decrosslinking and DNA purification 
To elute the precipitated DNA from dynabeads, beads were resuspended in 230 !l ChIP 
elution buffer and incubated for 15 min at 65°C while intensively shaking. The beads were 
sedimented with a magnetic rack and 200 !l of the eluted DNA was transferred to a fresh 
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reaction tube. 200 !l fresh ChIP elution buffer was added to the beads, the incubation was 
repeated and again 200 !l were transferred to the tubes. Afterwards, 16.8 !l 5 M NaCl was 
added to the 400 !l eluate. The input samples were filled up with elution buffer to a 
volume of 400 !l. To revert the cross-linking, the samples were incubated at 65°C for at 
least 6 h while shaking. Then, 1 !l RNase A (1 mg/ml stock concentration) was added and 
the samples incubated for 1 h at 37°C, followed by addition of 2 !l proteinase K  (1 mg/ml 
stock concentration) and incubation at 45°C for 2 h. The DNA was purified by phenol-
chloroform extraction. To this end, 420 !l phenol-chloroform-isoamyl alcohol was added, 
the samples were vortexed and centrifuged for 10 min at 20,000 x g at RT. The upper 
phase (~390 !l) was transferred to a new 1.5 ml reaction tube, 2.5 sample volumes 100% 
EtOH, 1/10 sample volume 3 M Na-acetate pH 5.2 and 2 !l glycoblue (Life technologies, 
15 mg/ml) were added. The samples were incubated for 30 min at -80°C, centrifuged for 
30 min at 20,000 x g and the DNA pellet was washed with 80 % EtOH. After air-drying, 
the DNA pellet was solubilized in 250 !l ddH2O. For quantitative real-time PCR, 5 !l of 
chromatin was used per reaction (see 3.2.12.2). 
 
3.4 Next-generation sequencing 
3.4.1 ChIP for deep sequencing 
For ChIP-Sequencing the standard ChIP procedure was performed with a few exceptions. 
The amount of cells, antibody and dynabeads were increased approximately 5 fold. The 
precipitated and purified DNA was solubilized in 40 !l ddH2O and quantified using the 
Quanti-iTTM PicoGreen® dsDNA Assay Kit (Life technologies). 
3.4.2 mRNA isolation, fragmentation and cDNA synthesis for RNA-
Sequencing 
For RNA-Sequencing, total RNA was isolated with RNeasy® Mini Columns (see 3.2.10.2). 
Quality of the RNA was analyzed using the Experion™ Automated Electrophoresis 
System (Biorad) with RNA standard sense Chips according to manufacturers’ protocol. 
RNA used for RNA-Sequencing had at least a RNA quality indicator (RQI) of 9. The RQI 
can range from 10 (intact RNA) to 1 (degraded RNA). After quality analysis, 1 !g total 
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RNA was used to isolate mRNA with the NEBNext® Poly(A) mRNA Magnetic Isolation 
Module according to the manufacturer’s instructions. Agencourt AMPure XP Beads 
(Beckman Coulter) were used to purify the double stranded cDNA and used for library 
preparation starting with the DNA end repair. 
3.4.3 Library preparation 
3.4.3.1 NEBNext® Ultra™ RNA Library Prep Kit for Illumina® 
RNA library preparation was performed according to manufactures’ instructions. Libraries 
were size-selected using Agencourt AMPure XP Beads followed by amplification with 12 
PCR cycles. Libraries were quantified and the library size was determined with the 
Experion Automated Electrophoresis System (Bio-Rad). 
3.4.3.2 NEBNext® ChIP-Seq Library Prep Master Mix Set for Illumina® 
ChIP-Seq libraries were prepared following the instruction manual. Libraries were size-
selected on an agarose gel and purified by gel extraction (Qiagen). Libraries were 
amplified with 18 PCR cycles. Quantification and size determination was performed with 
the Experion Automated Electrophoresis System (Bio-Rad). 
3.4.4  Sequencing data analysis 
For sequencing data analysis, FASTQ-files were generated, aligned to the human genome 
“hg19” with BOWTIE v.0.12.8 and the resulting .sam files were converted into binary 
.bam files by Samtools. All further analyses were performed in R v3.1.1. 
For RNA-Sequencing, the program edgeR was used to analyze the data sets for differential 
gene expression. 
All bioinformatical analyses of deep-sequencing data were performed by Dr. Björn von 
Eyß. 
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4 Results 
4.1 MYC is a ubiquitinated protein 
MYC is a well-established target of the ubiquitin-proteasome system. Nevertheless, it 
remained open which lysines in MYC are ubiquitin acceptor sites. To identify 
ubiquitinated lysine residues in MYC, mass spectrometric analysis of immunoprecipitated 
MYC was performed in collaboration with the mass spectrometry technology platform of 
the Max-Delbrück Centre (MDC) in Berlin headed by Dr. Gunnar Dittmar. To analyze 
samples by mass spectrometry, proteins are fragmented by tryptic digestion. When a lysine 
is ubiquitinated, the two C-terminal glycine residues of ubiquitin remain attached to the 
respective target lysine residue after trypsin digestion, resulting in a characteristic shift of 
the expected molecular weight of the peptide (Peng et al., 2003). 
Flag-tagged MYC was immunoprecipitated from HeLa cell lysates and a fraction of the 
eluate was subjected to SDS-PAGE analysis followed by silver staining. Cells transfected 
with the corresponding vector served as a control. The silver staining showed a band at the 
expected molecular weight in the eluate of Flag-tagged MYC-expressing cells, which was 
absent in the eluate of vector-expressing cells (Fig. 4.1 A). The presence of Flag-MYC in 
the eluate was confirmed by immunoblot analysis (Fig. 4.1 B). Mass spectrometric analysis 
identified lysine 148 and lysine 389 as ubiquitin acceptor sites in MYC (Fig. 4.1 C, marked 
in red). 
Kim et al. performed a global mass spectrometric approach to characterize the human 
ubiquitin-modified proteome and identified seven lysines in endogenous MYC as being 
ubiquitinated; three lysines in the N-terminal region (K52, K148 and K157) and four 
lysines in the C-terminal region of MYC (K323, K355, K389, K412) (Kim et al., 2011) 
(Fig. 4.1 C, marked in black and red). These analyses show that exogenous and 
endogenous MYC is post-translationally modified with ubiquitin. 
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Figure 4.1: Identification of ubiquitin acceptor sites in MYC 
A) Silver staining of eluates from vector and Flag-MYC-expressing cells. Flag-MYC was 
immunoprecipitated under denaturing conditions from transiently transfected HeLa cells and 
eluted with Flag-peptide. 
B) Immunoblot analysis of eluates from vector and Flag-MYC-expressing cells. Presence of Flag-
MYC in the eluate was detected with a Flag antibody. 
C) Schematic domain structure of MYC. Lysines marked in red were identified as ubiquitin 
acceptor sites by mass spectrometry. Ubiquitinated lysine residues identified by (Kim et al., 
2011) are marked in red or black. 
D) In vivo ubiquitination assay of wild type (WT) and K-less MYC. HeLa cells were transfected 
with His-tagged ubiquitin and either N-terminally HA-tagged WT or K-less MYC. 48 h after 
transfection, His-ubiquitin modified proteins were precipitated under denaturing condition with 
Ni2+-NTA-agarose and analyzed by immunoblotting. An input sample (10%) was analyzed as a 
control. 
This figure was submitted for publication in similar form in (Jaenicke et al., under review). 
4.1.1 K-less MYC is not ubiquitinated in vivo 
Ubiquitin-modified MYC can be detected by an in vivo ubiquitination assay. To compare 
the ubiquitination status of wild type (WT) and K-less MYC in this assay, HeLa cells were 
transfected with His-tagged ubiquitin and either HA-tagged WT or K-less MYC. 48 h after 
transfection all His-ubiquitin modified proteins were precipitated under denaturing 
conditions with Ni2+-NTA-agarose. Subsequent immunoblot analysis revealed that WT 
MYC is modified with His-ubiquitin due to characteristic slower migrating ubiquitin-MYC 
conjugates (Fig. 4.1 D). Consistently, ubiquitin-MYC conjugates are absent in K-less 
MYC overexpressing cells. In both precipitated samples a band at a molecular weight of 
about 60 kDa is detected with a HA antibody, representing unmodified WT and K-less 
MYC that bind unspecifically to the Ni2+-NTA-agarose (Fig. 4.1 D). The ubiquitination 
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assay demonstrates that ubiquitinated WT MYC, but not K-less MYC is ubiquitinated in 
vivo. 
 
4.2 K-less MYC retains significant biological activity 
4.2.1 K-less MYC interacts with known MYC interaction partners 
Since the mutation of lysine to arginine residues in K-less MYC could influence the 
structure and thereby the general function of the protein, it was investigated whether the 
mutations affect binding to known MYC interaction partners. 
The interaction of MYC with MAX is crucial for DNA-binding and transcriptional 
regulation. MYC heterodimerizes via its helix-loop-helix-leucine zipper domain with 
MAX and several lysine residues are located within this region (Blackwood and Eisenman, 
1991). To test whether K-less MYC is able to interact with MAX, a co-
immunoprecipitation assay was performed from HeLa cells transiently expressing HA-
tagged WT or K-less MYC. Endogenous MAX was precipitated and co-precipitated MYC 
was detected by immunoblotting with an antibody against the N-terminal HA-tag. Both 
WT and K-less MYC co-precipitated with MAX revealing that the mutation of lysines to 
arginines does not interfere with MAX binding (Fig. 4.2 A, lane 1 and 2). The 
immunoprecipitation was specific since depletion of endogenous MAX by co-transfected 
shRNAs resulted in decreased co-precipitation of MYC and no protein was precipitated 
with the unspecific IgG control (Fig. 4.2 A lane 3 and 4). 
The helix-loop-helix domain mediates interaction of the MYC/MAX heterodimer with the 
transcription factor MIZ1, which form a repressive complex (Peukert et al., 1997). To 
investigate whether mutation of lysine residues in MYC abrogates interaction with MIZ1, 
co-immunoprecipitation assays of transfected HeLa cells were performed. WT and K-less 
MYC interacted with MIZ1 with the same efficiency (Fig. 4.2 B, lane 2 and 3). The 
interaction was specific since MYC was neither detected in the IgG precipitation nor in the 
samples that did not overexpress MIZ1 (Fig. 4.2 B, lanes 1 and 4 for IgG control and lanes 
8 and 9). This result was further verified by MYC immunoprecipitation and detection of 
co-precipitated MIZ1 (Fig. 4.2 B, lanes 5-7). 
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Figure 4.2: K-less MYC interacts with MAX and MIZ11 
A) Co-Immunoprecipitation of WT and K-less MYC with endogenous MAX. HeLa cells were 
transiently transfected with N-terminally HA-tagged WT or K-less MYC and either a control 
shRNA that does not target any gene or shRNAs targeting MAX. 48 h after transfection cell 
lysates were prepared and either MAX was immunoprecipitated or an immunoprecipitation 
with unspecific rabbit anti-IgG was performed. Precipitated proteins were detected by 
immunoblotting with the indicated antibodies. 
B) Exogenous co-immunoprecipitation of WT and K-less MYC with MIZ1. HeLa cells transiently 
expressing HA-tagged WT or K-less MYC and MIZ1 were harvested 48 h after transfection 
and subjected to immunoprecipitation using either a MYC or MIZ1 specific antibody or an 
unspecific rabbit anti-IgG. Immunoprecipitated proteins were detected by immunoblot 
analysis. 
 
These results illustrate that K-less MYC interacts with known MYC-interaction partners 
suggesting that the mutation of lysines to arginine residues does not affect basic properties 
of MYC. 
4.2.2 K-less MYC is a nuclear, chromatin-associated protein 
Ubiquitination of proteins can influence their cellular localization and chromatin 
association (see 1.2.4). Therefore, it was important to assess whether both WT and K-less 
MYC are located in the nucleus and show the same distribution in fractionation assays. 
To determine the cellular localization of WT and K-less MYC, immunofluorescence 
staining of immortalized mammary epithelial cells (IMECs) stably expressing HA-tagged 
WT or K-less MYC was performed. Both proteins localized to the nucleus as revealed by 
the co-localization of the HA-signal with Hoechst (Fig. 4.3 A). 
 
 
 
 
 
1This figure was published in similar form in (Popov et al., 2010). 
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Figure 4.3: K-less MYC localizes to the nucleus and is chromatin-associated2 
A) Immunofluorescence staining of WT and K-less MYC. Cells stably expressing WT-HA or K-
less-HA MYC were seeded on cover slips and their localization was detected with a HA 
antibody. Vector-infected cells served as a control. Nuclei were stained with Hoechst.  
Scale bar = 20 !m  
B) Fractionation assay of cells stably expressing vector, WT-HA or K-less-HA. Cell lysates were 
separated into cytosolic, nucleoplasmic and chromatin-enriched fraction and the presence of 
WT and K-less MYC was determined with a HA antibody. Tubulin served as a control for 
cytosolic, H2B and HELLS for the chromatin-enriched fraction. 
 
To test whether WT and K-less MYC bind to chromatin, cell lysates of cells stably 
expressing vector, WT-HA or K-less-HA were separated by centrifugation and Benzonase 
digestion into cytosolic, nucleoplasmic and chromatin-enriched fraction. This separation 
produced pure fractions, since tubulin (a cytoplasmic protein) could only be detected in the 
cytosolic fraction whereas histone H2B was present in the chromatin-enriched fraction. 
The DNA helicase HELLS was used as an example of a nuclear protein that is associated 
with chromatin (Yan et al., 2003). Consistently, HELLS was detected in the chromatin-
enriched and nucleoplasmic fraction. MYC is a predominately nuclear protein that shuttles 
between nucleus and cytosol (Arabi et al., 2003). In agreement, WT MYC was detected in 
the chromatin-enriched fraction and to some extent in the cytosolic and nucleoplasmic 
fractions. Importantly, WT and K-less MYC showed a similar distribution in this assay 
(Fig. 4.3 B). Thus, the absence of lysine residues in K-less MYC does not change its 
cellular localization or chromatin-association. 
 
2This figure was submitted for publication in similar form in (Jaenicke et al., under 
review) (see also following pages). 
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4.2.3 K-less MYC activates an E-box luciferase reporter 
To assess whether K-less MYC retains basic transactivating functions, a luciferase reporter 
assay was performed. The prothymosin-α promoter contains a canonical E-box, which was 
subcloned in front of the firefly luciferase open reading frame (Gaubatz et al., 1995). 
 
 
Figure 4.4: WT and K-less MYC activate an E-box luciferase reporter2 
HeLa cells were transfected with the indicated MYC-expression vectors and a luciferase reporter 
construct containing the prothymosin-α promoter. An expression vector encoding for β-
galactosidase was co-transfected. 48 h after transfection luciferase activity was determined and 
normalized to β-galactosidase activity. Error bars represent standard deviation of biological 
triplicates. MYC expression was confirmed by immunoblot analysis. VINCULIN served as a 
loading control. 
 
Expression of increasing amounts of WT MYC resulted in an increased luciferase activity. 
Expression of K-less MYC had the same effect and transactivated the luciferase reporter to 
the same extent as WT MYC (Fig. 4.4). Thus, K-less MYC activated an E-box-luciferase 
reporter as efficiently as the WT protein. 
4.2.4 K-less MYC has an increased half-life 
MYC is a short-lived protein that is rapidly turned over by the ubiquitin-proteasome 
system (Farrell and Sears, 2014) and lysines are the major acceptor site for ubiquitin 
(Komander and Rape, 2012). Accordingly, mutation of all lysine residues of a short-lived 
protein to arginine is expected to increase its half-life. 
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Figure 4.5: K-less MYC has an increased half-life compared to WT MYC2 
A) Comparison of steady-state MYC protein levels of WT and K-less MYC. Protein lysates of 
WT and K-less MYC-expressing cells were analyzed by immunoblot analysis. Cells were 
either treated with EtOH (-MG) or MG132 (+MG) 4 h prior to cell lysis. Cell lysates were 
analyzed by immunoblotting for the abundance of WT and K-less MYC using a MYC-specific 
antibody. VINCULIN served as a loading control. 
B) Cycloheximide decay assay of WT and K-less MYC-expressing cells. IMECs stably expressing 
WT or K-less MYC were treated with MG132 (+MG) or EtOH (-MG) 2 h prior to 
cycloheximide (CHX) addition. Additionally, cells were treated with cycloheximide for the 
indicated timepoints. Cell lysates were analyzed by immunoblotting with the indicated 
antibodies. VINCULIN was used as a loading control. 
C) Quantification of cycloheximide decay assays. Three biological independent experiments were 
quantified, MYC level were normalized to VINCULIN and the relative MYC level were 
averaged. Relative MYC level were plotted over time of cycloheximide treatment. Error bars 
represent standard error of the mean of three independent biological experiments. 
 
Stable expression of WT and K-less MYC in IMECs revealed a higher steady-state level of 
K-less MYC compared to WT MYC level (Fig. 4.5 A, -MG). MG132 is a membrane-
permeable inhibitor that blocks the proteolytic activity of the proteasome by binding to the 
active sites of the 20S core particle (Lee and Goldberg, 1996). Consequently, treating cells 
with MG132 should increase the abundance of short-lived proteins. As expected, WT and 
K-less MYC steady-state level were equalized by the treatment with the proteasome 
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inhibitor MG132 (Fig. 4.5 A). This result suggests that K-less MYC has an increased 
protein half-life compared to WT. 
To confirm differences in protein half-life of WT and K-less MYC, a cycloheximide decay 
assay was performed. Protein half-life was determined by addition of the protein 
translation inhibitor cycloheximide for various time points. Thereby, new protein synthesis 
is blocked and turnover of a protein can be followed by immunoblot analysis. To assess, 
whether the protein turnover is mediated by proteasomal degradation, the cycloheximide 
decay assay was performed in the presence and absence of proteasome inhibition. 
WT MYC was rapidly turned over as judged by the decreasing MYC-level over time. This 
effect was proteasome-dependent since treatment with MG132 abolished MYC turnover 
and completely stabilized the protein (Fig. 4.5 B, compare WT –MG with WT +MG). 
Quantification revealed a half-life of WT MYC in IMECs of approximately 13 min. K-less 
MYC was more stable with a half-life of 53 min. The remaining K-less MYC turnover 
could be rescued by proteasomal inhibition (Fig. 4.5 B and C). Therefore, mutation of 
ubiquitin-acceptor-sites in the short-lived protein MYC increases its protein half-life by 
attenuating proteasome-mediated degradation. 
4.3 K-less MYC is unable to induce proliferation and apoptosis in 
immortalized mammary epithelial cells 
K-less MYC retains significant biological activity and acts similar to the WT protein in 
several functional tests. However, previous reports clearly implicate that ubiquitination has 
a regulating effect on MYC activity (see 1.3.3.2.4). Thus, the biological effect of mutating 
ubiquitin acceptor sites in MYC was investigated in mammary epithelial cell lines, which 
show a strong biological response upon MYC expression and, therefore, are a useful 
system to study MYC-induced phenotypes. 
MCF10A cells are non-transformed human epithelial cells from the mammary gland. They 
were spontaneously immortalized, harbor a MYC amplification and CDKN2A deletion 
(Kadota et al., 2010; Soule et al., 1990; Worsham et al., 2006). Their endogenous MYC 
level is comparable to the transformed human osteosarcoma cell line U2OS but lower 
compared to the transformed human cervix adenocarcinoma cell line HeLa (Fig. 4.6). 
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Figure 4.6: Endogenous MYC level in different cell lines 
Comparison of endogenous MYC level in different cell lines. Endogenous MYC level of two 
transformed cell lines were compared to the level of two non-transformed immortalized mammary 
epithelial cell lines. Cell lysates were analyzed by immunoblotting using a MYC-specific antibody 
and VINCULIN as a loading control. 
 
The non-transformed human mammary epithelial cell line IMECs (immortalized mammary 
epithelial cells) was immortalized by stably overexpressing the catalytic subunit of human 
telomerase (hTERT) (DiRenzo et al., 2002). IMECs express little endogenous MYC on 
protein level relative to transformed cell lines like HeLa or U2OS or the non-transformed 
MCF10A cell line (Fig. 4.6). 
4.3.1 WT but not K-less MYC induces apoptosis in MCF10A cells 
One major phenotype observed in MCF10A cells after MYC overexpression is a strong 
induction of apoptosis (Wiese et al., 2015). To analyze whether K-less MYC is able to 
induce apoptosis in these cells, MCF10A cells were transduced with lentiviruses encoding 
for WT or K-less MYC or an empty vector control. While vector- and K-less MYC-
expressing cells showed only minor signs of apoptosis, WT MYC-expressing cells were 
strongly apoptotic (Fig. 4.7 A). 
 
Figure 4.7: K-less MYC is unable to induce apoptosis in MCF10A cells 
A) Microscopy pictures of MCF10A cells stably expressing vector, WT or K-less MYC.  
Scale bar =25 !m  
B) Immunoblot analysis of cell lysates from vector, WT and K-less MYC-expressing 
MCF10A cells. Apoptosis induction was analyzed by detection of cleaved-PARP. CDK2 
was used as a loading control. 
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Apoptosis induction by elevated WT MYC level was confirmed by detection of cleaved 
poly(ADP-ribose) polymerase (PARP), a marker of apoptosis. Cleaved PARP was detected 
only in WT MYC-expressing but not in vector or K-less MYC-expressing cells, showing 
that absence of lysine residues decreased MYC’s ability to induce apoptosis in MCF10A 
cells (Fig. 4.7 B). 
4.3.2 WT but not K-less MYC induces proliferation in IMECs 
Ectopic expression of MYC induces proliferation of IMECs (Cowling et al., 2007). To 
assess whether K-less MYC promotes proliferation, IMECs were transduced with 
lentiviruses encoding for WT or K-less MYC or an empty vector control. As expected, WT 
MYC induced proliferation compared to vector-expressing cells, as determined by crystal 
violet staining of the cells. Interestingly, K-less MYC-expressing cells did not show 
enhanced proliferation (Fig 4.8 A). This result could further be verified by a cumulative 
growth curve. Expression of WT but not K-less MYC resulted in an increase in cell 
number compared to vector-infected cells, although K-less MYC was expressed at higher 
level (Fig. 4.8 B). 
To investigate whether the growth advantage of WT MYC-expressing IMECs is cell-
autonomous, a single-color competition assay was performed. Expression of vector, WT 
and K-less MYC was coupled to GFP by an internal ribosomal entry site (IRES). 20 % of 
infected, GFP-positive cells either expressing vector, WT or K-less MYC were mixed with 
80% uninfected GFP-negative cells and the percentage of GFP-positive cells was 
monitored by FACS over time. The percentage of GFP-positive, WT MYC-expressing 
cells increased over time whereas the fraction of K-less MYC or vector-expressing cells 
remained constant (Fig. 4.8 C), demonstrating that vector or K-less MYC cells do not have 
a growth advantage compared to uninfected IMECs. In contrast, WT MYC induces a 
growth advantage in IMECs. The absence of lysine residues in K-less MYC, therefore, 
resulted in an inability to induce proliferation in IMECs. 
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Figure 4.8: Proliferation assays in IMECs expressing WT or K-less MYC2 
A) Crystal violet staining of IMECs expressing vector, WT or K-less MYC. Equal cell 
numbers of IMECs stably expressing vector, WT or K-less MYC were seeded. After six 
days, cells were stained with crystal violet. 
B) Cumulative growth curve of IMECs expressing vector, WT-HA or K-less-HA MYC. 
Results are presented as mean ± SD of triplicates (left panel). MYC expression was 
confirmed by immunoblot analysis using a HA antibody recognizing the C-terminal HA-
tag of MYC. VINCULIN served as a loading control (right panel). 
C) Single-color competition experiment of IMECs expressing vector, WT and K-less MYC 
coupled to GFP expression. Infected GFP-positive cells were mixed with uninfected GFP-
negative cells and percentage of GFP-positive population was monitored over time by 
FACS analysis. Results are presented as mean ±SD of triplicates (left panel). Immunoblot 
analysis of the corresponding stable cell lines documents MYC expression (right panel). 
4.3.3 K-less MYC is impaired in inducing S-phase entry of starved IMECs 
Mammary epithelial cells can be arrested in G1-phase by withdrawal of the mitogen EGF 
(Abukhdeir et al., 2008). To analyze whether MYC expression induces S-phase entry in 
the absence of growth factors, IMECs expressing doxycycline-inducible WT-HA or K-
less-HA MYC were starved of EGF and MYC expression was induced by addition of 
doxycycline (Dox). MYC-induction was documented by immunoblot analysis (Fig. 4.9 A). 
Vector-expressing cells were used as a control to exclude effects of Dox alone on S-phase 
entry. Subsequently, S-phase entry was analyzed by BrdU/PI-FACS. 
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Figure 4.9: WT but not K-less MYC induces S-phase entry of starved IMECs2 
A) Immunoblot analysis of lysates from starved IMECs expressing Dox-inducible MYC-HA 
after 18 h Dox (+) treatment or EtOH (-) as a control. Immunoblot documents MYC 
expression. VINCULIN served as a loading control. 
B) BrdU/PI-FACS of IMECs expressing vector or doxycycline-inducible MYC-HA after 24 h 
starvation and further 18 h of Dox administration. Depicted is a representative example 
from biological triplicates. Dashed box marks BrdU-positive cells. 
C) Quantification of S-phase entry of starved IMECs after 18 h of MYC-HA induction by 
Dox administration. Treatment with EtOH served as a control. Error bars represent 
standard deviation of biological triplicates. P-value was calculated with a Student’s t-test. 
 
7-10% of the EtOH treated cells were present in S-phase (BrdU-positive, higher population 
with DNA-content between 2n and 4n). 18 h after Dox-treatment, 10% of vector 
expressing cells were BrdU-positive (Fig. 4.9 B, C). WT MYC-expression induced S-
phase entry and approximately 27% of WT MYC-expressing cells were BrdU-positive. 
Upon K-less MYC-expression, around 12% of the cells were present in S-phase (Fig. 4.9 
B, C). This shows that K-less MYC is significantly less efficient in S-phase induction than 
WT MYC in EGF-starved IMECs. 
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4.4 K-less MYC binds to known MYC-regulated promoters 
4.4.1 Genome-wide binding profile of WT and K-less MYC 
Ubiquitination of a transcription factor can affect recruitment to promoters and thereby 
influence its activity (see figure 1.3). Differential binding of WT and K-less MYC to 
MYC-regulated promoters could explain the observed differences in induction of MYC-
mediated phenotypes. To analyze whether WT and K-less MYC differ in binding to MYC-
regulated promoter, chromatin immunoprecipitation (ChIP) experiments were performed 
from IMECs stably expressing WT-HA, K-less-HA or vector as a control. 
WT-HA MYC was strongly enriched over IgG at the transcriptional start site (TSS) of 
known MYC-regulated promoters such as FBXW8 and NCL, whereas K-less MYC showed 
only a weak binding compared to WT MYC. No specific enrichment could be detected in 
vector-infected cells, demonstrating the specificity of the HA antibody. As a control, MYC 
binding to an intergenic region on chromosome 11 was analyzed, where no MYC binding 
was expected. WT MYC was strongly (36-fold) enriched at the FBXW8 TSS over control 
region whereas K-less MYC was only enriched threefold (Fig. 4.10 A). 
Although K-less MYC is a nuclear and chromatin-associated protein with a higher steady-
state level compared to WT MYC (Fig. 4.3 A, B), less K-less MYC could be immuno-
precipitated at MYC-regulated promoters. One explanation for this observation is that K-
less MYC is recruited to different sites in the genome compared to WT MYC. To analyze 
this hypothesis, the genome-wide binding profiles of WT and K-less MYC in IMECs were 
determined by ChIP-Sequencing (ChIP-Seq). To this end, ChIPs with a HA antibody were 
performed from IMECs stably expressing WT-HA and K-less-HA MYC, followed by deep 
sequencing. The bioinformatical analyses of these and all following deep-sequencing data 
were performed by Dr. Björn von Eyss. 
For every condition, more than 2.4x107 reads were generated and around 98% of the reads 
could be mapped to the human genome (Fig. 4.10 B). 4118 MYC peaks were identified in 
WT-HA MYC expressing cells with 1453 bound promoters in a window of 1500 bp 
around the TSS. For K-less MYC-expressing cells, 568 MYC peaks were identified with 
13 bound promoters (Fig. 4.10 B). One of the best-bound genes by WT MYC was GNL3. 
The ChIP-Seq track for WT-HA MYC showed a strong peak at the TSS of GNL3 whereas 
no peak was detectable in the input track. K-less MYC also showed a clear peak at the TSS 
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of GNL3 with fewer tags. Thus, K-less MYC binding to the GNL3 TSS appeared weaker 
compared to binding of WT MYC (Fig. 4.10 C). 
Figure 4.10: Genome-wide binding profiles of WT and K-less MYC2 
A) Chromatin-immunoprecipitation of WT-HA and K-less-HA MYC-expressing IMECs. 
Chromatin of IMECs stably expressing WT-HA, K-less-HA or vector was 
immunoprecipitated with a HA antibody or an unspecific IgG as a control. Precipitated and 
purified DNA was analyzed by qPCR with primers amplifying the transcriptional start site 
(TSS) of the indicated genes or an intergenic control region (Ctrl region). Data are 
represented as mean ± SD. 
B) Summary of the ChIP-Sequencing (ChIP-Seq) results. Comparison of reads, binding sites 
and bound promoters for the different samples is shown. 
C) Genome browser picture displaying ChIP-Seq tracks for WT-HA, K-less-HA and the input 
sample. Shown is a genomic region on chromosome 3 with the genes GNL3 and GLT8D1. 
D)  Binned dot plot of peaks, which were detected in the WT-HA sample. Here, the tags were 
counted in the peaks of the WT-HA sample and the K-less sample, respectively. The 
windows were derived from the peaks of the WT sample. All peaks were sorted according 
to their tag counts in the K-less MYC sample and summarized as 30 bins for WT and K-
less (92 genes per bin). For each bin, the median was plotted. 
E) Histogram of peak distance from TSS. Mean tag density (tags / 50 bp windows) of WT 
MYC peaks were plotted in a region -/+ 2 kb from the TSS. Tags of K-less MYC peaks 
within these windows were counted and plotted accordingly. 
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To compare the genome-wide binding of WT and K-less MYC, a plot for tags within MYC 
peaks (of WT-HA and K-less-HA MYC) was generated. For WT MYC peaks, a window 
±200 bp of the peak summit was defined and tags within these windows were counted for 
WT and K-less MYC samples. For better illustration, the peaks were grouped into bins. 
For K-less-HA MYC, each bin includes the same genomic coordinates as WT-HA MYC 
and the median tag number was plotted against WT tags (Fig 4.10 D). Globally, the 
binding of K-less MYC appeared weaker. 
To determine the relative positioning of the identified peaks to the TSS, tags of peaks 
identified for WT MYC were counted in 50 bp windows within a distance of 2 kb around 
the TSS. The mean density was then plotted in a histogram (Fig. 4.10 E). WT MYC peaks 
had a mean density of around 32 tags and were positioned at the TSS. To compare the 
positioning to K-less MYC peaks, tags within the same windows were counted and plotted 
in the same histogram. K-less MYC peaks had less tags compared to WT with a mean 
density of around 9 tags. Importantly, the distribution of the peaks did not differ and were 
localized exactly as the WT MYC peaks. 
Taken together, the ChIP-Seq data revealed that K-less MYC shows an identical binding 
profile to WT MYC even though the binding strength appears weaker. 
4.4.2 K-less MYC is present at MYC-regulated promoters 
The ChIP-Seq results suggested that K-less MYC is less present at MYC-binding sites 
compared to WT MYC. During the ChIP procedure, formaldehyde is used to cross-link 
proteins to DNA. Formaldehyde cross-linking occurs between amino and imino groups of 
DNA bases and different amino acids like lysine, histidine and cysteine or the amino-
terminus of a protein (Kuo and Allis, 1999). Here, lysine-residues are preferentially cross-
linked, in particular during the short incubation time with formaldehyde used in a ChIP 
procedure (Lu et al., 2010; Toews et al., 2008). Therefore, the mutation of the most cross-
linkable amino acid lysine to an arginine in K-less MYC most likely results in a less 
efficiently cross-linked protein. This suggests that K-less MYC might bind as efficiently to 
chromatin as the WT protein but is not as efficiently cross-linked resulting in a poor 
enrichment in ChIP assays. 
To analyze whether K-less MYC binds as efficiently to MYC-regulated promoter as the 
WT protein, native ChIPs from either vector, WT-HA or K-less-HA MYC infected IMECs 
were performed. In a native ChIP, no cross-linkers are used but the DNA is fragmented by 
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MNase digestion and the immunoprecipitation occurs under mild, native conditions 
(Kasinathan et al., 2014). K-less MYC showed a strong enrichment over vector and control 
region at the previously identified MYC-binding site in the GNL3 promoter and the 
binding seemed even stronger compared to WT MYC (Fig. 4.11 A). 
Figure 4.11: K-less MYC binds to MYC-regulated promoters2 
A) Native ChIP from IMECs stably expressing vector, WT-HA or K-less-HA. The ChIP was 
performed with a HA antibody under native conditions and binding to the GNL3 TSS or, as 
a negative control, to the U2 promoter was analyzed by qPCR. Results are given as mean 
±SD (left panel). The native ChIP was performed by Dr. Björn von Eyß. Immunoblot 
analysis confirmed expression of WT and K-less MYC. VINCULIN was used as a loading 
control (right panel).  
B) Analysis of GNL3 mRNA expression by qPCR. Cells stably expressing Dox-inducible 
WT-HA, K-less-HA or vector were treated either with EtOH (-) or Dox (+) for 4 h. Results 
are given as mean ±SD. 
 
GNL3 is not only bound but also induced by WT MYC. Interestingly, although K-less 
MYC bound to the GNL3 TSS, it was unable to induce GNL3 mRNA expression, 
indicating that the defect in induction of GNL3 mRNA is associated with a post-DNA-
binding step (Fig. 4.11 B). 
The binding of K-less MYC to MYC-regulated promoters was further confirmed by its 
ability to replace other BR-HLH/LZ transcription factors from E-boxes. In addition to 
MYC, MAX heterodimerizes with proteins of the MXD family. These heterodimers bind 
to E-boxes but repress transcription by recruiting histone deacetylase complexes (Adhikary 
and Eilers, 2005). MXD6 (MNT) is co-expressed with MYC in proliferating cells (Hurlin 
et al., 1997). Since MXD6/MAX dimers also bind E-box sequences, MYC expression is 
expected to displace MXD6 from these sites whereas MAX occupancy should not change. 
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Figure 4.12: K-less MYC binds to MYC-regulated promoters2 
A) Expression of WT-HA or K-less-HA was induced by addition of Dox for 3 h. ChIP assays 
were performed with either a HA, MXD6 or MAX antibody. Precipitated and purified 
DNA was analyzed by qPCR with primers amplifying the TSS of GNL3 or a control region 
(Ctrl region). Fold displacement and fold recruitment was calculated in reference to the 
corresponding EtOH treated sample. Results are given as mean ±SD (upper left and lower 
panels). Immunoblot analysis documents induction of MYC expression 3 h after Dox 
administration. Lysates were further analyzed for MXD6 and MAX expression (upper right 
panel). 
B) ChIP of MYC-expressing IMECs. Formaldehyde cross-linked chromatin of IMECs stably 
expressing the indicated MYC-HA alleles or vector was immunoprecipitated with a HA 
antibody. Precipitated and purified DNA was analyzed by qPCR with primers amplifying 
the TSS of GNL3 or a control region (Ctrl region). Data are represented as mean ± SD 
(upper panel). MYC expression was analyzed by immunoblotting with a HA antibody. 
VINCULIN served as a loading control (lower panel) (see Fig. 4.15 for detailed description 
of the mutants). 
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Activation of MYC in IMECs stably expressing Dox-inducible WT or K-less MYC 
resulted in a strong recruitment of WT MYC to the TSS of GNL3 whereas recruitment of 
K-less MYC appeared to be much weaker (Fig. 4.12 A upper panel, left). MAX and 
MXD6 protein level were not affected by induction of MYC expression (Fig. 4.12 A upper 
panel, right). 
Importantly, recruitment of WT MYC to the GNL3 TSS displaced MXD6 from this site but 
had no effect on MAX binding and induction of K-less MYC also resulted in an equivalent 
displacement of MXD6 (Fig. 4.12 A lower panel, left and right). 
In line with these observations, cross-linking efficiency and the resulting ChIP signal 
increased with number of reconstituted lysine residues in K-less MYC. A MYC mutant 
harboring one lysine residue at position 52 (K52o) showed similar binding to K-less MYC. 
When the seven N-terminal lysines were reconstituted (WTN-KC) the ChIP signal increased 
and it further increased with a MYC mutant harboring 18 C-terminal lysine residues (-
KNWTC) (Fig. 4.12 B, for a detailed description of the mutants see Fig. 4.15). 
4.5 K-less MYC is a weaker transcriptional regulator 
The inability of K-less MYC to induce GNL3 mRNA expression indicated that K-less 
MYC is a weak transcriptional activator (see figure 4.11 B). To analyze whether K-less 
MYC is generally compromised in transcriptional activation, global gene expression 
profiles of WT and K-less MYC were compared by RNA-Sequencing (RNA-Seq). IMECs 
were transduced with lentiviruses encoding for Dox-inducible WT-HA or K-less-HA MYC 
or the empty vector. Vector, WT-HA and K-less-HA MYC-expressing cells were treated 
for 4 h either with EtOH as a control or with Dox to induce MYC expression. MYC 
expression was verified by immunoblot analysis (Fig. 4.13 A), RNA was isolated and 
libraries were prepared from mRNA samples followed by deep sequencing. 
The log2 fold change (FC) (Dox versus EtOH) of the genes was plotted over their 
abundance (logCPM, counts per million) in a MA-plot. Significantly regulated genes 
(log2FC>0, padj<0.05) were colored in red. More genes were significantly up- or 
downregulated upon WT MYC expression compared to K-less MYC (Fig. 4.13 B). 
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Figure 4.13: K-less MYC is a weaker transcriptional activator2 
A) Immunoblot analysis of IMECs stably expressing Dox-inducible WT-HA or K-less-HA 
MYC or empty vector. Cells were treated with EtOH (-) or Dox (+) for 4 h and subjected to 
immunoblot analysis. VINCULIN was used as a loading control. 
B) MA-plot for WT-HA and K-less-HA samples. All detected transcripts were plotted 
according to their abundance (logCPM) against the log2 fold change (FC) (Dox/EtOH). 
Transcripts that were significantly (padj < 0.05) up- or downregulated are colored in red. 
C) Histogram of peak distance from TSS for MYC-activated (green) and repressed genes 
(red). Normalized tags of WT MYC peaks of regulated genes were plotted in a region -/+ 5 
kb from the TSS. This plot was submitted for publication in similar form (von Eyss et al., 
in revision). 
D) Binned dot plot of RNA-Seq results from WT and K-less MYC activated genes. Each dot 
represents the median log2 fold change of 30 genes ranked by WT log2 fold change 
induction. Red dotted line represents the progression if WT and K-less MYC induce the 
genes in the same manner. 
E) Validation of the RNA-Seq results by qPCR. IMECs expressing Dox-inducible WT-HA 
MYC, K-less-HA MYC or the empty vector were treated for 4 h either with EtOH (-) or 
Dox (+). RNA was isolated and the mRNA level of the indicated genes were analyzed by 
qPCR. Expression was normalized to !2M. The relative mRNA expression was set in 
relative to the corresponding EtOH treated sample. Data are represented as mean ±SD of 
technical triplicates. 
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To analyze whether the up- and downregulated genes after WT MYC expression are direct 
MYC targets, genes were grouped into activated and repressed genes and their normalized 
tag density from the ChIP-Seq result was plotted over distance from the TSS (Fig. 4.13 C). 
MYC activated genes showed a peak at the TSS whereas hardly any enrichment for MYC 
binding was detectable at MYC repressed genes. This suggests that downregulated genes 
are not directly repressed by MYC in IMECs since no MYC binding could be detected at 
these promoters. Therefore, to study direct MYC effects, only activated genes were taken 
into consideration in the subsequent analyses. 
To globally compare the transcriptional activity of WT and K-less MYC, genes from the 
RNA-Seq significantly induced by WT MYC compared to vector infected cells (log2FC > 
0, padj < 0.05) were sorted according to their log2 fold change. Genes were then grouped 
into 45 equally sized bins with 30 genes per bin and the median of the bin was plotted as a 
dot. For K-less-HA MYC, each bin includes the same genes as WT-HA and the median 
log2 fold change was calculated. Bins were plotted in a dot plot with the log2 fold change 
of WT MYC regulated genes on the X-axis and the log2 fold change of these genes in K-
less-HA MYC expressing cells on the Y-axis (Fig 4.13 D). The dot plot shows that K-less 
MYC is globally a weaker transcriptional activator. The bins are shifted below the dotted 
red line, which represents the position when both WT and K-less MYC would activate the 
genes to a similar extent. 
This global result was validated for individual genes by qPCR. The direct MYC target 
genes PLD6, TFAP4 and RRP12 were induced by WT MYC after 4 h Dox treatment. K-
less MYC induced these genes to a lesser extent and no induction was detectable in vector 
expressing cells (Fig. 4.13 E). 
RNA-Seq data were further analyzed with Gene Set Enrichment analysis (GSEA) to 
compare the expression profiles with published gene sets. Comparing the gene expression 
profiles of WT MYC with the C6 oncogenic signatures from the Molecular Signature 
Database (MSigDB) (Subramanian et al., 2005), the gene set with the strongest enrichment 
was the MYC_UP signature (Fig. 4.14, left panel). The enrichment was statistically 
significant with a nominal p-value < 0.001 (NOM p-value) and a false discovery rate 
(FDR) or q-value < 0.001. The MYC_UP signature was generated from human mammary 
epithelial cells overexpressing MYC compared to GFP as a control (Bild et al., 2006). For 
K-less MYC expression profiles, the MYC_UP signature was also the signature with the 
strongest statistically significant enrichment (NOM p-value < 0.001; FDR < 0.001) (Fig. 
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4.14, right panel). Comparison of the normalized enrichment score (NES) showed that the 
enrichment for the WT MYC profile was better than for the K-less MYC profile (compare 
WT NES 2.4 to K-less NES 1.98), supporting the notion that K-less MYC is a weaker 
transcriptional activator. 
 
Figure 4.14: Gene Set Enrichment Analysis of WT-HA and K-less-HA expressing IMECs2 
Gene expression profiles of WT-HA and K-less-HA MYC expressing IMECs were compared to 
published gene sets from the oncogenic signatures (C6) from the Molecular Signature Database. 
NES: normalized enrichment score; NOM p-val: nominal p-value; FDR q-val: false discovery rate 
 
4.6 Distinct lysine residues can restore K-less MYC function 
The previous results showed that the presence of lysine residues is important for MYC’s 
transcriptional activity and MYC-mediated phenotypes. To investigate whether positioning 
of lysines in MYC is important, two MYC mutants were generated which either harbored 
seven N-terminal lysines (WTN-KC) or eighteen lysines located in the C-terminal region of 
MYC (-KNWTC). WTN-KC includes the lysines from MBI (K51 and K52) to K206, which 
is located shortly after MBIIIa but all other lysines are mutated to arginine. -KNWTC 
possesses eighteen lysines starting from K269 in MBIIIb to K430 located in the LZ but the 
first seven lysines are mutated to arginine (Fig. 4.15). 
 
Figure 4.15: Position of lysine residues present in the MYC mutants WTN-KC and -KNWTC2 
Numbers indicate the amino acid position of the lysine residues present in the respective mutant. 
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4.6.1 Reconstitution of individual lysine residues in K-less MYC rescues its 
turnover 
As described previously, mass spectrometry analysis revealed that at least three lysine 
residues within the N-terminal region of MYC and at least four lysine residues in the C-
terminal part of MYC can be ubiquitinated (Fig. 4.1 C) (Kim et al., 2011). To analyze 
whether ubiquitination of WTN-KC and –KNWTC can be detected in an in vivo 
ubiquitination experiment, HeLa cells were transfected with His-tagged ubiquitin and the 
indicated HA-MYC alleles. As a control for the specificity of the HA antibody, a vector 
control was included. Ubiquitinated proteins were precipitated using Ni2+-NTA agarose 
and HA-MYC was detected with a HA antibody. WT MYC showed a strong ubiquitination 
signal, which was absent in K-less MYC. For K-less MYC, only a signal of the unmodified 
protein was detected as shown in Figure 4.1 D. Strinkingly, WTN-KC MYC showed a clear 
ubiquitination pattern demonstrating that N-terminal lysines can function as ubiquitin 
acceptor sites. The ubiquitination signal of WT MYC was stronger than for WTN-KC MYC 
indicating that additional lysines in the C-terminal region might be ubiquitinated. 
Accordingly, ubiquitination of -KNWTC MYC could also be detected (Fig. 4.16 A). 
The absence of ubiquitin acceptor sites in K-less MYC resulted in a more stable protein 
compared to WT MYC (see Fig. 4.5). Since lysines in the N- and C-terminal region in 
MYC can serve as ubiquitin-acceptor sites, it was investigated whether these ubiquitination 
events can increase protein turnover compared to K-less MYC. A cycloheximide decay 
assay was performed to compare the half-life of WT, K-less, WTN-KC and -KNWTC MYC 
in IMECs. While K-less MYC showed the longest half-life of around 49 min, 
reconstitution of either the N- or C-terminal lysines resulted in similar turnover rates as for 
WT MYC (Fig. 4.16 B). 
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Figure 4.16: Reconstitution of distinct sets of lysine residues rescues protein turnover2 
A) In vivo ubiquitination assay of WT, K-less, WTN-KC and -KNWTC MYC. HeLa cells were 
transfected with His-tagged ubiquitin and the corresponding HA-MYC plasmids. Vector 
transfected cells served as a control. 48 h after transfection, His-ubiquitin modified 
proteins were pulled down under denaturing condition with Ni2+-NTA-agarose and 
analyzed by immunoblotting. A 10% input sample was analyzed as a control. CDK2 served 
as a loading control. 
B) Cycloheximide decay assay of WT, K-less, WTN-KC and -KNWTC MYC-expressing cells. 
IMECs stably expressing the indicated MYC alleles were treated with cycloheximide 
(CHX) for the indicated time points. Cell lysates were analyzed by immunoblotting with 
the indicated antibodies. VINCULIN served as a loading control. The mean calculated 
half-life of at least three independent experiments is depicted next to representative 
immunoblots (upper panel). The lower panel illustrates the quantification of the 
cycloheximide decay assay. Time points were set in reference to time point 0 (100%). 
Error bars represent standard error of the mean of at least three independent biological 
replicates. 
 
 
To analyze whether the presence of lysine residues within the N- or C-terminal part in 
MYC can rescue K-less MYC’s inability to induce proliferation, IMECs were infected 
with lentiviruses carrying either vector, WT, K-less, WTN-KC or -KNWTC MYC linked to 
GFP and their expression was confirmed by immunoblot analysis (Fig. 4.17 A, right 
panel). In a single-color competition assay, WT, WTN-KC and -KNWTC were all capable to 
overgrow the uninfected cell population whereas the percentage of K-less and vector 
expressing cells remained constant (Fig. 4.17 A, left panel). 
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Figure 4.17: Restoration of N- or C-terminal lysines in MYC rescues MYC transcriptional 
activity and biological phenotypes2 
A) Single-color competition experiment of IMECs stably expressing vector, WT, K-less, 
WTN-KC or -KNWTC MYC coupled to GFP-expression. Infected GFP-positive cells were 
mixed with uninfected GFP-negative cells and percentage of GFP-positive population was 
monitored over time by FACS measurement (left panel). MYC expression was analyzed by 
immunoblot (right panel). 
B) Quantification of BrdU/PI-FACS of IMECs stably expressing Dox-inducible WT, K-less, 
WTN-KC or -KNWTC MYC. Cells were starved for 24 h and MYC expression was induced 
for 18 h by Dox addition. Error bars indicate standard deviation of the mean of biological 
triplicates (left panel). Immunoblot analysis of lysates from starved IMECs after 18 h Dox-
induction. MYC expression was determined with a MYC-specific antibody. VINCULIN 
was used as a loading control (right panel).  
C) MYC target gene induction by WT, K-less, WTN-KC and -KNWTC MYC was analyzed by 
qPCR. IMECs stably expressing Dox-inducible WT-HA, K-less-HA, WTN-KC or -KNWTC 
MYC were treated for 4 h either with EtOH (-) or Dox (+). RNA was isolated and mRNA 
expression of the indicated genes was analyzed by qPCR. Expression was normalized to 
!2M. The relative mRNA expression was set in reference to the corresponding EtOH 
treated sample. Error bars indicate standard deviation of the mean of technical triplicates. 
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Moreover, WTN-KC and -KNWTC MYC’s ability to induce S-phase entry of EGF-starved 
IMECs was investigated. IMECs expressing doxycycline-inducible WT-HA, K-less-HA, 
WTN-KC-HA or -KNWTC-HA MYC were starved and cells were treated with Dox for 18 h 
to induce MYC-expression or with EtOH as a control. Expression of MYC was verified by 
immunoblot analysis (Fig. 4.17 B, right). WT-HA and WTN-KC-HA expressing cells were 
both able to induce S-phase entry to the same extent whereas expression of K-less-HA had 
a weak effect on S-phase. -KNWTC-HA MYC-expressing cells showed an intermediate 
phenotype and more cells entered S-phase compared to K-less MYC-expressing cells (Fig. 
4.17 B, left). 
Since the presence of either N- or C-terminal lysine residues was sufficient to induce 
MYC-mediated proliferation, it was further investigated, whether these MYC mutants are 
able to induce expression of MYC target genes. Thus, expression of WT, K-less, WTN-KC 
and -KNWTC MYC was induced for 4 h by Dox and induction of direct MYC target genes 
was analyzed by qPCR. Consistent with the effects on proliferation, both, WTN-KC and -
KNWTC MYC were able to induce the expression of PLD6 and TFAP4 mRNA similarly to 
WT MYC. In contrast, K-less MYC induced these genes to a much weaker extent (Fig. 
4.17 C). Therefore, restoration of either N- or C-terminal lysines in MYC is sufficient to 
re-establish MYC’s transcriptional activity. 
4.6.2 Reconstitution of a known ubiquitin-acceptor site largely rescues MYC-
mediated phenotypes 
Lysines are not only acceptor sites for ubiquitin but can also be acetylated. In the N-
terminal region of MYC, K52 was shown to be ubiquitinated but not reported to be 
acetylated (see 1.3.3.2.1 and Fig. 4.1 C). To investigate whether ubiquitination is important 
for the observed phenotype, a MYC mutant was generated harboring only lysine 52 in MBI 
but all other lysines were mutated to arginine (K52only MYC, K52o) (Fig. 4.18 A). 
Ubiquitination of K52 could be confirmed by an in vivo ubiquitination assay - K52o MYC 
was efficiently ubiquitinated, albeit weaker when compared to WT MYC (Fig. 4.18 B). 
Reconstitution of K52 reduced the half-life of K-less MYC from 49 min to 18 min, which 
was only 1.5 times longer than the half-life of WT MYC with 12 min (Fig. 4.18 C). 
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Figure 4.18: Reconstitution of K52 partially rescues MYC-mediated turnover2 
A) Position of lysine 52 present in the MYC mutant K52o. 
B) In vivo ubiquitination assay of K52o MYC. HeLa cells were transfected with plasmids 
encoding His-tagged ubiquitin, WT-HA, K-less-HA, K52o-HA or vector as a control. The 
assay was performed as described in Fig. 4.16 A. VINCULIN was used as a loading 
control. 
C) Cycloheximide decay assay of WT, K-less and K52o MYC-expressing cells. The assay and 
quantification was performed as described in Fig. 4.16 B. Note that WT and K-less MYC 
quantification is the same as shown in Fig. 4.16 B. 
 
To analyze the impact of K52 reconstitution on MYC-mediated phenotypes, a single-color 
competition assay was performed. K52o MYC-expressing cells were able to overgrow the 
uninfected cell population in contrast to K-less MYC- and vector-expressing cells. The 
proliferative capacity, however, was not as high as in WT MYC-expressing cells (Fig. 4.19 
A). 
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Figure 4.19: K52o MYC largely rescues MYC-mediated phenotypes and target gene 
expression2 
A) Single-color competition experiment of IMECs stably expressing vector, WT, K-less or 
K52o MYC coupled to GFP expression. Infected GFP-positive cells were mixed with 
uninfected GFP-negative cells and percentage of GFP-positive population was monitored 
over time by FACS measurement (left panel). MYC expression was confirmed by 
immunoblot analysis (right panel). 
B) Target gene induction by K52o MYC. MYC expression was activated in IMECs stably 
expressing WT-HA, K-less-HA and K52o-HA by Dox administration for 4 h. The relative 
mRNA expression is given in reference to the corresponding EtOH treated cells. Data are 
represented as mean ±SD (left panel). Immunoblot documents MYC expression (right 
panel). 
 
To analyze how the ability to induce proliferation relates to MYC target gene expression, 
K52o transcriptional activity was analyzed by qPCR. As previously shown, WT-HA MYC 
expression in IMECs by addition of Dox for 4 h resulted in an induction of PLD6 and 
TFAP4 expression whereas K-less MYC was impaired in target gene induction. K52o 
MYC induced TFAP4 to the same extent as WT MYC and PLD6 expression was partially 
rescued (Fig. 4.19 B).  
These results suggest that the presence of a single ubiquitin acceptor site in MYC largely 
rescues transcriptional activity and MYC-induced proliferation. 
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4.7 Proteasomal activity is required for MYC target gene induction 
4.7.1 Depletion of FBW7 does not influence MYC target gene induction 
Several E3 ligases are known to ubiquitinate MYC. Since lysines are important for MYC 
function and reconstitution of K52, a known ubiquitination site, can largely rescue defects 
of K-less MYC, the impact of E3 ubiquitin ligases on MYC target gene induction was 
investigated. The two F-box proteins FBW7 and SKP2 were of particular interest since 
both were shown to be present at MYC-regulated promoters, suggesting that they could 
promote promoter-associated turnover of MYC and both ligases bind close to K52 (Farrell 
et al., 2013; Lehr et al., 2003). Moreover, SCF-SKP2 mediates proteasomal turnover of 
MYC but is also important for MYC transcriptional activity (Kim et al., 2003; Lehr et al., 
2003; Zhang et al., 2013). 
If ubiquitination by one of these ubiquitin ligase complexes is the critical modification for 
MYC activity, depletion of the F-box proteins should result in a reduced transcriptional 
activity of MYC and mimic K-less MYC. 
To analyze the impact of FBW7 and SKP2 on MYC transcriptional activity, cells were 
transfected with the corresponding siRNAs and MYC’s ability to induce gene expression 
was analyzed by qPCR. FBW7 was depleted to 30% relative to siCtrl-transfected cells and 
SKP2 knockdown efficiency was 90% (Figure 4.20 A, upper panel). While MYC target 
genes TFAP4 and PLD6 were still induced after FBW7 depletion, the induction of these 
genes was impaired when SKP2 was depleted, arguing that SCF-SKP2 might be the critical 
ubiquitin ligase to stimulate MYC transcriptional activity (Figure 4.20 lower panel). 
Depletion of FBW7 or SKP2 had a subtle effect on MYC protein level when MYC 
expression was induced for 4 h by Dox administration (Figure 4.20 B). 
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Figure 4.20: Effect of depleting FBW7 and SKP2 on MYC target gene induction2 
A) IMECs stably expressing Dox-inducible WT-HA MYC were transfected with siRNAs 
targeting FBW7, SKP2 or a non-targeting siRNA as a control. 44 h after siRNA 
transfection, MYC expression was induced for 4 h with Dox (+). Depletion of FBW7 or 
SKP2 and MYC target gene induction was analyzed by qPCR. Expression was normalized 
to !2M. The relative mRNA expression was set in reference to the siCtrl EtOH (-) treated 
sample. Error bars indicate standard deviation of the mean of technical triplicates. 
B) Immunoblot analysis documents MYC expression. VINCULIN was used as a loading 
control. 
4.7.2 Depletion of SKP2 does not globally affect MYC transcriptional activity 
Depletion of SKP2 showed a strong effect on the induction of two direct MYC target genes 
analyzed by qPCR. Therefore it was investigated whether depletion of SKP2 has a global 
effect on WT MYC target gene induction by RNA-Seq. 
IMECs stably expressing Dox-inducible WT-HA MYC were transfected with siSKP2 or 
siCtrl and MYC expression was induced by Dox-treatment for 4 h. Depletion of SKP2 had 
no effect on MYC protein level as determined by immunoblotting (Fig 4.21 A). RNA was 
isolated for RNA-Seq and depletion of SKP2 was confirmed by qPCR. Depletion 
efficiency was 80-90% (Fig. 4.21 B). 
To determine whether depletion of SKP2 had a global effect on MYC target gene 
induction, density profiles for the log2FC of the RPKM (reads per kilobase per million 
mapped reads; to normalize for total read length and the number of sequencing reads) for 
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the control siRNA (siCtrl) and siSKP2 situation were generated. To this end, only genes 
that were significantly regulated by WT MYC in the previous RNA-Seq experiment were 
considered (see figure 4.13, log2FC>0.5, padj<0.05; RPKM>1). Depletion of SKP2 did not 
generally affect WT MYC target gene induction (Fig. 4.21 C). 
 
Figure 4.21: Global effects of SKP2 depletion on MYC transcriptional activity2 
A) Immunoblot analysis of cell lysates from IMECs stably expressing Dox-inducible WT-HA. 
Cells were transfected with siRNAs targeting either SKP2 or a non-targeting siRNA 
control (siCtrl). 44 h after siRNA transfection, cells were treated for 4 h with Dox (+) to 
induce WT MYC expression or EtOH (-) as a control. Lysates were blotted for MYC and 
VINCULIN as a loading control. 
B) Depletion of SKP2 was confirmed by qPCR. Cells were treated a described in A. 
Expression was normalized to !2M. The relative SKP2 mRNA expression was set in 
reference to the siCtrl EtOH (-) treated sample. Error bars represent standard deviation of 
the mean of technical triplicates. 
C) Density profiles for the log2FC Dox/EtOH of RPKM values for siCtrl and siSKP2 samples. 
The p-value was calculated using a one-sided Wilcoxon rank sum test. 
D) Dot plot for log2FC Dox/EtOH of RPKM values. Genes ranked according to the difference 
log2FC Dox/EtOH_siCtrl-log2FC Dox/EtOH_siSKP2. The top 350 genes were plotted. The 
continuous black line depicts the result for the difference of log2FC_Dox/EtOH_siCtrl and 
log2FC_Dox/EtOH_siSKP2. Genes left of the dashed black line denote the top 50 genes. 
 
To analyze whether a subset of MYC target genes were SKP2-dependent, deregulated 
genes were ranked according to difference of their log2FC in the siCtrl and siSKP2 
situation and the top 350 genes were plotted (log2FC_siCtrl-log2FC_siSKP2) (Fig. 4.21 D, 
left panel). The top 50 genes were regulated in a SKP2-dependent manner. Comparison of 
these 50 SKP2-dependent genes with the other 300 genes in a boxplot showed that these 50 
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genes were indeed significantly regulated in a SKP2-dependent manner, whereas activation 
of the other 300 genes did not depend on SKP2 (Fig. 4.21 D, right panel). 
In summary, a subset of MYC target genes is activated in a SKP2-dependent manner. 
However, depletion of SKP2 does not globally affect MYC target gene induction. 
 
4.7.3 Proteasomal inhibition results in a decreased in transcriptional activity 
of MYC 
While depletion of SKP2 did have an effect on some MYC target genes, it did not result in 
a global loss of transcriptional activity of MYC. This suggests that there are additional 
ubiquitin ligases, which can regulate MYC in a redundant manner. The majority of 
ubiquitin ligases targeting MYC promote its proteasome-dependent turnover. Therefore the 
effect of proteasomal inhibition on MYC transcriptional activity was investigated. 
IMECs stably expressing Dox-inducible WT-HA, K-less-HA or WTN-KC-HA MYC were 
treated with the proteasome inhibitor MG132 and either Dox or EtOH for 4 h. Proteasome 
inhibition increased WT and WTN-KC MYC protein level, while K-less MYC level 
remained unchanged, showing that the treatment with MG132 resulted in proteasome 
inhibition and the accumulation of short-lived proteins (Fig. 4.22 A). 
Effects of proteasome inhibition on MYC transcriptional activity were analyzed by qPCR. 
MG132 treatment did not influence expression of the MYC transgenes, indicating that 
transcription per se is not influenced (Fig. 4.22 B). However, induction of the target genes 
PLD6 and TFAP4, which were both induced after expression of WT and WTN-KC MYC, 
was strongly impaired when proteasome activity was blocked (Fig. 4.22 C). 
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Figure 4.22: Proteasome inhibition blocks MYC transcriptional activity2 
A) Immunoblot analysis of cell treated with the proteasome inhibitor MG132. IMECs stably 
expressing Dox-inducible WT-HA, K-less-HA or WTN-KC-HA MYC were either treated 
with MG132 (+MG) or EtOH (-MG) as a control. At the same time, either Dox (+) or 
EtOH (-) was administered to induce MYC expression. Lysates were analyzed for MYC 
and VINCULIN expression. 
B) Analysis of MYC mRNA induction after proteasome inhibition. Cells were treated as 
described in A and MYC mRNA level were analyzed. Expression was normalized to !2M. 
The relative mRNA expression was set in reference to the corresponding EtOH (-) treated 
sample. Error bars indicate standard deviation of the mean of technical triplicates. 
C) Analysis of MYC target gene induction after proteasome inhibition. The qPCR was 
analyzed as decribed in B. 
D) ChIP experiment of IMECs stably expressing Dox-inducible WT-HA MYC in the presence 
(+MG) and absence (-MG) of the proteasome inhibitor MG132. Cells were treated as 
described in A. Formaldehyde cross-linked chromatin was immunoprecipitated with a HA 
antibody. Precipitated and purified DNA was analyzed by qPCR with primers amplifying 
the MYC-binding site in the PLD6 and TFAP4 promoter or an intergenic control region 
(Ctrl region). Data are represented as mean ±SD. P-values were calculated with a Student’s 
t-test. 
 
To analyze whether MYC is recruited to target gene promoters in the presence of 
proteasome inhibition, ChIP experiments were performed. To this end, IMECs stably 
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expressing Dox-inducible WT-HA MYC were treated with EtOH (-) or Dox (+) to induce 
MYC expression in the presence (+MG) or absence (-MG) of proteasome inhibitor and 
MYC binding to the TFAP4 and PLD6 promoter was analyzed. Binding of MYC to the 
analyzed promoters was not affected after MG132 treatment, indicating that the inability of 
MYC to induce TFAP4 or PLD6 when proteasome activity is inhibited occurs after binding 
to the promoters (Fig. 4.22 C). 
 
To assess whether proteasome inhibition globally inhibits MYC transcriptional activity, 
RNA-Seq was performed. 
 
Figure 4.23: Proteasome inhibition globally affects MYC transcriptional activity2 
A) Effect of MG132 treatment on all unstable transcripts. Unstable transcripts have been 
described previously (Schwanhäusser et al., 2011). Log2 reads of all unstable transcripts 
was plotted after EtOH (-MG) or MG132 (+MG) treatment. The p-value was calculated 
with a two-sided Wilcoxon rank sum test. 
B) Density plot for the log2FC of RPKM of MYC target genes for WT-HA, K-less-HA or 
WTN-KC-HA in the presence (+MG) or absence (-MG) of proteasome inhibition. P-value 
was calculated with a two-sided Wilcoxon rank sum test. 
 
Since MG132 treatment could potentially inhibit transcription on a global level 
independently of MYC activity, expression of unstable transcripts was compared in the 
presence (+MG) and absence (-MG) of proteasome inhibition. Unstable transcripts were 
analyzed because cells were treated with MG132 only for a brief time (4 h). If MG132 
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treatment generally inhibits transcription, this should result in a drop of unstable 
transcripts. The expression of unstable transcripts did not change upon treatment with 
MG132, demonstrating that proteasome inhibition does not have a global effect on 
transcription (Fig. 4.23 A). 
To analyze the effect of proteasome inhibition on MYC target gene induction, genes were 
filtered for being significantly activated by WT MYC in the first RNA-Seq experiment 
(see Fig. 4.13; log2FC>0.5, padj<0.05, RPKM>1). 
WT and WTN-KC MYC induced target gene expression in the absence of proteasome 
inhibition, which was significantly reduced upon MG132 treatment. In contrast, 
proteasome inhibition had no detectable effect on MYC target genes in K-less MYC-
expressing cells (p=0.999) (Fig. 4.23 B). 
This shows that inhibition of proteasome activity globally inhibits MYC target gene 
induction. 
4.8 Release of elongating RNAPII is impaired in K-less MYC expressing 
cells 
MYC affects several stages of the transcription cycle: recruitment of RNAPII to promoters, 
increase of transcription initiation and stimulation of transcriptional elongation (Bouchard 
et al., 2004; Lin et al., 2012; Nie et al., 2012; Rahl et al., 2010; Walz et al., 2014). 
Experimentally, these different steps in transcription can be discriminated by the analysis 
of the phosphorylation status of RNAPII. The C-terminal repeat domain (CTD) of RNAPII 
contains multiple consensus heptarepeats with the sequence 1YSPTSPS7. RNAPII is 
recruited to promoters in a hypo-phosphorylated state and becomes phosphorylated at Ser5 
of the CTD during transcription initiation, primarily by the CDK7 subunit of the general 
transcription factor TFIIH (Heidemann et al., 2013). Transcription elongation is regulated 
by phosphorylation of Ser2 in the CTD, which was shown to be primarily mediated by P-
TEFb but other kinases like CDK12 and CDK13 might also be involved in Ser2 
phosphorylation (Heidemann et al., 2013). 
To analyze if there are differences between WT and K-less MYC in regulating one of these 
transcriptional steps, ChIP assays were performed using antibodies that recognize the 
different phosphorylated forms of RNAPII.  
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Figure 4.24: WT but not K-less MYC increases Ser2p RNAPII at the TES  
A) IMECs stably expressing Dox-inducible WT-HA or K-less-HA MYC were treated with 
Dox (+) or EtOH as a control (-) for 4 h. MYC expression was confirmed by immunoblot 
analysis. VINCULIN served as a loading control. 
B) ChIP of RNAPII after 4 h MYC induction. Cells were treated as described in A. 
Formaldehyde cross-linked chromatin was immunoprecipitated with antibodies 
recognizing total RNAPII, RNAPII phosphorylated at Ser5 (Ser5p) or Ser2 (Ser2p) in its 
C-terminal domain. Precipitated and purified DNA was analyzed by qPCR with primers 
spanning the TSS or the transcriptional end site (TES) of the MYC target gene GNL3. The 
fold change was calculated in reference to the corresponding EtOH (-) treated sample. Data 
are represented as mean ±SD. 
 
Expression of either WT or K-less MYC was induced in IMECs by Dox administration for 
4 h and expression was confirmed by immunoblot analysis (Fig. 4.24 A). 
ChIP assays were performed with antibodies recognizing either total RNAPII, RNAPII 
phosphorylated at Ser5 or Ser2 of the CTD. After WT and K-less MYC induction, total 
RNAPII increased at the transcriptional start site (TSS) of the MYC target gene GNL3. 
Moreover, an increase of Ser5p RNAPII was detected at the GNL3 TSS indicating that 
both WT and K-less MYC stimulated transcription initiation. Elongating RNAPII 
phosphorylated at Ser2 is detectable in the gene body of actively transcribed genes and 
increases towards the 3’end of the gene (Heidemann et al., 2013). An increase in Ser2p 
RNAPII at the transcriptional end site (TES) of GNL3 was detected after WT but not after 
K-less MYC induction (Fig. 4.24 B), suggesting that K-less MYC is deficient in promoting 
the transition from transcription initiation to productive elongation. 
4.8.1 K-less MYC globally induces RNAPII recruitment and initiation but not 
elongation at direct MYC target genes 
To investigate whether the defect of K-less MYC in gene activation could be due to 
impaired transcriptional elongation, distribution of total RNAPII, and its Ser5- and Ser2-
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phosphorylated forms was analyzed by ChIP-Seq. IMECs stably expressing Dox-inducible 
WT-HA or K-less-HA MYC were treated with Dox for 4 h to induce MYC expression or 
EtOH as a control. Total RNAPII was immunoprecipitated with an antibody recognizing 
an epitope at the N-terminus of RNAPII. Ser5- and Ser2-phosphorylated RNAPII were 
immunoprecipitated with antibodies recognizing the corresponding phosphorylated form of 
the CTD of RNAPII. 
RNAPII distribution along genes was visualized by generating metagenes. To this end, all 
genes were divided into 400 windows. The promoter of every gene was divided into 80 
windows each consisting of 50 bp covering the region from -2000 to +2000 bp around the 
TSS. The end of a gene was divided into 120 windows consisting of 50 bp ranging from -
2000 to +4000 bp around the TES. The tags within these windows were counted and 
divided by the number of genes. To normalize for different transcript lengths, the gene 
body was divided into 200 windows and the tags within the first 50 bp of the respective 
window were counted. Normalized tag densities of total RNAPII were plotted within this 
metagene for the EtOH and MYC-activated situation respectively to visualize RNAPII 
distribution along the genes (Fig. 4.25). 
 
 
Figure 4.25: Distribution of RNAPII along all genes 
A) Metagene plot of total RNAPII at all genes. Position of the TSS and TES is indicated. 
B) Ser5-phosphorylated RNAPII at the TSS of all genes. 
C) Ser2-phosphorylated RNAPII along the gene body and the TES of all genes.  
 
A sharp RNAPII peak was detected at the TSS of all genes, fewer tags were present in the 
gene body and tag density slightly increased again at the TES, the side of 3’end processing 
where RNAPII slows down and accumulates (Fig. 4.25 A). 
The initiating Ser5-phosphorylated form of RNAPII is detectable at the TSS of a gene and 
the signal decreases towards the 3’end of the gene. Accordingly, RNAPII phosphorylated 
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at Ser5 showed a peak at the TSS (Fig. 4.25 B). Ser2-phosphorylated polymerase was 
detectable within the gene body and the signal increased at the TES of the gene (Fig. 4.25 
C). Induction of WT MYC by Dox administration did not increase total RNAPII, Ser5p or 
Ser2p RNAPII suggesting that in this cellular system, MYC does not induce recruitment 
and phosphorylation of RNAPII at all genes. 
 
To analyze MYC-dependent effects on RNAPII, only those genes were selected that were 
bound and activated by MYC according to the first RNA- and ChIP-Seq experiments 
(log2FC > 0.5, see Fig. 4.10 and Fig. 4.13). 
 
 
Figure 4.26: Activation of WT MYC increases recruitment and release of RNAPII2 
A) Distribution of total RNAPII along directly MYC-activated genes after WT MYC (left) or 
K-less MYC (right) activation. 
B) Magnification of the gene body and TES of directly MYC-activated genes with total 
RNAPII distribution. 
 
The amount of total RNAPII increased at the TSS after WT MYC induction. This was also 
the case after K-less MYC induction, although to a lesser extent (Fig. 4.26 A). Inspection 
of the gene body and TES showed an increase of total RNAPII after WT MYC induction. 
In contrast, induction of K-less MYC did not result in an increase of RNAPII in the gene 
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body or at the TES. In this case, RNAPII distribution after Dox or EtOH treatment was 
indistinguishable (Fig. 4.26 B). 
 
Activation of both WT and K-less MYC led to an increase of Ser5p RNAPII at the TSS 
(Fig. 4.27 A). 
 
Figure 4.27: Activation of WT and K-less MYC stimulates the initiation of RNAPII2 
A) Distribution of Ser5-phosphorylated RNAPII at the TSS of directly MYC-activated genes 
after WT MYC (left) or K-less MYC (right) activation. 
B) Distribution of Ser2-phosphorylated RNAPII along the gene body and at the TES of 
directly MYC-activated genes after WT MYC (left) or K-less MYC (right) activation. 
 
Interestingly, only activation of WT MYC led to an increase of Ser2p RNAPII within the 
gene body and the TES, highlighting that WT MYC stimulates transcriptional elongation 
of its target genes. Activation of K-less MYC did not affect the level of Ser2p RNAPII, 
suggesting that the presence of lysine residues is important for the transition from 
transcription initiation to efficient elongation (Fig. 4.27 B). 
To quantify MYC-mediated effects on initiating and elongating RNAPII, the log2FC 
(DOX/EtOH) of Ser5p RNAPII was plotted for the TSS and gene body, respectively. 
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Induction of WT MYC increased Ser5p RNAPII at the TSS and gene body while K-less 
MYC only increased Ser5p RNAPII at the TSS (Fig. 4.28 A). While the difference of 
Ser5p RNAPII at the TSS and gene body is not significant for WT MYC-expressing cells, 
K-less MYC-expressing cells showed a statistically significant difference of Ser5p 
RNAPII present at the TSS and gene body. This was further reflected by the change of 
Ser2p RNAPII in the gene body and TES after MYC expression. As expected from the 
metagenes, WT MYC induction by Dox increased Ser2p RNAPII in the gene body and at 
the TES, whereas K-less MYC expression led to a marginal increase of Ser2p RNAPII at 
these sites (Fig. 4.28 B). 
 
Figure 4.28: K-less MYC is impaired in releasing elongating RNAPII2 
A) Boxplot of changes in Ser5-phosphorylated RNAPII at the TSS and gene body of MYC-
bound genes after MYC induction. Log2 fold changes of Ser5-phosphorylated RNAPII in 
Dox versus EtOH treated cells were plotted for WT and K-less at TSS and gene body. P-
value was calculated with a two-sided Wilcoxon rank sum test. 
B) Boxplot of changes in Ser2-phosphorylated RNAPII at the gene body and TES of MYC-
bound genes after MYC induction. Log2 fold changes of Ser2-phosphorylated RNAPII in 
Dox versus EtOH treated cells were plotted for WT and K-less at the gene body and TES.  
C) Boxplot of Ser5-phosphorylated RNAPII at the TSS normalized to total RNAPII after 
MYC-induction (Dox). P-value was calculated with a two-sided Wilcoxon rank sum test. 
 
Since WT MYC increased the amount of total RNAPII at the TSS somewhat better than K-
less MYC (Fig. 4.26 A), the amount of Ser5p RNAPII at the TSS was normalized to total 
RNAPII after WT and K-less MYC-induction, respectively. While no change in the Ser5p 
to total RNAPII ratio was observed in WT MYC-expressing cells, a significant increase of 
the Ser5p/total RNAPII ratio was detected in K-less MYC-expressing cells, suggesting that 
Ser5p RNAPII accumulates at the TSS of K-less MYC-expressing cells (Fig. 4.28 C). 
Thus, expression of WT MYC increases the amount of total, initiating and elongating 
RNAPII whereas K-less MYC induces only total and initiating RNAPII at the TSS. These 
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results strongly suggest that in K-less MYC expressing cells the transition from initiation 
to elongation is blocked, resulting in an accumulation of initiating RNAPII at the TSS. 
4.9 K-less MYC is impaired in the recruitment of cofactors to MYC-
regulated promoters 
4.9.1 K-less MYC is impaired in inducing histone acetylation 
MYC has an established role in stimulating transcription by recruiting HATs to promoters, 
which induce histone acetylation (see 1.3.2.1) (Bouchard et al., 2001; Frank et al., 2003; 
McMahon et al., 2000). To study whether both WT and K-less MYC induce histone 
acetylation in this cellular system, changes in histone acetylation at the GNL3 promoter 
were analyzed by ChIP assays after MYC induction. IMECs stably expressing Dox-
inducible WT-HA or K-less-HA MYC were treated with Dox for 3 h. Total H3, H3Ac and 
H4Ac were immunoprecipitated and changes in histone acetylation were normalized to 
total H3. 
 
Figure 4.29: Expression WT but not K-less MYC induces histone acetylation2 
IMECs stably expressing Dox-inducible WT-HA or K-less-HA MYC were treated with Dox (+) or 
EtOH as a control (-) for 3 h. Formaldehyde cross-linked chromatin was immunoprecipitated with 
antibodies recognizing total H3, acetylated H3 (H3Ac) and acetylated H4 (H4Ac). Precipitated and 
purified DNA was analyzed by qPCR with primers amplifying the TSS of the MYC target gene 
GNL3 or a Ctrl region. Histone acetylation was normalized to total H3 and the fold change was 
calculated in reference to the corresponding EtOH (-) treated sample. Data are represented as mean 
±SD. 
 
Induction of WT MYC increased H3 and H4 acetylation more than twofold. This effect 
was specific for MYC-regulated promoters since no increase in histone acetylation could 
be observed in an intergenic control region. In contrast to WT MYC, K-less MYC 
expression did not result in increased histone acetylation (Fig. 4.29), indicating that K-less 
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MYC is impaired in recruiting HATs to target gene promoters or that the activity of HATs 
at the promoters is decreased. 
4.9.2 Recruitment of BRD4 and CDK9 is impaired in K-less MYC expressing 
cells 
The absence of elongation competent Ser2-phosphorylated RNAPII in K-less MYC-
expressing cells could be due to an inability to resolve the promoter-proximal pausing state 
of RNAPII. As mentioned previously, RNAPII pauses transcription after promoter escape 
in a promoter proximal position and is bound by the pausing factors DSIF and NELF. For 
efficient transcriptional elongation, the pausing state needs to be resolved. A critical 
protein to release elongating polymerase from the paused state is P-TEFb. P-TEFb 
phosphorylates DSIF and NELF, leading to dissociation of NELF from the RNAPII and 
turning DSIF from a negative into a positive elongation factor (Adelman and Lis, 2012). 
Moreover, productive elongation requires Ser2 phosphorylation of RNAPII, which serves 
as a binding platform for several RNA-processing factors. Different kinases have been 
shown to phosphorylate Ser2 with P-TEFb being the best characterized (Eick and Geyer, 
2013; Saunders et al., 2006). Recruitment of P-TEFb to promoters can be facilitated by 
transcription factors like MYC or by interaction with BRD4, a bromodomain protein which 
binds acetylated H3 and H4 (Bisgrove et al., 2007; Dey et al., 2003; Eberhardy and 
Farnham, 2002; Yang et al., 2005). 
Therefore, binding of BRD4 and CDK9, the kinase subunit of P-TEFb, to the MYC-
regulated GNL3 promoter was analyzed by ChIP. 
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Figure 4.30: Expression of WT but not K-less MYC leads to recruitment of BRD4 and 
CDK92 
A) IMECs stably expressing Dox-inducible WT-HA or K-less-HA MYC were treated with 
Dox (+) or EtOH (-) for 4 h. Formaldehyde- and DSG-cross-linked chromatin was 
immunoprecipitated with an antibody recognizing BRD4 or IgG as a control. Precipitated 
and purified DNA was analyzed by qPCR with primers amplifying TSS of GNL3 or a 
negative control region (Ctrl region). Data are represented as mean ±SD. 
B) Cells were treated as described in A). Chromatin was immunoprecipitated with a CDK9 
antibody or IgG as a control. 
C) Immunoblot analysis of IMECs stably Dox-inducible WT-HA or K-less-HA MYC. Cells 
were treated with Dox (+) or EtOH as a control (-) for 4 h. MYC and CDK9 expression 
was analyzed. VINCULIN served as a loading control. 
 
Upon WT MYC induction by Dox treatment, more BRD4 was detected at the GNL3 
promoter whereas activation of K-less MYC did not increase BRD4 binding (Fig. 4.30 A). 
Concomitantly, expression of WT MYC resulted in an increase of CDK9 binding at the 
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GNL3 promoter whereas total CDK9 protein level remained unaffected. Expression of K-
less MYC neither affected CDK9 binding at the GNL3 promoter nor total CDK9 protein 
level in the cell (Fig 4.30 B and C). 
Thus, induction of histone acetylation as well as BRD4 and CDK9 recruitment to the 
GNL3 promoter was impaired in K-less MYC-expressing cells. This could result in an 
inability to release paused RNAPII and consequently to unproductive elongation. 
 
4.10 Identification of a MYC-PAF-complex as an intermediate in 
transcriptional activation 
4.10.1 K-less MYC interacts with the PAF complex, a positive elongation 
factor, at MYC-regulated genes 
Besides the requirement of P-TEFb for the release of elongating RNAPII, several positive 
elongation factors are important for productive elongation. The PAF complex (RNA 
polymerase II-associated factor) is a multiprotein complex, which plays an important role 
in transcription elongation, RNA processing and histone modification (Sims et al., 2004). 
CTR9, a subunit of the PAF complex, was identified as an interaction partner of the MYC-
related protein N-MYC by mass spectrometry (Anne Carstensen, personal 
communication). 
CTR9 associates with elongating RNAPII and can be detected within the coding region of 
actively transcribed genes. Its occupancy peaks at the 3’end of genes similar to the 
occupancy of Ser2-phosphorylated RNAPII (Rahl et al., 2010). To investigate whether 
CTR9 travels with RNAPII at MYC-regulated genes, CTR9 occupancy at the TES of 
GNL3 was analyzed. WT or K-less MYC expression was induced for 4 h by Dox treatment 
and CTR9 was immunoprecipitated. A robust CTR9 signal could be detected at the TES of 
GNL3. CTR9 occupancy increased upon WT MYC expression demonstrating that also at 
MYC-regulated genes CTR9 travels with RNAPII. K-less MYC expression did not 
increase CTR9 occupancy at the GNL3 TES (Fig. 4.31 A). 
Further, it was analyzed, whether physical association between CTR9 and MYC is 
regulated by ubiquitination and/or protein turnover. MYC was immunoprecipitated from 
IMECs stably expressing WT or K-less MYC alleles using a MYC-specific antibody and 
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the precipitate was analyzed for CTR9. Vector infected cells were used as control. 
 
Figure 4.31: The PAF complex is a positive elongation factor at MYC-regulated genes and 
interacts with stabilized MYC2 
A) Cells were treated as described in Fig. 4.29 A. Formaldehyde- and DSG-cross-linked 
chromatin was immunoprecipitated with an antibody recognizing CTR9 or IgG as a 
control. Precipitated and purified DNA was analyzed by qPCR with primers amplifying the 
TES of GNL3 or a control region (Ctrl region). Data are represented as mean ±SD. 
B) MYC was immunoprecipitated from IMECs stably expressing vector, WT or K-less MYC. 
2% input sample, precipitated MYC and co-precipitated endogenous CTR9 were analyzed 
by immunoblotting.  
C) HeLa cells were treated with EtOH (-) or MG132 (+) for 4 h. Endogenous MYC was 
immunoprecipitated from nuclear extracts. As a control, an immunoprecipitation with the 
unspecific rabbit IgG was performed. 1% input and the immunoprecipitated samples were 
analyzed by immunoblotting. l.e. longer exposure 
D) HeLa cells were treated as indicated in C. Endogenous CDK9 was immunoprecipitated and 
the precipitation with the unspecific rabbit IgG served as a control. 1% input and the 
immunoprecipitated samples were analyzed by immunoblotting. *depicts the heavy chain 
of the antibody. This experiment was performed by Dr. Nikita Popov. 
 
Strikingly, an interaction between K-less MYC and CTR9 could be detected whereas no 
binding between WT MYC and CTR9 could be observed (Fig. 4.31 B). This suggests that 
the MYC-CTR9 interaction is very transient and that the interaction is enhanced by an 
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attenuated MYC turnover, as it is the case for K-less MYC. 
In line with the observation that a more stable MYC protein interacts stronger with CTR9, 
an interaction between MYC and CTR9 could only be detected upon proteasome inhibition 
in HeLa cells (Fig. 4.31 C). 
This shows that either a stable version of MYC or proteasome inhibition stabilizes the 
interaction between MYC and the elongation factor CTR9. A similar effect, albeit not as 
pronounced, was found with another PAF component, CDC73, and the DSIF component 
SPT5, which were also previously identified as N-MYC interacting proteins (Fig. 4.31 C; 
Anne Carstensen, personal communication). Proteasomal inhibition led to an enhanced 
interaction between MYC and CDC73 or SPT5 (Fig. 4.31 C). Interestingly, the opposite  
was observed for the interaction of CDK9 with MYC. In this case, the interaction was 
strongly reduced when cells were treated with MG132 (Fig. 4.31 D). 
The stronger interactions of PAF components with K-less or MG132-stabilized MYC 
indicate that the association of MYC with PAF is very transient. This complex may 
represent an intermediate step in MYC-mediated transcriptional activation, which is 
stabilized in the absence of P-TEFb at the promoters. 
4.10.2 Phosphorylation of MBI enhances the interaction with the PAF complex 
Interestingly, the PAF complex components CTR9 and CDC73 were identified by mass 
spectrometry to interact with WT N-MYC but not with a N-MYC mutant, which could not 
be phosphorylated at T58 and S62 (N-MYC T58A/S62A) (Anne Carstensen, personal 
communication). Moreover, it was reported that CDC73 and CTR9 interact with RNAPII 
phosphorylated at Ser5 and Ser2 (Qiu et al., 2012). Therefore it was investigated whether 
CTR9 and CDC73 interact with MYC in a phosphorylation-dependent manner.  
T58 and S62 lie within MBI, which is highly conserved region between MYC and N-MYC 
(Fig. 4.32 A). Binding of CDC73 and CTR9 to MBI was analyzed with a peptide pulldown 
assay. Biotinylated N-MYC MBI peptides spanning residues 28-89 with unmodified T58 
and S62, phosphorylated T58 or S62 or doubly phosphorylated T58 and S62 were 
incubated with HeLa nuclear extracts. A robust binding of CDC73 to the MBI peptide 
could be detected, which was enhanced when the peptide was phosphorylated at one or 
both phosphorylation sites. CTR9 showed a modest binding to doubly phosphorylated MBI 
(Fig. 4.32 B). 
 112 
#
Results 
 
# #
 
Figure 4.32: The PAF complex interacts with phosphorylated MYC box I2 
A) Alignment of MYC and N-MYC MYC box I sequence. The residues T58 and S62 are 
marked in red. 
B) Pulldown of CDC73 and CTR9 with N-MYC MYC box I (MBI) peptides. MBI petides 
were coupled to streptavidin magnetic beads and incubated with nuclear extracts from 
HeLa cells. Beads without MBI peptide were used as a negative control (Ctrl). Eluates 
from the pull down were analyzed by immunoblotting with the indicated antibodies (left 
panel). Binding of CDC73 to the indicated MYC box I peptides was quantified and is 
given relative to the binding to non-phosphorylated MBI peptide. Data are represented as 
mean ± SEM from three independent experiments (right panel). 
C) Lysates from IMECs expressing Dox-inducible WT-HA and K-less-HA MYC were 
analyzed by immunoblotting for total, T58-phosphorylated (T58p) and S62-phosphorylated 
(S62p) MYC after 4 h and 8 h Dox administration or EtOH (0 h) as a control (upper panel). 
Lower panels document the quantification of three independent experiments. Data were 
normalized to VINCULIN and error bars represent SEM. 
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Since the PAF-MYC complex is stabilized with K-less MYC, the phosphorylation status of 
K-less MYC was investigated with phospho-specific antibodies. In line with the result that 
CDC73 interacts stronger with phosphorylated MBI, K-less MYC accumulated in a form 
that is phosphorylated at S62p whereas T58p increased to a weaker extent (Fig. 4.32 C). 
Together, these data suggest that the PAF complex is recruited by phosphorylated MYC 
and is transferred on RNAPII upon CTD phosphorylation by P-TEFb. 
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5  Discussion 
The transcription factor MYC is a short-lived protein rapidly turned over by the ubiquitin-
proteasome system. Many ligases have been shown to ubiquitinate MYC and these 
ubiquitination events can have a negative or a positive effect on MYC transcriptional 
activity and MYC-mediated phenotypes. Despite the fact that many ubiquitin ligases for 
MYC have been identified, the contribution of MYC ubiquitination to its function 
remained unresolved. Therefore the objective of this thesis was to elucidate the direct 
effect of MYC ubiquitination on its transcriptional activity. 
5.1 MYC ubiquitination occurs on multiple lysines 
To identify ubiquitination sites in MYC, a mass spectrometric approach was used. Two 
lysines in MYC (K148, K389) could be identified as ubiquitin acceptor sites. Besides the 
identification of ubiquitinated MYC peptides, peptides of ubiquitin itself were detected 
with a di-glycin at lysine 48, showing that ubiquitin chains with the linkage K48 were 
present in the sample. This suggests that K148 and K389 could be ubiquitinated with a 
K48-linked ubiquitin chain. 
The identified ubiquitinated lysine K148 is located next to MBII, an important domain in 
MYC that mediates the interaction with several co-activators and is therefore crucial for 
MYC transcriptional activity (Conacci-Sorrell et al., 2014). Ubiquitination at this lysine 
could interfere with the binding of cofactors and thereby inhibit MYC transcriptional 
activity. On the other hand, degradation via this lysine could mark transcriptionally 
inactive MYC since it is devoid of cofactors and would consequently be removed from the 
cellular MYC pool. 
The second identified ubiquitin acceptor site in MYC, K389, is located in the helix-loop-
helix domain, which is important for interaction with MAX and MIZ1. Ubiquitination of 
this lysine could interfere with the binding of these interaction partners. MYC forms a 
repressive complex with MIZ1. At promoters with a high MYC/MIZ1 ratio MYC acts as a 
transcriptional activator, while a lower MYC/MIZ ratio is observed at repressed genes. 
Ubiquitination at K389 could antagonize MYC/MIZ1 complex formation, shifting the 
balance to a high MYC/MIZ1 ratio. This could stimulate MYC-mediated transcriptional 
activation in a manner that has been demonstrated for HUWE1 (Peter et al., 2014). 
HUWE1 degrades MIZ1 and thereby prevents the assembly of MYC/MIZ1 repressive 
 115 
#
Discussion 
 
#  
complexes at MYC-responsive genes. Since HUWE1 also acts as a ubiquitin ligase for 
MYC, ubiquitination at K389 could further prevent the formation of a repressive complex 
(Adhikary et al., 2005). 
In parallel to the study at hand, a manuscript by the Gygi and Harper laboratories 
published the human ubiquitin-modified proteome. In contrast to our approach, they 
performed tryptic digestion of whole cell lysates and enriched for ubiquitinated proteins by 
precipitating modified-proteins with an antibody recognizing the di-glycine at the modified 
lysine (Kim et al., 2011). Moreover, the mass spectrometric approach was different since 
Kim et al. performed SILAC (stable isotope labeling with amino acids in cell culture) to 
monitor changes in di-glycine site abundance for example upon proteasome inhibition. In 
total, Kim et al. identified seven lysines in MYC with a di-glycine (K52, K148, K157, 
K323, K355, K389, K412), including the two identified lysines from our study. This 
confirms that K148 and K389 are indeed bona fide ubiquitination sites in MYC. The 
enrichment for ubiquitinated proteins with an antibody recognizing the di-glycin isopeptide 
is a more sensitive approach than the identification of ubiquitination sites of ectopically 
expressed and purified MYC since one enriches for ubiquitinated peptides. Moreover, Kim 
et al. treated the cells with the proteasomal inhibitor bortezomib leading to accumulation of 
ubiquitinated proteins. This could explain why we identified only two out of seven 
ubiquitinated lysines. 
K148 and K389 might be accessible for ubiquitination when MYC is not sequestered in a 
protein complex with interaction partners. Upon MYC overexpression, binding partners 
might be limiting and the respective lysines might become accessible for ubiquitination. 
Therefore, under this situation, ubiquitination of K148 and K389 might be the most 
abundant sites of modification. 
Besides ubiquitin, the active forms of the two ubiquitin-like modifiers NEDD8 and ISG15 
contain two C-terminal glycines. Like ubiquitin, NEDD8 and ISG15 are attached to a 
lysine of the substrate protein via the C-terminal glycine. Thus, in case of a NEDD8- or 
ISG15-modified lysines, tryptic digestion also generates a di-glycine, which remains 
attached to the substrate protein. Therefore, it cannot be ruled out that K148 or K389 could 
also be modified by NEDD8 or ISG15. ISG15 expression is induced upon viral infection 
and it is undetectable in unstimulated cells (Kim et al., 2011). Thus, modification with 
ISG15 in unstimulated cells is rather unlikely. Neddylation is an important post-
translational modification of cullin-RING ligases and has an activating effect on their E3 
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ligase activity (Deshaies et al., 2010). Kim et al. showed that only a maximum of 6% of the 
di-glycine-modified sites in the human proteome were due to neddylation indicating that 
neddylation, compared to ubiquitination, is a rather rare event (Kim et al., 2011). 
Moreover, the identification of di-glycine-modified peptides of ubiquitin itself points to the 
possibility that K148 and K389 were indeed modified with a ubiquitin chain. 
Therefore it can be concluded that MYC becomes ubiquitinated at multiple lysine residues, 
which are distributed all over the protein. 
5.2 K-less MYC, a tool to study effects of MYC ubiquitination 
The impact of MYC ubiquitination on its activity is complex. Most of the ubiquitin ligases 
target MYC for proteasomal degradation leading to a global reduction of MYC protein in 
the cell and thus a reduction of MYC activity (see 1.3.3.2.4). However, three ubiquitin 
ligases, HUWE1, SCF-SKP2 and SCF-FBXO28, were reported to stimulate MYC 
transcriptional activity. While SKP2-mediated ubiquitination also leads to proteasomal 
turnover of MYC, ubiquitination by SCF-FBXO28 and HUWE1 was shown to stimulate 
MYC transcriptional activity by recruitment of cofactors (Adhikary et al., 2005; Cepeda et 
al., 2013; Kim et al., 2003; Lehr et al., 2003). Additionally, as discussed previously, 
HUWE1 stimulates MYC transcriptional activity by degrading MIZ1 and thereby 
counteracting the formation of repressive MYC/MIZ1 complexes at MYC-activated target 
gene promoters (Peter et al., 2014). 
Since many different ligases ubiquitinate MYC leading to diverse effects on MYC 
function, it is difficult to elucidate the mechanisms how MYC ubiquitination stimulates its 
activity by depleting individual ubiquitin ligases. Furthermore, it is conceivable that certain 
ubiquitin ligases act in a redundant manner making it impossible to pinpoint the relative 
contribution of a specific ligase to MYC’s transcriptional output. 
When this project was initiated, the ubiquitin acceptor sites in MYC were not yet 
identified. Moreover, for other substrates it has been shown that multiple lysine residues 
can act as redundant ubiquitin acceptor sites (Hou et al., 1994; King et al., 1996). 
To this end, a non-ubiquitinatable MYC mutant was generated (K-less MYC), in which all 
lysine residues are mutated to arginine residues, which maintain the positive charge but do 
not provide a free amino group for ubiquitin conjugation. 
K-less MYC was used as a tool to investigate the direct impact of ubiquitination on the 
function and activity of MYC. Nevertheless, it is important to note that lysine residues do 
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not solely serve as acceptor sites for ubiquitin but also for other posttranslational 
modifications including acetylation and sumoylation. Therefore, analyzing K-less MYC 
might produce a mixed picture of effects generated by the absence of ubiquitination but 
also by the absence of other posttranslational modifications. Consequently, it is important 
to validate potential results for K-less MYC with methods that specifically probe 
ubiquitination such as proteasomal inhibition or depletion of ubiquitin ligases. 
The replacement of ubiquitin-acceptor sides in K-less abolished basal ubiquitination of 
MYC as shown in an in vivo ubiquitination assay (Fig. 4.1 D). 
Previously, it has been shown that K-less MYC can be ubiquitinated at its amino-terminus 
when ubiquitin ligases are ectopically expressed (Popov et al., 2010). Under physiological 
conditions, the native amino-terminus of MYC starts with a methionine followed by a 
proline. The methionine is most likely removed by aminopeptidases, leaving the proline as 
the amino-terminal amino acid being suboptimal for N-terminal ubiquitination (Meinnel et 
al., 2005). Therefore, no ubiquitin chain could be detected by in vivo ubiquitination assays 
in the absence of ectopic ubiquitin ligases. 
5.2.1 K-less MYC retains basic functionality 
MYC contains 25 lysines, which have been replaced by arginine residues in K-less MYC. 
To rule out adverse effects of these mutations, biochemical properties of K-less MYC were 
compared to WT MYC. Co-immunoprecipitation experiments showed that neither MYC’s 
ability to bind to its interaction partner MAX nor its interaction with MIZ1 was affected 
(Fig. 4.2). Moreover, K-less MYC showed a subcellular localization and chromatin 
binding that resembled the WT protein (Fig. 4.3). 
Importantly, K-less MYC was able to activate a synthetic canonical E-box reporter as 
efficiently as WT MYC (Fig. 4.4). 
These results demonstrate that mutation of lysine to arginine residues do not affect basic 
structural and biochemical properties of MYC. Additionally it shows that K-less MYC 
does bind to DNA and is able to activate transcription, at least from episomal DNA 
templates. 
5.2.2 K-less MYC is a stable protein 
Since MYC is a short-lived protein that is rapidly turned over by the ubiquitin-proteasome 
system, mutation of the ubiquitin-acceptor sites should result in a more stable protein. 
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Indeed, steady-state level of WT and K-less MYC proteins substantially differed when 
they were stably expressed in immortalized breast epithelial cells (IMECs). Treatment with 
the proteasome inhibitor MG132 equalized WT and K-less MYC protein level, indicating 
that K-less MYC is impaired in proteasomal degradation. Consistently, K-less MYC had a 
4-fold longer protein half-life compared to WT MYC as determined by cycloheximide 
decay assays, showing that turnover of MYC is primarily mediated by lysine 
ubiquitination. Notably, K-less MYC was still detectably turned over and treatment with 
MG132 completely stabilized the protein (Fig. 4.5). Several pathways could account for 
the residual proteasomal degradation of K-less MYC. 
First, MYC harbors a central PEST sequence and a D-element. Both elements enhance 
MYC turnover without affecting its ubiquitination status (Gregory and Hann, 2000; Herbst 
et al., 2004). This suggests that the remaining proteasomal turnover of K-less MYC occurs 
via these domains and is mediated independently of ubiquitination. Indeed, several proteins 
are known to be degraded by the proteasome in a ubiquitin-independent manner. For 
example, ornithine carboxylase (ODC) is degraded by the proteasome without being 
ubiquitinated (Murakami et al., 1992; Rosenberg-Hasson et al., 1989). The cell-cycle 
inhibitor p21Cip1 can be degraded in a ubiquitin-dependent and -independent manner, 
showing that a single protein may be targeted by different degrading pathways (Lu and 
Hunter, 2010; Sheaff et al., 2000). 
Second, in some cases, atypical ubiquitination can occur when ubiquitin is conjugated to 
cysteine residues via a thioester bond or to serine and threonine residues via an ester bond. 
For example, the N-terminal fragment of the cleaved pro-apoptotic protein BID (BH3 
interacting-domain death agonist) is ubiquitinated on cysteine, serine and threonine 
residues (Tait et al., 2007). While ubiquitination at serine or threonine residues of K-less 
MYC should be detected in the in vivo ubiquitination assay, ubiquitination at cysteine 
residues cannot be ruled out. The thioester bond is sensitive to DTT, which is included in 
the sample buffer for SDS-PAGE. 
Additionally, if the N-terminal methionine is not cleaved off by aminopeptidases, 
ubiquitination of the α-amino group of the methionine in K-less MYC could occur. N-
terminal ubiquitination of K-less MYC was observed upon overexpression of E3 ubiquitin 
ligases and therefore may be relevant in some in vivo contexts (Popov et al., 2010). The 
absence of a detectable ubiquitin chain in the in vivo ubiquitination assay might be due to 
limitations in detection sensitivity. 
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Thus, with the absence of detectable ubiquitination, an increased stability but correct 
localization and association with crucial interaction partners, K-less MYC is a useful tool 
to study the impact of lysine modifications on MYC function. 
5.2.3 K-less MYC fails to promote proliferation and apoptosis 
To investigate the biological importance of lysine residues on MYC function, cell lines 
were generated that stably express WT or K-less MYC. In the immortalized mammary 
epithelial cell line MCF10A, ectopic expression of MYC induced apoptosis (Fig. 4.7) 
(Wiese et al., 2015). MCF10A cells harbor a MYC amplification and therefore express 
endogenous MYC at levels comparable to the transformed cell line U2OS (Fig. 4.6). 
Additional expression of WT MYC resulted in an apoptotic phenotype documented by 
changes in cell morphology and detection of cleaved PARP. Expression of K-less MYC in 
MCF10A cells did not result in induction of apoptosis and the cells (Fig. 4.7). Since MYC-
mediated apoptosis induction in MCF10A cells is dependent on repression by MYC/MIZ1 
(Wiese et al., 2015), this points to an additional role of MYC ubiquitination in repression. 
As direct repression by MYC was not observed in IMECs (Fig. 4.13 C), this work focused 
on the connection between MYC’s transactivating functions and MYC ubiquitination. 
Ectopic expression of MYC induces proliferation in the immortalized mammary epithelial 
cell line IMECs, in which the endogenous MYC level is very low (Cowling et al., 2007). 
Interestingly, K-less MYC did not stimulate proliferation although it was expressed at 
higher levels than WT MYC. This effect was documented by several assays, all yielding 
the same result (Fig. 4.8). 
Since proliferation defects documented by a cumulative growth curve or crystal violet 
staining could be influenced by induction of apoptosis, the ability to stimulate proliferation 
was analyzed in a more direct way by measuring BrdU incorporation. While induction of 
WT MYC stimulated S-phase entry in the absence of growth factors in IMECs, K-less 
MYC was clearly impaired in promoting the entry into S-phase (Fig. 4.9). 
Therefore, lysine residues in MYC are important for MYC-induced phenotypes in 
mammary epithelial cells. 
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5.2.4 K-less MYC binds to MYC-regulated promoters but poorly regulates 
transcription 
Ubiquitination of a transcription factor can affect its functionality in multiple ways. As 
mentioned previously, ubiquitination can help to recruit activators to specific promoters or 
it can mediate the opposite effect and help to extract activators from chromatin (see 1.2.4). 
To this end, it was investigated whether K-less MYC is present at known MYC-regulated 
promoters. 
In ChIP experiments, K-less MYC was detectable at known MYC binding sites but with a 
lower enrichment compared to WT MYC. Global analysis by ChIP-Seq confirmed this 
observation. However, K-less MYC could not be detected at promoters where WT MYC 
did not bind. Instead, K-less MYC was present at the same sites as WT MYC but with a 
decreased binding intensity (Fig. 4.10). 
A likely explanation for the apparent weaker binding of K-less MYC is a lower cross-
linking efficiency of K-less MYC to DNA. During the ChIP procedure, proteins are cross-
linked to DNA by formaldehyde. Cells are incubated with formaldehyde for 15 min, a 
short time when preferentially free amino groups of lysine residues are used for the cross-
linking reaction (Toews et al., 2008). Therefore, the mutations from lysine to arginine 
residues in K-less MYC do not only abolish a potential ubiquitination site but also impair 
the ability to cross-link MYC to DNA. This suggests that K-less MYC is actually present 
at known MYC-binding sites but cannot be cross-linked as efficiently to DNA as WT 
MYC. During the ChIP procedure, nuclei are lysed with a SDS-containing lysis buffer and 
the chromatin is intensively sonified. Under these conditions, protein-DNA interactions, 
which are not fixed by formaldehyde, are lost, and consequently, this would result in a 
weak ChIP efficiency as observed for K-less MYC. 
The ChIP-Seq results alone cannot rule out that ubiquitination of MYC is involved in 
defining a binding site specificity of MYC. If ubiquitination helps to recruit MYC to 
promoters, K-less MYC could be unspecifically distributed along the chromatin and this 
would not result in a significant enrichment of K-less MYC at these sites. 
Therefore, it was investigated whether K-less MYC is present at MYC-regulated 
promoters but not efficiently cross-linked. To this end, a native ChIP was performed, 
where the proteins are not cross-linked to DNA by formaldehyde and the DNA is 
fragmented by MNase treatment instead of sonication. Indeed, under these native 
 121 
#
Discussion 
 
#  
conditions, K-less MYC bound to the GNL3 promoter equally well as WT MYC (Fig. 
4.11). In agreement with the native ChIP, K-less displaced the E-box binding protein 
MXD6 from the GNL3 promoter as efficiently as WT MYC (Fig. 4.12). Although K-less 
MYC was present at the GNL3 promoter, it was incapable of inducing GNL3 mRNA 
expression, suggesting that K-less MYC fails to promote a step in transcriptional activation 
subsequent to chromatin recruitment. 
In line with these experiments, reconstitution of lysine residues increased the ability to 
detect MYC binding at promoters and the detected binding increased with the number of 
reconstituted lysines (Fig. 4.12). Importantly, this was not correlated with the ability to 
induce gene expression since both mutants, either containing the seven N-terminal or the 
18 C-terminal lysines, were able to induce MYC target gene expression (Fig. 4.17). 
These experiments support the hypothesis that K-less MYC is present at known MYC-
bound promoters and that lysine modifications are dispensable for MYC binding to its 
target sites. 
MYC is a transcriptional regulator that mediates biological processes by modulating 
expression of multiple target genes. It was previously shown that ubiquitination of MYC 
by specific E3 ligases stimulates its transcriptional activity (Adhikary et al., 2005; Kim et 
al., 2003; Lehr et al., 2003). Therefore, it was likely that the inability of K-less MYC to 
stimulate MYC-mediated phenotypes was due to a weaker transcriptional regulation of 
MYC target genes. This was already indicated by its inability to induce GNL3 mRNA 
expression (Fig. 4.11). 
Global gene expression profiles of WT and K-less MYC were compared in IMECs stably 
expressing Dox-inducible MYC and vector-expressing cells as a control. 
The gene expression profiles revealed that K-less is a weaker transcriptional activator. Dox 
alone did not influence gene activation since no induction was observed in vector-
expressing cells (Fig. 4.13). Gene set enrichment analysis showed that a MYC-specific 
signature was the best enriched signature for both WT and K-less MYC, demonstrating 
that K-less MYC regulates the same set of genes as WT MYC, albeit to a lesser extent, as 
shown by the lower normalized enrichment score (NES) (Fig. 4.14). 
These data confirm the importance of lysine residues on MYC transcriptional activity at a 
post-DNA binding step. 
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5.3 MYC function can be mediated by diverse ubiquitin acceptor sites 
The previous results indicate that lysine residues in MYC are important for its 
transcriptional activity. To investigate whether lysines need to be present at a certain 
position in MYC, two MYC mutants were generated either harboring the seven N-terminal 
lysines (WTN-KC) or the eighteen C-terminal lysines (-KNWTC). Importantly, these two 
MYC mutants do not have any common lysines (Fig. 4.15). Both mutants are efficiently 
ubiquitinated, confirming that several lysines in MYC can function as ubiquitin acceptor 
sites. Accordingly, restoration of these lysine resulted in the same turnover rate as 
observed for WT MYC (Fig. 4.16). 
WTN-KC MYC was similar to WT MYC in terms of transcriptional activity and 
downstream cellular phenotypes suggesting that the seven N-terminal lysines are sufficient 
for MYC activity. Reconstitution of the eighteen C-terminal lysines could also rescue the 
proliferation phenotype and transcriptional activity of MYC (Fig. 4.17), indicating that 
ubiquitin acceptor sites in MYC are redundant. This goes in line with the observation that 
several ubiquitin ligases targeting MYC have binding sites in the N- and C-terminal part of 
the protein, suggesting that they can target lysines in different positions (see Fig. 1.4). 
Zhang et al. reported that ubiquitination of MYC within the TRD by the ubiquitin ligase 
SCF-SKP2 is critical for canonical target gene induction and transformation. Blockage of 
this ubiquitination via binding of the tumor suppressor protein ARF to the TRD resulted in 
induction of apoptosis (Zhang et al., 2013). Zhang et al. used a MYC mutant, in which the 
six N-terminal lysines were mutated to arginine (MYCN6KR), generating a protein that is 
similar to -KNWTC MYC. In contrast to our study, the Zhang mutant was substantially 
more stable than WT MYC and unable to induce E-box containing canonical target genes. 
To determine protein stability, Zhang et al. performed cycloheximide assays with 
transfected Cos7 cells (Zhang et al., 2013). Already WT MYC, with a half-life of 63 min, 
was more stable compared to the assessed WT MYC protein half-life in this study. By 
transient overexpression, it is conceivable that the E3 ligases degrading MYC become 
limiting. Moreover, in Cos7 cells, the expression of MYC-targeting E3 ligases might be 
different to IMECs, which would also result in a different turnover. A differential 
expression of C-terminal targeting ligases could explain why the Zhang mutant MYCN6KR 
is more stable than WT MYC but -KNWTC MYC in IMECs has the same half-life. 
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Three of the seven N-terminal lysines of WTN-KC MYC (K52, K148, K157) were 
identified as ubiquitin acceptors (Fig. 1 C) (Kim et al., 2011). K148 and K157 were also 
reported to be acetylated (Zhang et al., 2005). It is a common observation that 
ubiquitination and acetylation sites overlap and that there is a cross-talk between 
ubiquitination and other posttranslational modifications (Danielsen et al., 2011). In several 
cases, acetylation of a known ubiquitination site stabilizes the target protein (Caron et al., 
2005; Grönroos et al., 2002). However, the exact opposite effect was also described and 
acetylation accelerated protein turnover (Caron et al., 2005). As mentioned previously, 
MYC acetylation can have opposite effects on its stability (see 1.3.3.2.1), highlighting the 
complexity of lysine modifications. 
To preferably study effects of lysine ubiquitination on MYC-mediated phenotypes and 
transcriptional activity, the role of K52, one of the identified ubiquitination sites that is not 
acetylated, was investigated. In vivo ubiquitination assays confirmed that K52 is efficiently 
ubiquitinated and the reconstitution of K52 as a single ubiquitin acceptor site substantially 
rescued MYC turnover. This suggests that ubiquitination at K52 can mediate efficient 
proteasomal turnover of the protein (Fig. 4.18). Furthermore, reconstituting K52 largely 
rescued induction of proliferation and target genes in IMECs, highlighting that a single 
ubiquitin acceptor site of MYC can mediate MYC function (Fig 4.19). Importantly, in 
agreement with the published observation that K52 was not identified as an acetylation 
site, there was no evidence that K52o MYC is acetylated (Wenshan Xu, personal 
communication). This suggests that K52o is an efficient ubiquitin acceptor but not an 
acetylation site. Thus, the rescue effects by the single K52o MYC are most likely not due 
to acetylation of this mutant. 
To further strengthen this point and to support the idea that the rescue effect of K52o MYC 
is independent of acetylation, an acetylation-mimicking mutant could be investigated. To 
mimic acetylation, lysine residues are often mutated to glutamine (Wang and Hayes, 
2008). Thus, if the mutant does not rescue it would suggest that acetylation at this specific 
site is not important for MYC’s function. 
In contrast to the ubiquitin-conjugation cascade with around 40 E2 conjugating enzymes, 
the SUMO conjugation cascade relies on a single E2 conjugating enzyme, UBC9 (Gareau 
and Lima, 2010). Consequently, depletion of UBC9 by siRNA blocks sumoylation. 
Although the biological effect is unclear, MYC was reported to be sumoylated (see 
1.3.3.2.2). Importantly, depletion of UBC9 did not inhibit MYC target gene induction 
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arguing that the absence of sumoylation in K-less MYC is not responsible for its inability 
to induce target gene expression (data not shown). 
Collectively, these data demonstrate a close correlation between proteasomal turnover and 
transcriptional activity of MYC, suggesting that the absence of ubiquitination sites in K-
less MYC is responsible for its inability to induce target gene expression. 
 
5.4 Proteasomal activity is required for MYC target gene induction 
5.4.1 MYC targeting ubiquitin ligases might have redundant roles 
In line with previous publications, the results presented here suggest that ubiquitination of 
MYC is crucial for its function. 
To further support this hypothesis, the effect of depleting MYC-targeting ubiquitin ligases 
was analyzed. The ubiquitin ligase SCF-SKP2 was previously reported to promote MYC 
turnover and to stimulate MYC transcriptional activity (Kim et al., 2003; Lehr et al., 2003; 
Zhang et al., 2013). FBW7 binds to a phosphodegron in MBI of MYC and is one of best-
studied ubiquitin ligases targeting MYC for proteasomal degradation (Welcker et al., 
2004b). Both ligases were previously detected at MYC regulated promoters, suggesting 
that chromatin-bound MYC can be ubiquitinated by these ligases (Farrell et al., 2013; Lehr 
et al., 2003). 
Thus, the effects of these two ubiquitin ligases on MYC’s activity were analyzed. 
Depletion of FBW7 had only very mild effects, whereas depletion of SKP2 led to a 
reduced activation of several tested MYC target genes (Fig. 4.20). This confirms the 
previously published results that SKP2 stimulates MYC transcriptional activity. However, 
depletion of SKP2 did not globally influence MYC target gene induction (Fig. 4.21), 
suggesting that the effect of SKP2 is specific for a subset of MYC target genes and 
different ubiquitin ligases may have redundant roles in controlling MYC ubiquitination at 
target gene promoters. 
Neither the depletion of FBW7 nor SKP2 depletion affected MYC protein level (Fig. 
4.20). This further supports the hypothesis that different MYC-targeting ubiquitin ligases 
can redundantly control MYC turnover and activity. 
Several previous reports further support the idea that SKP2 is not the only ubiquitin ligase 
required for MYC activity. First, while a Myc knockout is embryonically lethal, Skp2 
 125 
#
Discussion 
 
#  
knockout mice are viable. Skp2-/- mice are smaller than their WT littermates and contain 
cells with enlarged nuclei and multiple centrosomes (Nakayama et al., 2000). Importantly, 
a critical substrate of SKP2 is p27Kip1, a negative cell cycle regulator, which is upregulated 
in Skp2-/- mice. Skp2-/- phenotypes are not manifested in the Skp2/p27Kip1 double knockout 
mice suggesting that p27Kip1 is the critical target of SKP2 (Nakayama et al., 2004; Zhu, 
2010). Consindering the very different phenotypes of Myc and Skp2 knockout mice, it is 
unlikely that MYC activity is solely dependent on the presence of SKP2 (Jin and Harper, 
2003). Furthermore, loss of Skp2 had only modest effects on MYC-induced proliferation 
and tumorigenesis in a E!-MYC transgenic mouse model (Old et al., 2010). Thus, 
additional ubiquitin ligases could compensate for the loss of SKP2 in stimulating MYC 
activity. 
5.4.2 Proteasomal inhibition abolishes MYC transcriptional activity 
For several transcription factors it has been shown that ubiquitination is required for their 
transcriptional activity. While the ubiquitination itself is sufficient for some transcription 
factors to enhance their activity, others require proteasomal turnover for full transcriptional 
activity (see 1.2.3). 
Salghetti et al. investigated how ubiquitination within the transactivation domain (TAD) of 
VP16 affects its activity. The VP16 TAD requires ubiquitination by the E3 ligase Met30 
for its function. The requirement for ubiquitination by Met30 could be circumvented by a 
fusion of ubiquitin to the amino terminus of VP16. The Ub-VP16 fusion protein was fully 
active even in a Met30 knockout background but was not degraded by the proteasome. 
This suggests that under these circumstances ubiquitination has a function independent of 
proteasomal degradation (Salghetti et al., 2001). 
On the other hand, other transcription factors do not only require ubiquitination but also 
proteasomal degradation for their function. The E3 ligase complex SCF-CDC4 
ubiquitinates the yeast transcription factor Gcn4 leading to its proteasomal degradation. 
Lipford et al. showed that proteasomal turnover is required for Gcn4 activity. Treatment of 
cells with the proteasome inhibitor MG132 or mutation in ubiquitin (K48R) that prevented 
formation of K48-linked degrading ubiquitin chains reduced Gcn4 transcriptional activity. 
Moreover, mutations of the kinases that generate the phosphodegron recognized by SCF-
CDC4 or deletion of the E3 ligase itself compromised Gcn4 activity (Lipford et al., 2005). 
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To investigate whether ubiquitination per se or proteasomal turnover is required for MYC 
transcriptional activity, linear fusions of non-removable ubiquitin to the amino-terminus of 
K-less MYC were generated. However, the fusion of WT ubiquitin to K-less MYC was 
unstable and could not be expressed. When ubiquitin in which all lysines were mutated to 
arginine residues (K0) was fused to K-less MYC, the fusion protein was expressed but did 
not to rescue the proliferation defect of K-less MYC (data not shown), and did not allow 
straightforward interpretation of the data. It may suggest that MYC needs to be modified 
with a ubiquitin chain and monoubiquitination is not sufficient for MYC function. 
Alternatively, ubiquitination at a specific acceptor site may be required, although the fact 
that reconstitution of lysines in completely different regions in MYC (see 4.6.1) could 
rescue the proliferation defect would argue against this possibility. Fusion of ubiquitin 
bearing a K48R mutation could potentially address this question but the use of ubiquitin 
mutants in the mammalian system is difficult since the abundant endogenous ubiquitin 
may promote the assembly of different (undesired) ubiquitin chains. Furthermore, 
ubiquitin chains linked via lysines other than K48 promote proteasomal degradation, which 
would confound the interpretation (Kirkpatrick et al., 2006). 
Consequently, the effect of proteasomal inhibition on MYC activity was investigated. 
While proteasomal inhibition did not influence binding of MYC to target gene promoters, 
target gene induction was strongly impaired (Fig. 4.22 and 4.23). Global analysis by RNA-
Seq confirmed that proteasomal activity is required for induction of MYC target genes. 
It would be interesting to analyze, whether ubiquitinated MYC accumulates at MYC-
regulated promoters after proteasomal inhibition. This would suggest that ubiquitination 
per se is not required for MYC activity but the turnover at the promoter is the important 
mechanism. No accumulation of MYC after MG132 treatment could be detected, which 
raises the question whether turnover of MYC actually occurs at promoters. 
Notwithstanding, it cannot be excluded that the analyzed sites are already saturated and 
therefore no additional MYC-binding could be observed after proteasomal inhibition. 
Ubiquitin ligases targeting MYC as well as proteasomal subunits were detected at MYC-
regulated promoters in a MYC-dependent manner, indicating that turnover of MYC can 
indeed take place at promoters (Farrell et al., 2013; Lehr et al., 2003). 
To experimentally investigate whether ubiquitinated MYC is present at promoters, 
sequential ChIP experiment could be performed. To this end, cells would be treated with 
MG132 and the lysis buffer would be supplemented with the alkylating reagent N-
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ethylmaleimide (NEM) to inhibit activity of deubiquitinating enzymes. MYC would be 
immunoprecipitated according to the standard ChIP protocol with an antibody recognizing 
the C-terminal HA-tag followed by an elution step with a peptide. This eluate would be 
used for a second IP to precipitate specifically ubiquitinated proteins using for instance 
MultiDsk, a ubiquitin-specific affinity resin, or TUBE (tandem-repeated ubiquitin-binding 
entities) (Hjerpe et al., 2009; Wilson et al., 2012). However, in a ChIP experiment, DNA 
fragments, where the protein of interest binds to, are precipitated and analyzed. This 
implies that as soon as other ubiquitinated proteins are bound to the same DNA-fragment 
as MYC, ubiquitinated histones for example, they would be immunoprecipitated and could 
result in a misleading interpretation of the experiment. Generating an antibody specifically 
recognizing ubiquitinated MYC could circumvent this problem. To this end, a MYC 
peptide would be synthesized and used as an immunogen that is branched with the last 
ubiquitin amino acids at the site where MYC is ubiquitinated, for example at K52. This 
approach was used for the generation of antibodies specific for ubiquitinated H2B (Minsky 
et al., 2008). 
Since proteasome inhibition abrogated MYC target gene induction, it is likely that turnover 
of MYC at its promoters is needed for its transcriptional activity. To experimentally 
support this suggestion, a K-less MYC version was generated, whose proteasomal 
degradation can be induced with the auxin-inducible degradation (AID) system. In this 
system, degradation of an AID-tagged protein can be induced by administration of the 
plant hormone auxin (Holland et al., 2012; Nishimura et al., 2009). 
To this end, a stable IMEC cell line was generated expressing the plant F-box protein 
TIR1, which can be incorporated into the human SCF complex, and MYC with an AID at 
its C-terminus. Administration of auxin to the cell culture medium enables the recognition 
of the AID by TIR1, leads to polyubiquitination of the degron and subsequent proteasomal 
degradation (Nishimura et al., 2009). If the inducible degradation of K-less MYC rescues 
target gene induction, it would demonstrate that proteasomal turnover of MYC is required 
for its activity. Unfortunately, even in the absence of auxin the K-less-AID fusion protein 
was unstable and it was not possible to express the fusion protein to the same level as WT 
MYC. The AID-tag contains several lysine residues thus it is likely that these introduced 
lysines lead to turnover of K-less MYC even in the absence of auxin. 
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5.5 K-less MYC is impaired in promoting efficient elongation 
The previous results show that K-less MYC is impaired in transcriptional activation and 
suggest that MYC-mediated transcription requires proteasomal activity. Therefore we 
aimed to pinpoint the step in MYC-mediated transcription, which requires turnover. 
As mentioned previously, MYC stimulates transcription by the recruitment of RNAPII to 
promoters but also by increasing the rate of transcription initiation and elongation (see. 
1.3.2.1). To understand whether WT and K-less MYC act differently at one of these steps, 
ChIP-Seq experiments were performed for total RNAPII, the initiating Ser5p RNAPII and 
elongating Ser2p RNAPII after 4 h of WT or K-less MYC induction. 
Analyzing the effects of MYC activation at the promoters of all genes, no change in total, 
initiating or elongating polymerase could be observed, indicating that MYC does not 
globally lead to enhanced stimulation of initiation or elongation in this cellular system 
(Fig. 4.25). 
Filtering the genes for MYC bound and activated genes, WT and K-less MYC stimulated 
the recruitment of RNAPII to MYC-regulated promoters (Fig. 4.26). Since no difference 
was observed at all genes, the changes at MYC-regulated promoters are indeed due to 
direct effects by MYC. Strikingly, while activation of WT MYC also led to an increase of 
total RNAPII within the gene body and at the end of the gene, activation of K-less MYC 
resulted solely in an increase of RNAPII at the TSS, suggesting that the release of 
elongating RNAPII is impaired. This is further supported by the effect of MYC activation 
on Ser5p and Ser2p RNAPII. WT and K-less MYC both stimulated transcription initiation 
but only WT MYC expression increased the density of elongating polymerase in the gene 
body and TES (Fig. 4.27 and 4.28). The fact that Ser5p RNAPII was increased at the TSS 
by both WT and K-less MYC expression but only WT MYC increased Ser5p RNAPII in 
the gene body is a good internal quantitative control of the experiment. It demonstrates that 
the differences observed in the gene body are not due to ChIP-to-ChIP variations since this 
would lead to a global difference of the signal. Thus, the results suggest that RNAPII is not 
released from the promoter in K-less MYC expressing cells. 
It can be concluded that recruitment of RNAPII and transcription initiation do not depend 
on ubiquitination of MYC. In contrast, the transition to efficient elongation requires the 
presence of lysine residues and most likely the turnover of MYC. Thus, the defect of K-
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less MYC to activate gene expression is due to a block in transcriptional elongation, 
resulting in an accumulation of Ser5p RNAPII at the TSS (Fig. 4.28 C). 
Several connections between the ubiquitin-proteasome system and transcription elongation 
have been described (see 1.2.2). In particular, the 19S particle of the proteasome stimulates 
elongation for example by reducing the nucleosome density. However, since 19S does not 
possess the catalytic activity of the proteasome, these effects were independent of 
proteasomal activity (Chaves et al., 2010; Ferdous et al., 2001; 2002). In contrast to these 
studies, MYC transcriptional activity was abrogated upon proteasome inhibition (Fig. 
4.23). Thus, it is unlikely that the absence of the 19S proteasome subunit accounts for the 
defect in transcriptional elongation in K-less MYC-expressing cells. Observations that the 
recruitment of proteasome subunits can be mediated by H2B ubiquitination or by 
interaction with the H4 tail argues against a scenario in which K-less MYC is defective in 
recruiting the proteasome to promoters (Chaves et al., 2010; Ezhkova and Tansey, 2004; 
Geng and Tansey, 2012). 
Interestingly, in 2005 a study from the Tansey lab described a connection between 
ubiquitination-dependent turnover of the inducible yeast transcription factor Gal4 and the 
transcription cycle. Degradation of the transcriptionally active Gal4 is mediated by F-box 
protein Dsg1 and this turnover is required for productive transcription. More precisely, the 
Gal4 ubiquitination was specifically required for the phosphorylation of RNAPII at Ser5, 
which was reduced in Δdsg1 strains due to a defect in recruitment of the corresponding 
kinase (Bur1) to the promoter. The authors concluded that RNAPII recruitment occurs 
independently of Gal4 ubiquitination and Gal4 turnover is required to disassemble the 
initiation-competent RNAPII complexes to allow kinases and the RNA processing 
machinery to associate with the transcribing RNAPII (Muratani et al., 2005). This was one 
of the first studies to identify the step in the transcription cycle that requires turnover of an 
activator. This study shows some parallels but also several differences with the effects 
observed with K-less MYC. While in both studies recruitment of the RNAPII is unaffected 
or only marginally reduced, K-less MYC is proficient in mediating Ser5 phosphorylation 
while a Δdsg1 strains is impaired in this transcriptional step. Moreover, in K-less MYC-
expressing cells RNAPII is poorly released from the promoter and consequently no 
increase of total RNAPII or Ser5- and Ser2-phosphorylated RNAPII could be detected 
within the gene body and TES after K-less MYC induction. In a Δdsg1 strains, the 
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polymerase continues transcribing the transcript, generating a full-length RNA, which is 
not translated due to impaired Ser5 phosphorylation of RNAPII (Muratani et al., 2005). 
In contrast, K-less MYC is clearly impaired in induction of mRNAs transcription (see 4.5). 
The ability of K-less MYC to promote Ser5 phosphorylation, a modification that stimulates 
the recruitment of the 5’end capping machinery, suggests that the nascent transcripts are 
capped. Since defects in Ser2 phosphorylation of RNAPII were observed after K-less 
MYC induction, it is possible that polyadenylation of the transcript is affected. Since K-
less MYC cells are impaired in releasing RNAPII, it is likely that short, capped nascent 
transcripts are synthesized but no further transcription is taking place. It would be 
interesting to analyze, whether these transcripts are detectable in K-less MYC expressing 
cells. 
Considering both studies it shows that ubiquitination of a transcriptional activator can 
affect different steps in the transcription cycle. 
An increase of total and Ser2p RNAPII in the gene body and TES after WT MYC 
induction can be interpreted in two different ways. First, the released polymerases are 
transcribing slower through the gene resulting in an accumulation within the gene body 
and TES. Second, the higher RNAPII density is due to an enhanced release of RNAPII 
from the TSS, which would be in line with the observed induction of gene expression. 
With the static ChIP-Seq data presented in this study, it is not possible to draw any 
conclusion about the speed of the polymerase. Moreover, it is still under debate what is the 
rate-limiting step in the transcription cycle and whether gene expression can be regulated 
at the level of pause release (Ehrensberger et al., 2013). Thus, from the RNAPII 
sequencing data it cannot be concluded, which MYC-dependent step of the transcription 
cycle is rate limiting. 
To this end, it would be necessary to investigate whether and how MYC activation 
influences the speed of elongating polymerase. This could be performed with a 
DRB/GRO-Seq experiment. Here, cells are treated with 5,6-dichloro-1-β-D-
ribofuranosylbenzimidazole (DRB), a reversible inhibitor of P-TEFb activity. Treatment 
with DRB results in a loss of SPT5 and RNAPII Ser2 phosphorylation and thus inhibits the 
progression of the initiated RNAPII to productive elongation, leading to a synchronization 
of the transcription cycle (Saponaro et al., 2014). After inhibitor removal, RNAPII is 
released and can resume elongation. By using DRB-treatment in combination with global 
run-on sequencing (GRO-Seq), a method that labels newly synthesized RNAs with 
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bromouridine-triphosphate (BrUTP), the position of RNAPII in the gene body can be 
analyzed. Labeling of nascent transcripts at different time points after DRB release allows 
assessing the speed of the elongating RNAPII (Saponaro et al., 2014). 
Nevertheless, the increased RNAPII density after WT MYC induction in the gene body 
was observed at activated MYC target genes. Thus, the RNAPII sequencing data in 
combination with the results from the RNA-Seq suggest that WT but not K-less MYC 
expression stimulates efficient elongation. 
5.6 Ubiquitination of MYC is required for cofactor recruitment 
In order to further characterize the steps in MYC-dependent transcriptional activation, 
which depend on ubiquitination, MYC-induced histone acetylation was investigated. While 
WT MYC induced acetylation of histone H3 and H4 at the GNL3 promoter, K-less MYC 
was impaired in this process (Fig. 4.29). One explanation of the inability to induce histone 
acetylation could be an impaired recruitment of HATs to MYC-regulated promoters. 
Several histone acetyltransferases are known to interact with MYC; one of them is GCN5, 
a component of the STAGA complex (SPT3/TAF9/GCN5 acetyltransferase complex) (Liu 
et al., 2003; McMahon et al., 2000). If the recruitment of this HAT is dependent on 
ubiquitinated MYC, it is likely that a component of the STAGA complex possesses an 
ubiquitin-binding domain. Interestingly, the STAGA complex contains a so-called 
deubiquitinating module (DUB module) consisting of several proteins including the 
deubiquitinating enzyme USP22 (Zhao et al., 2008b). USP22 deubiquitinates histone H2A 
and H2B and is required for MYC transactivation activity (Zhang et al., 2008; Zhao et al., 
2008b). Moreover, in yeast it has been reported that Ubp8 (the USP22 orthologue) 
mediated deubiquitination of H2B is required for Ser2 phosphorylation of RNAPII (Wyce 
et al., 2007). Thus, the STAGA complex was an interesting candidate to study. However, 
in IMECs, USP22 was not detected at MYC-regulated promoters; neither did USP22 
depletion have a consistent effect on MYC target gene induction (data not shown). 
Moreover, depletion of GCN5 had only subtle effects on MYC target gene induction, 
suggesting that HATs might act redundantly during transactivation by MYC (data not 
shown). 
It was previously described that the recruitment of p300 to MYC target gene promoters is 
stimulated by ubiquitinated MYC (Adhikary et al., 2005; Cepeda et al., 2013). Therefore, 
p300 recruitment by K-less MYC might be impaired. Another possibility is that turnover 
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of MYC might help to displace histone deacetylases from promoters. In line with this idea, 
MYC was shown to bind several HDACs (Kurland and Tansey, 2008). On the other hand, 
MYC might recruit HUWE1 to promoters, which degrades HDAC2 (Zhang et al., 2011). 
Alternatively, turnover of MYC might be required for the efficient recruitment of 
HATs to target gene promoters. This mechanism has been previously described for the 
estrogen receptor (ER). ER-mediated transactivation requires continuous cycling of the ER 
on the promoter to recruit cofactors including HATs and the cycling is mediated by 
proteasomal turnover of the ER (Métivier et al., 2003; Reid et al., 2003). This would 
indicate that continuous turnover of MYC on the promoter maintains the cycling and 
enables productive recruitment of HATs. It is also possible that ubiquitin-dependent 
recruitment and degradation are interdependent. In this scenario, ubiquitination would first 
help to recruit HATs to promoters and then subsequently lead to proteasomal degradation 
to maintain the cycling. 
In line with this model, a previous study reported that MYC cycles at promoters in a 
proteasome- and PIN1-dependent manner (Farrell et al., 2013). MYC phosphorylated at 
Ser62 is isomerized by PIN1, facilitating FBW7-mediated degradation. Farrell et al. 
demonstrated that PIN1 enhances recruitment of Ser62-phosphorylated MYC to target 
gene promoters, which is associated with its subsequent degradation. They suggested that 
the dynamic MYC binding to promoters is associated with enhanced recruitment of 
cofactors including HATs and thus contributing to MYC target gene induction (Farrell et 
al., 2013). 
To experimentally test whether proteasomal turnover of MYC is required for induction of 
histone acetylation, ChIP experiments after proteasomal inhibition with MG132 could be 
performed. Under MG132 treatment, WT MYC should be impaired in inducing histone 
acetylation and mimic the K-less situation, where no induction of histone acetylation could 
be detected. Concomitantly, recruitment of BRD4 by K-less MYC induction was also 
impaired (Fig. 4.20). 
BRD4 is important to regulate the activity of P-TEFb, which is kept in an inactive complex 
containing the kinase inhibitor HEXIM, the 7SK small nuclear RNA and two auxiliary 
proteins LARP7 and MePCE (Chen et al., 2014). BRD4 releases P-TEFb from the 
repressive complex and recruits it to promoters (Jang et al., 2005; Yang et al., 2005; Zhou 
and Yik, 2006). Thus, the inability of K-less MYC to induce histone acetylation might 
block this whole cascade, resulting in an impaired recruitment of P-TEFb (with its kinase 
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subunit CDK9) to promoters and compromising the release of paused polymerase (Fig. 
4.20 and 5.1). Consequently, proteasome inhibition would lead to decreased histone 
acetylation, preventing BRD4 and CDK9 recruitment to MYC-regulated promoters. This 
would give one explanation why the MYC-CDK9 interaction was strongly reduced upon 
proteasome inhibition (Fig. 4.31 D).  
 
Figure 5.1: Proposed model for turnover-dependent histone acetylation and cofactor 
recruitment 
A) Proteasome-mediated cycling of MYC at promoters might enable efficient recruitment of 
histone acetyltransferases (HAT) leading to increased histone acetylation and subsequent 
BRD4 and P-TEFb recruitment. P-TEFb phosphorylates RNAPII at Ser2, releasing 
elongating RNAPII. 
B) K-less MYC is impaired in HAT recruitment, preventing induction of histone acetylation, 
BRD4 and CDK9 recruitment. Consequently, RNAPII is not released from the promoter 
and accumulates in a Ser5-phosphorylated state. 
 
MYC was also suggested to directly recruit P-TEFb to promoters (Rahl et al., 2010) even 
though structure-function analyses using CDK9-binding deficient MYC mutants are 
missing. 
The impaired recruitment of CDK9 to MYC-regulated promoters after K-less MYC 
expression can explain the effects observed on RNAPII phosphorylation and release. 
Interestingly, induction of K-less MYC mimics the situation when P-TEFb activity is 
inhibited with flavopiridol. Upon CDK9 inhibition, RNAPII is depleted from the gene 
body and remains associated with the promoter-proximal site (Rahl et al., 2010). 
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5.7 Impaired MYC turnover enables the identification of an 
intermediate step in MYC-dependent transcription 
WT MYC induction led to a significant increase of the total and Ser2p RNAPII density in 
the gene body (Fig. 4.28). However, as MYC associates with positive elongation factors, 
which enhance the processivity and speed of RNAPII, this may lead to an underestimation 
of MYC-mediated effects on RNAP Ser2p density. 
MYC was shown to associate with positive elongation factors like CTR9 or CDC73, which 
are components of the PAF complex (Anne Carstensen, personal communication) (Dingar 
et al., 2015). The PAF complex is a multiprotein complex involved in transcription-
coupled histone modifications and mRNA processing (Krogan et al., 2003; Zhu et al., 
2005). In yeast it has been demonstrated that the PAF complex promotes H2B 
monoubiquitination by recruiting E2 and E3 enzymes to chromatin. H2B 
monoubiquitination in turn is important for recruitment of the histone chaperone FACT, 
which mediates efficient elongation through nucleosomes (Formosa, 2012; Tomson and 
Arndt, 2013). 
Upon induction of WT but not K-less MYC, CTR9 accumulated at the 3’end of the MYC 
target gene GNL3, indicating that it travels with the elongating polymerase supporting 
efficient elongation at MYC-regulated genes (Fig. 4.31). Surprisingly, 
immunoprecipitation experiments did not detect an interaction between WT MYC and 
CTR9, whereas K-less MYC robustly bound CTR9 (Fig. 4.31 B). This result suggested 
that the interaction between MYC and CTR9 is very transient and is stabilized by 
attenuated turnover of K-less MYC. Similarly, interaction of WT MYC with CTR9 was 
enhanced upon proteasome inhibition. Supporting this idea, interaction with the other PAF 
component CDC73 and the DSIF protein SPT5 was also enhanced after proteasome 
inhibition (Fig 4.31). It can be speculated that MYC acts as an assembly factor; first 
promoting loading of RNAPII and stimulating initiation independently of proteasomal 
turnover, which is followed by turnover-dependent induction of histone acetylation, CDK9 
recruitment and transfer of positive elongation factors onto RNAPII. Inhibition of the 
turnover decelerates the conveyance and enables the detection of a MYC-PAF complex 
most likely as an intermediate step in MYC-mediated transcription. 
The PAF complex binds Ser5- and Ser2-phosphorylated RNAP CTD (Qiu et al., 2012). 
Notably, CDC73 and CTR9 were both identified per mass spectrometry to interact with 
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WT N-MYC but not with the phosphorylation mutant N-MYC T58A/S62A (Anne 
Carstensen, personal communication). These phosphorylation sites are located within the 
highly conserved MBI. Consistently, CDC73 interacted with N-MYC MBI peptide and 
binding was enhanced when one or both residues were phosphorylated (Fig. 4.32). Only a 
faint signal for CTR9 was detectable for doubly phosphorylated MBI, suggesting that other 
regions in MYC might be important for CTR9 binding. 
 
 
Figure 5.2: Alignment of MYC phosphorylation sites in MBI and RNAPII CTD 
Upper panel shows alignment of the sequence surrounding MYC phosphorylation sites in MBI 
with two repeats of RNAPII CTD. Lower panel shows alignment of the sequence surrounding 
MYC phosphorylation sites in MBI with one repeats of RNAPII CTD. Numbers indicate amino 
acid position within one RNAPII CTD repeat or within MYC respectively Amino acids marked in 
red indicate the respective phosphorylation sites. 
 
Interestingly, the phosphorylation sites in MBI show some homology to the RNAPII CTD 
spanning Ser5 and Ser2 on two adjacent heptad repeats (Fig. 5.2, upper panel) and less 
homology the RNAPII CTD spanning Ser5 and Ser2 on one repeat (Fig. 5.2, lower panel). 
It is possible that phosphorylated MBI acts as a platform to transiently recruit the PAF 
complex. In this model, RNAPII becomes the preferred binding partner for the PAF 
complex when its CTD is phosphorylated at Ser2 by P-TEFb (Figure 5.3). 
Figure 5.3: Proposed model for the transfer of the PAF complex from MYC onto RNAPII 
The PAF complex binds to phosphorylated MYC. DSIF and NELF keep RNAPII in a paused state. 
Upon P-TEFb recruitment and phosphorylation of DISF and RNAPII, NELF dissociates, DSIF is 
turned into a positive elongation factor and the PAF complex is transferred onto RNAPII. 
 
In line with this idea, K-less MYC is present in an S62-phosphorylated state, which was 
reported to be the active form of MYC (Fig. 4.32 C) (Farrell et al., 2013). The impaired 
recruitment of CDK9 in K-less expressing cells leads to a decreased phosphorylation status 
of RNAPII CTD, preventing the transfer of the PAF complex onto RNAPII CTD and 
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enabling the detection of the MYC/PAF complex. DSIF acts initially as a negative 
elongation factor stimulating transcriptional pausing that is turned into a positive 
elongation factor upon phosphorylation by P-TEFb (Kwak and Lis, 2013; Yamada et al., 
2006). Despite its positive role on elongation, the PAF complex was also described to 
block elongation at promoters of erythroid genes (Bai et al., 2010). Bai et al. suggested that 
PAF serves a dual function similar to DSIF, first inhibiting elongation but is converted into 
a positive elongation factor at later stages. Also at MYC regulated promoters the PAF 
complex may first support the pausing state but act as a positive elongation factor upon 
RNAPII Ser2 phosphorylation and transfer onto RNAPII. 
 
One interesting question remains: Why is K-less MYC able to activate an E-box luciferase 
reporter but is impaired in activating endogenous MYC target genes? The firefly luciferase 
gene of the reporter construct is a short intronless gene. Previously, it has been reported 
that Ser2 phosphorylation of RNAPII by P-TEFb is not required for efficient transcription 
of some short intronless genes, suggesting that the impaired recruitment of CDK9 by K-
less MYC might be irrelevant for reporter gene activation (Medlin et al., 2005). Moreover, 
since the reporter construct is not an integrated reporter and thus not properly 
chromatinized, transactivation could occur independently of positive elongation factors 
such as FACT and the PAF complex. It can be speculated that K-less MYC is able to 
activate the reporter construct because CDK9 recruitment and the conveyance of positive 
elongation factors onto RNAPII is not required. 
5.8 Cancer-associated mutations stabilize MYC – how does that fit to 
the model? 
Tumor-associated mutations in the MYC gene are relatively rare events. However, in 
Burkitt’s lymphoma, point mutations in MYC cluster in MBI and have a stabilizing effect 
on the MYC protein. For example, the mutation of Thr58 to an alanine disrupts the 
phosphodegron recognized by FBW7, stabilizes MYC and increases its ability to drive 
lymphomagenesis (Hemann et al., 2005). How do tumor-associated stabilizing mutations 
of MYC fit to the model that proteasomal turnover of MYC is required for its 
transcriptional activity? 
Cycloheximide decay assays used to determine MYC protein stability cannot discriminate 
between the turnover of MYC on target gene promoters and in different subcellular 
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compartments. It is possible, that different pools of MYC exist, whose turnover is 
differentially regulated. A cancer-associated mutation, such as T58A, could inhibit 
FBW7γ mediated degradation of MYC in the nucleolus but not the turnover at promoters 
mediated by different ubiquitin ligases.  
Muratani et al. suggested that proteasomal turnover of different pools of the yeast 
transcription factor Gal4 has different outcomes. Turnover of the chromatin-associated, 
transcriptionally active Gal4 is required for its activity. In contrast, stabilization of the 
“inactive” pool has a stimulating effect by increasing the total amount of Gal4, which is 
available for gene activation (Muratani et al., 2005). Thus, these cancer-associated 
mutations in MYC could increase the overall pool of MYC available for transcription 
thereby enhancing its activity. In line with this hypothesis, it was shown that chromatin-
associated MYC has a different half-life than the soluble MYC pool (Tworkowski et al., 
2002). 
Farrell et al. noted that, similar to non-transformed cells, MYC also dissociates from active 
promoters in cancer cells. However, the promoters were rapidly re-occupied by MYC, 
suggesting that this binding might result from the increased soluble pool of MYC, which is 
present in the cell (Farrell and Sears, 2014; Farrell et al., 2013). 
It is tempting to speculate that MYC turnover at promoters is initially required for target 
gene activation but at the same time shuts off the signal preventing a continued activation 
of transcription. Thus, turnover might ensure that only a persistent signal, e.g. due to an 
increased total pool of MYC molecules, leads to a continuous gene activation. 
Interestingly, the increased oncogenicity of MYC T58A in mouse models has been linked 
to an impaired induction of the direct MYC target gene Bim and compromised 
proapoptotic activity (Hemann et al., 2005; Muthalagu et al., 2014; Wang et al., 2011). 
This implies that transcriptional activity of the stabilized MYC is actually compromised. It 
would be interesting to analyze, whether MYC dynamics differ at distinct promoters with 
some requiring rapid turnover of MYC and others being not sensitive to changes in the 
turnover rate. Tumor cells might maintain a balance between enhanced MYC stability and 
an optimal rate of degradation. MYC stabilizing mutations might be compromised to an 
extent, which would block proapoptotic signaling, but would still allow efficient turnover 
at the promoter and expression of other genes required to maintain the malignant state. 
Here, it would be further beneficial that a T58A MYC mutant shows constitutive high S62 
phosphorylation, which is the active form of MYC (Farrell et al., 2013; Sears et al., 2000). 
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S62-phosphorylated MYC would enhance recruitment of positive elongation factors to 
stimulate transcription of these genes. 
Moreover, MYC degradation might be dispensable for transcriptional activation once 
histone acetylation has occurred and P-TEFb is recruited to promoters, implying that not 
each cycle of RNAPII release has to depend on MYC turnover. 
5.9 Cooperation of MBI and MBII in transcriptional activation 
The best-characterized function of MBII is the recruitment of HATs to MYC-regulated 
promoters, leading to increased histone acetylation (Bouchard et al., 2001; Frank et al., 
2003; McMahon et al., 2000). This recruitment seems to require ubiquitin-dependent 
turnover of MYC. BRD4 binds to acetylated histones, and in turn recruits P-TEFb to 
promoters. The PAF complex binds to phosphorylated MBI and is transferred onto the 
RNAPII CTD once P-TEFb phosphorylates it at Ser2. Therefore, it can be proposed that 
MBI and MBII cooperate to activate expression of MYC target genes (Figure 5.4). 
 
Figure 5.4: Proposed cooperation of MBI and MBII in transcriptional activation 
 
Collectively, the data suggest that turnover of MYC coordinates histone acetylation with 
recruitment and transfer of elongation factors on RNAPII involving the cooperation of 
MBI and MBII. 
During the last years, MYC was described to act as a transcriptional amplifier that globally 
enhances transcription (Lin et al., 2012; Nie et al., 2012; Wolf et al., 2015). However, so 
far there was no mechanism explaining this observation. The ability of MYC to stimulate 
multiple steps during transcriptional activation, including the transfer of elongation factors 
onto RNAPII, in combination with the observation that MYC binds to virtually all open 
promoters, may provide a mechanistic model for MYC’s ability to globally enhance 
transcription. 
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7 Appendix 
7.1 Abbreviations 
Prefixes 
p pico 
n nano 
! micro 
m milli 
c centi 
k kilo 
 
Units 
°C  degree celsius 
A  ampere 
Da  dalton 
g  gram 
h  hour 
l  liter 
m  meter 
min  minute 
M  mol/l 
s  second 
U  unit 
v/v  volumer per volume 
w/v  weight per volume 
 
Other Abbreviations 
A   adenine 
A   alanine, Ala 
aa   amino acid 
APS   ammoniumpersulfate 
ATCC   American type culture collection 
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ATP   adenosin-5’-triphosphate 
b2M   β2-microglobulin 
BET   bromodomain and extra-terminal 
bp   basepairs 
BR   basic region 
BrdU   5-bromo-2-deoxyuridine 
BSA   bovine serum albumine 
C   cytosine 
cDNA   complementary DNA 
CDK   cyclin-dependent kinase 
CDS   coding sequence 
ChIP   chromatin immunoprecipitation 
ChIP-Seq  chromatin  immunoprecipiation followed by deep-sequening 
CHX   cycloheximide 
CMV   cyctomegalovirus 
CUL   cullin 
CRL   cullin-RING ligase 
Ctrl   control 
ddH2O   bidestilled water 
DMEM  Dulbecco’s Modified Eagle-Medium 
DMSO  dimethylsulfoxide 
DNA   deoxyribonucleic acid 
dNTPs   deoxyribonucleoside-5’-triphosphate (dATP, dCTP, dGTP, dTTP) 
DTT   dithiothreitol 
DUB   deubiquitinating enzyme 
E   glutamic acid, Glu 
E1   ubiquitin-activating enzyme 
E2   ubiquitin-conjugating enzyme 
E3   ubiquitin ligase 
E4   ubiquitin-chain elongation factor 
E!   immunoglobulin heavy chain enhancer 
E.coli   Escherichia coli 
EDTA   ethylendiamintetraacetate  
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ECL   enhanced chemoluminescence 
e.g.   exempli gratia, for example 
EGF   epidermal growth factor 
FBS   fetal bovine serum 
FC   fold change 
FDR   false discovery rate 
Fig.   figure 
g   rcf, relative centrifugal force 
G   guanine 
GFP   green fluorescent protein 
GTP   guanosine-5’-triphosphate 
HLH   helix-loop-helix 
HECT   homologous to the E6-AP carboxl terminus 
HRP   horseradish peroxidase  
hygro   hygromycin 
IgG   immunoglobulin 
IF   immunofluorescence 
IP   immunoprecipitation 
IRES   internal ribosomal entry site 
K   lysine, Lys 
LB   lysogeny broth 
LZ   leucine zipper 
mRNA  messenger RNA 
NEM   N-ethylmaleimide 
NES   normalized enrichment score 
NLS   nuclear localization signal 
NP-40   Nonidet P-40 
NTA   nitrilotriacetic acid 
p   phospho 
P   proline, Pro 
PAGE   polyacrylamide-gelelectrophoresis 
PBS   phosphate-buffered saline 
PCR   polymerase chain reaction 
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PEI   polyethylenimin 
PEST   proline-, glutamate-, serine-, threonine-rich region 
PI   propidiumiodide 
PIC   preinitiation complex 
PMSF   phenylmethylsulfonyl fluoride 
PVDF   polyvinylidene difluoride 
qPCR   quantitative PCR 
R   arginine, Arg 
RING   really interesting new gene 
RNA   ribonucleic acid 
RNAPII  RNA polymerase II 
RNase   ribonuclease 
RPKM   reads per kilobase per million mapped reads 
RT   room temperature 
T   threonine, Thr 
t1/2   half-life 
TBE   Tris-borate EDTA buffer 
TBS   Tris-buffered saline 
TBS-T   Tris-buffered saline with tween-20 
TE   Tris-EDTA buffer 
TEMED  N,N,N’,N’-tetramethylethylendiamine 
TNT   Tris-NaCl-Triton X100 
TRD   transregulatory domain 
Tris   Tris-(hydroxymethyl)-aminomethan 
TRRAP  transactivation/ transformation-associated protein 
S   serine, Ser 
S   Svedberg 
SCF complex  SKP1-CUL1-F-box containing complex 
SD   standard deviation 
SDS   sodium dodecyl sulfate 
SDS-PAGE  SDS polyacrylamide gelelectrophoresis 
SEM   standard error of the mean 
siRNA   small interfering RNA 
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S-phase  synthesis phase 
U   uridine 
Ub   ubiquitin 
UPS   ubiquitin-proteasome system 
USP   ubiquitin-specific-protease 
UTR   untranslated region 
WT   wild type 
Y   tyrosine, Tyr 
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